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Abstract 
 
Hepatitis C Virus (HCV) is an emerging and challenging virus due to the problematic 
understanding of its persistence mechanisms. In fact, for many years scientists have been trying 
to resolve the issue of HCV lymphotropism, as the virus has been detected in peripheral blood 
mononuclear cells (PBMCs), lymph nodes and brain tissue. HCV isolates detected in these 
extrahepatic sites have unique mutations at positions 107, 204 and 243, distinct from liver and 
serum, in the internal ribosomal entry site (IRES) located in the 5’ UTR, one of the most well 
conserved regions of the HCV genome. In this study, divergent IRES variants were detected in 
the PBMCs of HCV-infected patients. Differences were found among plasma and PBMC derived 
5’ UTRs. Most of the PBMC-derived sequences contained the AAA mutations in the IRES 
affecting the aforementioned positions, a unique quasispecies population in PBMCs compared 
with plasma. 
 
The effect of mutations detected in the IRES was predicted based on its secondary structure. The 
three mutations alone and in combination detected in lymphotropic quasispecies were introduced 
in the 5’ UTR of HCV isolate JFH-1 and replicon genotype 1b to study the effect of these 
mutations on HCV replication in different cell lines. The replication capacity of HCV mutants 
was tested in the Huh7.5, Jurkat, EBV+ B and PBMC cell lines to examine whether such 
mutations had an effect on the efficiency of the virus to replicate in extrahepatic cell lines. All 
mutant constructs infected and showed robust replication in Huh7.5 cells. Jurkat cells failed to 
become infected while EBV+ B lymphocyte cells were shown to support HCV mutant replication. 
PBMCs failed to become infected with HCV mutants and transfection of such cells with siRNAs 
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against IRF3 and NF-kB did not improve this outcome as they appeared to not have an impact on 
the innate immune response through failure to inhibit IRF3 and NF-kB gene expression. On the 
other hand, all cell lines were found to be susceptible to infection with HCV containing plasma. 
HCV mutants were able to target cells of the immune system but replicated with reduced 
efficiency compared to hepatocytes. Mutations that were detected in HCV mutants following 
replication in extrahepatic cells caused changes in the thermodynamic stability of the IRES that 
resulted in predicted structural changes. 
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INTRODUCTION 
CHAPTER 1 
1.1 HCV Background 
1.1.1 Introduction 
Hepatitis C virus (HCV) represents an emerging viral infectious agent, a global health problem 
associated with chronic hepatitis, cirrhosis and the development of hepatocellular carcinoma. 
The virus is the cause of a major disease burden with an estimated 180 million people 
chronically infected worldwide, three to four million people infected every year, and more than 
350 thousand deaths from HCV related liver disease per year (2).  
 
It took years of different molecular approaches and a major research endeavour to isolate and 
characterise HCV. In the 1970s an infectious agent causing a large number of cases of 
parenterally transmitted viral hepatitis was described. Serological testing of many blood samples 
taken for post-transfusion hepatic viruses known at the time, hepatitis A (HAV) and B (HBV), 
gave negative results. By 1975, this newly identified infectious agent that was causing chronic 
hepatitis was referred to as Non-A, Non-B hepatitis (NANBH) (3-5).  
 
Due to the difficulties at the time to isolate NANBH in cell or organ culture, characterisation of 
the infectious NANBH agent was obtained after its successful transmission in chimpanzees (6). 
It was not until 1989 that, after years of intensive research a single positive clone, which was 
shown to derive from a single-stranded RNA molecule present in NANBH infections, to be of 
extra-chromosomal origin and which encoded an antigen associated specifically with NANBH 
infections, was eventually identified. This was achieved after applying a large cDNA expression 
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screening approach using a DNA library constructed from plasma containing the uncharacterised 
non-A, non-B hepatitis (NANBH) agent. This library was screened with serum from a patient 
diagnosed with NANBH and led to the isolation of a single positive clone (3). Subsequently, the 
entire genome was sequenced and the agent identified was recognised as a novel flavivirus that 
was renamed from NANBH to HCV (7). 
 
HCV is an enveloped virus with an icosahedral capsid that encloses a single-stranded positive 
sense genomic RNA of  approximately 9.5 kb in length (4). The virus is transmitted by direct 
contact with infected human blood and there is no vaccine available. The main current therapy is 
with polyethylene glycol (Peg)-conjugated interferon (IFN)-α given in combination with the 
guanosine analogue ribavirin (8). This type of therapy is long term, costly and with many side 
effects. Additionally, patients, many of whom become drug-resistant over time, do not respond 
well to this therapy as the virus has a remarkable ability to establish persistent infection. As a 
result, there is a need to discover alternative anti-HCV therapies. 
1.1.2 Taxonomy 
The study of the HCV genomic organisation and its morphological features established 
similarities between HCV with Flaviviruses and Pestiviruses, which are members of the 
Flaviviridae family (9). However, sequence analysis has indicated low sequence homology 
between HCV and other members of the Flaviviridae family. As a consequence of this, HCV is 
classified into a new genus termed Hepacivirus (10). 
 
Hepatitis C virus is the only member of the Hepacivirus genus in the Flaviviridae family 
together with GB virus B (GBV-B), a closely related virus which was isolated in New World 
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monkeys (Tamarins) after their inoculation with serum from a human patient with hepatitis (11-
13). Besides hepaciviruses, the Flaviviridae family, which consists of viruses with positive sense 
single-stranded RNA genomes, comprises three other genera; flaviviruses including yellow fever 
virus (YFV), Japanese encephalitis virus (JEV), the Dengue viruses (DENV) and West Nile virus 
(WNV); pestiviruses including bovine viral diarrhoea virus (BVDV) and classical swine fever 
virus (CSFV); and pegiviruses including the hepatitis G virus (HGV) or GBV-C (14, 15). 
 
Up to now the origin of HCV infection in humans remains a mystery. In 2011, canine 
hepacivirus (CHV) was identified in respiratory samples of domestic dogs and also detected in 
horses. It was not only the first non-primate hepacivirus (NPHV) discovered but also the closest 
genetic relative of HCV described to date together with bat hepacivirus (BHV) (15-18). The 
detection of GBV-B, which is distantly related to HCV, and the discovery of CHV suggested a 
nonhuman primate origin for HCV and that it might have been introduced into human 
populations via zoonotic transmission, in other words, a cross-species transmission from an as 
yet unidentified source. 
 
Hepatitis C virus has an extensive genetic variability due to its error-prone RNA-dependent RNA 
polymerase (RdRp) resulting in quasispecies variation, intra-host genetic variation within a 
single infection and divergent isolates based on the geographic region. There are numerous 
strains of HCV based on the sequence heterogeneity of their HCV RNA with at least six distinct 
genotypes and well over 80 subtypes (19, 20).  
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1.1.3 Epidemiology and transmission 
The prevalence of HCV varies across the world and the incidence rates have changed throughout 
the years due to the screening of blood, and effective awareness among intravenous drug users. 
However, it remains difficult to assess accurately prevalence rates as infections are often 
asymptomatic.  
 
The highest reported rate of HCV infection has been found in African and Asian regions, ranging 
from 1% to 10%, with the highest HCV prevalence levels in Pakistan with circa 10 million 
people infected and Egypt with circa 22% of its population being HCV seropositive (21).  
In Europe, the prevalence of HCV varies from circa 0.4% in Germany, Sweden and the 
Netherlands to 2-3% in Mediterranean and industrialized countries (Figure 1.1) (2, 22). Of the 
infected individuals about 85% develop chronic infection and circa 50-70% develop chronic liver 
disease depending on the geographic region, 10-20% of which progress to liver cirrhosis over 
time (23). Such patients are at increased risk of developing hepatocellular carcinoma (HCC). 
 
The prevalence rates of HCV infection focus mainly on the most significant risk factors such as 
injecting drug users, tattooing, body piercing and patients with haemophilia and thalassaemia, 
who are often dependent on blood products during their lifetime (24).  
Most studies on prevalence use blood donors to report the frequency of HCV usually by anti-
HCV antibody detection and often do not report follow-up HCV testing (22). Additionally, the 
detection of anti-HCV antibody by enzyme immunoassay (EIA) may be negative in early acute 
hepatitis C and in profoundly immunosuppressed patients. Additionally, in spontaneous or 
treatment-induced viral clearance, anti-HCV antibodies persist in the absence of HCV RNA (25). 
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Furthermore, many people are currently unaware of their infection. Thus, the estimated 
worldwide prevalence of HCV infection could be different to the true prevalence of infection, 
which is obtained with confirmatory HCV RNA testing. 
 
Transmission of HCV through contact with infected blood can occur by injections with 
contaminated equipment such as sharing of contaminated needles and syringes, contaminated 
blood transfusions, and perinatal transmission (being born to a hepatitis C-infected mother). The 
improvements in donor and blood screening techniques since 1990 have decreased the risk of 
HCV infection from blood transfusion, which was the main source of infection in the 1980s (26). 
 
HCV can also be transmitted in a less common and efficient manner through sex with an infected 
person, and through use of items with infected blood (27). The most common transmission 
remains through contaminated needles and syringes among drug users in Europe and North 
America (28). This often leads to HCV/HIV co-infection and many of these drug users including 
individuals who have in the past undergone blood transfusion with infected blood remain 
unaware of their infection status.  
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Figure 1.1: Geographic prevalence of HCV infection worldwide. 
Data from Centers for Disease Control and Prevention, 2012, Available at:  
http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-
travel/hepatitis-c.htm 
 
HCV transmission can also occur by tattooing, piercings and through intranasal drug use (29, 30). 
Thus screening for HCV is very important and available commercial assays can detect HCV 
RNA as early as two weeks after exposure to HCV, while anti-HCV antibodies can be detected 
eight to twelve weeks after exposure (31). 
 
1.1.4 HCV quasispecies 
As a result of its high spontaneous mutation rate, the virus exhibits genetic diversity and 
circulates in the plasma not as a single strain but as a population of closely related variants 
termed quasispecies as already stated. HCV is classified into six major genotypes with numerous 
subtypes based on the sequence heterogeneity of the HCV RNA. Of these genotypes, genotype 1 
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is found worldwide. Its subtypes, 1a and 1b, account for circa 60% of infections worldwide. On 
the other hand, genotype 2 is less common and is mainly found in Europe, Far East and West 
Africa. Genotype 3 is mainly prevalent in the Indian subcontinent and Southeast Asia, genotype 
4  in Africa  and  the  Middle  East, genotype 5 in South Africa and genotype 6 in Southeast 
Asian regions (Figure 1.2) (32). 
 
Figure 1.2:  Worldwide geographic distribution of HCV genotypes. 
Data from World Health Organisation, 2009, Available at:  
http://www.who.int/vaccine_research/documents/ViralCancer7.pdf 
 
 
These genotypes, which are further divided into subtypes, differ in their nucleotide sequences by 
30-35% and some have been linked to disease severity (33). The major nucleotide variability has 
been observed in the E1 and E2 regions whereas the core and non-structural regions remain more 
conserved.  
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This quasispecies diversity contributes to the chronic infection and immune escape associated 
with the virus. Additionally, HCV genotypes can help in the prediction of the possible outcome 
of antiviral therapy.  Genotype 1 is often associated with a poorer response to antiviral treatment 
compared to genotypes 2 and 3, while genotype 4, which is prominent in North Africa and the 
Middle East, has been shown to respond to treatment at an intermediate level compared to the 
other genotypes (34). 
 
1.1.5 Immune Response 
HCV infection triggers the host immune system by activating the innate immune response, which 
together with the acquired immune response, play an important role in determining the outcome 
of HCV infection. During the HCV incubation phase of several weeks, which varies between 
individuals, viraemia levels expressed as RNA copies/mL or IU/ml rise reaching a peak (Figure 
1.3). Maximum viraemia levels precede liver enzyme elevation such as that of alanine 
aminotransferase (ALT), which is released in the bloodstream as a result of liver injury. As 
viraemia levels decline and become steady, ALT levels reach 500-2000 international units per 
litre (IU/l) (Figure 1.3). At this stage, some individuals are able to clear the virus accounting for 
about 15% to 50% of cases, while 65% to 80% of patients with acute HCV infection develop 
chronic hepatitis C (CHC), some of whom will exhibit persistently normal ALT levels (PNALT) 
(35, 36). 
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Figure 1.3: Schematic depiction of the temporal relationship between viral and biochemical 
markers in acute and chronic HCV infection. 
A: Acute HCV infection followed by clinical recovery. 
B: HCV infection evolving to chronic stage. Anti-HCV antibodies appear two months after 
exposure. ALT levels reach a peak in the first two months and coincide with a decline of 2-3 logs 
in HCV RNA levels in acute infection leading to recovery. In contrast, serum HCV RNA levels 
remain high whilst ALT levels drop but remain elevated during the chronic phase of hepatitis. 
Adapted from Rehermann 2005 (37). 
 
The complicated relationship between the host and the virus in humans during HCV infection 
remains a difficult puzzle due to the various complicated virological and immunological 
characteristics. As seen in previous studies, patients with the highest viral titre were able to 
spontaneously clear the virus while patients with the lowest virus titre became chronically 
infected (38). This suggested that high viral titres can induce a stronger and more efficient 
immune response as the virus is more visible to the immune system contrary to low titres, which 
may result in low serum ALT activity and no detectable T cell responses.   
 
The ability to fight the infection, and in some cases the clearance of the virus, has been 
associated with a strong and multispecific T cell response,  (involving both CD4+ and CD8+  
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lymphocytes), whilst in chronic infections these responses are weak and of narrow repertoire 
(39). Total clearance of HCV has not only been associated with the strength and pattern of HCV-
specific CD4 cell responses but also with a shorter incubation period, absence of HIV co-
infection and ethnic origin of the patient (38, 40, 41). Additionally, previous studies indicated 
that host genetic differences such as polymorphisms in MHC class II loci and in some cytokine 
genes have an effect on the outcome of HCV infection (42, 43). 
 
HCV infection results in the initial activation of natural killer (NK) cells and processing of viral 
antigens by immature dendritic cells (iDCs), which after maturation (mDCs) activate CD4+ and 
NK T cells (Figure 1.4) (44). CD4+ cells secrete cytokines such as IFN-γ that increase antibody 
production by B cells, and prime and induce cytotoxic T lymphocytes (CTLs). Viral protein 
fragments (peptides) presented on the surface of host cells in association with class I human 
leukocyte antigens (HLA) are recognised by CTLs specific for that antigen. CTLs can then 
recognise and lyse the infected cells (Figure 1.4A). This mechanism allows the immune response 
to control HCV replication but unfortunately in some cases the production of ineffective or 
inappropriate cytokines fail to control HCV replication, leading instead to increased 
inflammatory activity in the liver due to accumulation of infiltrating lymphocytes, and 
hepatocyte damage (Figure 1.4B) (44).  
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Figure 1.4: Immune responses to HCV infection. 
A: Actions of the innate and acquired immune system to inhibit viral replication. B: Inability of 
the immune response to clear HCV infection leads to cell death due to accumulation of 
inflammatory cells. Persistent damage may lead to fibrosis. Adapted from Koziel 2005 (44). 
 
Antibody production against HCV, in particular against HCV core protein, is highly T cell 
dependent (45). Previous experiments indicated that a poor response in the generation of T-cells, 
CD4+ and CD8+, can result in the progression and persistence of HCV infection. On the other 
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hand, an early T cell response results in a rapid decrease in viraemia (38).  However, if viraemia 
is established, antiviral therapy is needed to decrease the level of viraemia and support directly 
and indirectly the immune response (39). Unfortunately, the cellular immune response induces 
liver injury by promoting inflammation and/or by causing direct osmotic lysis, or cytolysis of 
infected cells (44).  
 
 
Many other factors such as virus mutations, inefficient binding of antigen and the genetic 
characteristics of HLA alleles are involved in the outcome of the infection (46-48). Class I and 
Class II HLA play a key role in the T cell response by presenting HCV epitopes to CD8+ 
cytotoxic T cells and CD4+ helper T cells respectively (49). Thus, polymorphisms in binding 
regions of HLA molecules determine antigenic specificities and the strength of the immune 
response to HCV infection. In fact, previous studies indicated that several HLA alleles, which 
are extremely variable in the human population, have been shown to influence the outcome of 
chronic HCV infections (50).  
 
HLA class I alleles A03, B27, and Cw01 occurred more frequently in persons with viral 
clearance compared with chronically infected patients. The strongest association between any 
HLA allele and viral clearance has been observed for HLA-B27, which has been associated with 
spontaneous HCV clearance (51). HLA-B57 has also been found significantly more often in 
individuals with HCV clearance compared to chronically infected patients (52, 53). Cytokine 
polymorphisms have also been studied in HCV infection. Interleukin 10 (IL10) polymorphisms 
have been implicated with successful anti-HCV therapy and natural viral clearance. For example, 
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variants of IL10 and IL19/IL20 genes have been shown to be involved in natural clearance of 
HCV in the African-American population (54). 
 
Host factors also play an important role in HCV replication. In fact, infection with single-
stranded HCV RNA leads to the production of type I IFN by hepatocytes due to the activation of 
specific cell signalling pathways that promote a strong antiviral response through the expression 
of target genes (discussed in detail in section 1.4) (55). 
 
1.1.6 Therapy 
1.1.6.1 Vaccines 
Different issues have arisen in developing an effective HCV vaccine due to the different 
problems associated with the virus.  HCV is difficult to replicate in vitro and the chimpanzee is 
the only fully immunocompetent model. It has high genetic diversity with circa 30% of 
nucleotide divergence between genotypes and effective immune escape strategies including  the 
ability to infect naïve cells not only by cell-free virus infection but also through direct cell-cell 
contact in a CD81-independent way avoiding thus neutralising antibodies (Nabs) (56). 
Additionally, patients with chronic HCV infection produce about 1012 HCV particles per day and 
each one may contain a genome which is slightly different resulting in a population of closely 
related, yet heterogeneous, sequences within an individual due to the lack of proofreading 
capacity of its RNA polymerase that results in one mistake for every 10000 nucleotides (57). For 
all these reasons and other issues, including glycosylation site modifications and conformational 
changes in HCV glycoproteins, the development of prophylactic and therapeutic vaccines against 
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HCV, essential to prevent acute or chronic infection, remains difficult with many scientific and 
bioethical challenges (58, 59).  
1.1.6.1.1 Prophylactic vaccines 
Prophylactic vaccines have as a goal to prevent disease and have been designed either to induce 
T-cell responses or neutralising antibodies by targeting viral envelope glycoproteins. The current 
approaches to develop an HCV vaccine involve the use of recombinant proteins, plasmid DNA, 
and vector-based vaccines (60, 61). An example of prophylactic vaccines that has been shown to 
be safe and able to induce lymphocyte proliferation is the recombinant HCV envelope proteins 
E1E2 adjuvanted with MF59. This vaccine has been shown to reduce the rate of chronicity, 
however, it has not been successful in preventing infection or clearing the virus (62, 63).  
 
In recent clinical trials, recombinant viral vector vaccine alone or in combination with DNA or 
subunit vaccine has shown encouraging results (61), and as neutralising antibodies appear to 
correlate with HCV clearance (64), vaccine development has focused also on the induction of 
neutralising antibodies. Additional HCV vaccine approaches experimented in an animal model 
include the use of HCV virus-like particles to induce cross-neutralising antibodies (65). At the 
present time envelope glycoprotein-based and T cell-based vaccines are the most promising 
vaccines to boost the humoral response and T-cell immunity. However, due to the phenotype and 
complexity of T lymphocyte populations and the difficulties described earlier such as the 
heterogeneity of HCV, no licensed vaccine for HCV currently exists and therapeutic vaccine 
strategies have also been pursued to improve treatment outcome. 
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1.1.6.1.2 Therapeutic vaccines 
Therapeutic vaccine development is focussed in a similar way to prophylactic vaccines in 
enhancing T-cell-based immunity to control viral infection due to the high levels of neutralising 
antibodies and poor HCV-specific T-cell responses in HCV chronically infected patients (60). 
These vaccines unlike prophylactic vaccines have been tested in HCV infected patients or 
healthy volunteers and developed using different strategies such as heat-inactivated antigens 
from HCV-infected donors, DNA vaccines and peptide vaccines (66). Examples of therapeutic 
vaccines include the modified vaccinia Ankara vector expressing the HCV NS3, NS4a, NS5a 
and NS5b genes to boost CD4+ T helper and CD8+ cytolytic T cells, which has been shown to 
reduce viral load in phase I clinical trial, and the recombinant viral proteins (core or E1) 
adjuvanted with an adjuvant termed ISCOMATRIX that has been shown to induce T-cell 
responses and antibody production (65, 66). The use of therapeutic vaccines has been shown to 
stimulate HCV-specific immune responses and reduce viral titres but not to clear HCV infections. 
Additionally, the development of antiviral treatments has reduced the need for therapeutic 
vaccines (60, 66). 
1.1.6.2 Treatments 
 
The main treatment for HCV consists of pegylated (Peg)-IFNα, which consists of recombinant 
IFN covalently attached to Peg, in combination with the antiviral nucleoside analogue Ribavirin 
(RBV) (67). The duration of the treatment varies depending on the genotype of the virus, the 
severity of the liver disease and on other factors associated with the illness. 
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Peg-IFNα has a longer biological half-life than standard IFN-α and better pharmacokinetics. 
Additionally, Peg-IFNα has the ability to promote an intracellular antiviral state by stimulating 
interferon-stimulated genes (ISGs), which express antiviral proteins (68), while IFNs induce 
their synthesis by activating the Jak-STAT pathways (discussed in detail in section 1.4). 
 
The antiviral drug RBV used in combination with Peg-IFN, is a synthetic guanosine analogue, 
which is converted to the mono-di- and triphosphate forms within cells. In the triphosphate form, 
RBV has a direct effect on HCV replication and exerts many antiviral mechanisms to impede 
HCV RNA translation and replication. It has the ability to inhibit a host enzyme involved in the 
de novo synthesis of guanine nucleotides termed inosine monophosphate dehydrogenase 
(IMPDH), to induce mutagenesis by introducing a specific nucleotide into the viral RNA by the 
RNA- dependent RNA polymerase,  to promote early chain termination of viral RNA, and to 
cause a shift from a T-helper cell (Th) 2 response in favour of a Th1 immune response, 
increasing thus the production of cytokines such as IFN-γ, IL-2 and IL-3 (69, 70).  
 
The use of RBV alone without Peg-IFNα resulted in a small reduction in HCV viraemia 
compared to IFN-α (71). The use of both antiviral agents, Peg-IFNα and RBV, has proved to be 
more effective with almost double the response rate than that with IFNα monotherapy (72). 
Unfortunately, IFN therapies are associated with severe side effects, high cost, neuropsychiatric 
symptoms and in some cases failure especially with particular HCV genotypes such as genotype 
1, which is one of the most resistant to Peg-IFN-α and RBV treatment (73). Additionally, 
quasispecies can be a problem as drug resistant variants might become dominant. 
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Up to one-third of treated patients relapse after the end-of-treatment. The liver disease progresses 
to cirrhosis or HCC and the only available treatment before liver failure is liver transplantation.  
However, recurrent HCV infection occurs in liver-transplant recipients. Thus a more effective 
treatment for chronically infected patients is needed to prevent the need for liver transplantation. 
Hope in this respect has been forthcoming with the licensing of direct acting antivirals, such as 
the protease inhibitors telaprevir and boceprevir. In combination with the standard of care (Peg-
IFNα and RBV), they have been shown to be more effective at achieving a sustained virologic 
response (70-80%), even in difficult to treat patients with genotype 1 infection (74, 75). 
1.2 HCV genome 
1.2.1 Genome structure and organisation 
Similar to the viruses of the Flaviviridae family, HCV has a positive-sense single-stranded RNA 
genome, which is approximately 9.6 kb in length. The RNA is protected by the viral capsid 
protein, which is surrounded by the envelope, a lipid membrane into which are inserted the 
envelope proteins of the virus. The viral genome consists of a large open reading frame (ORF), 
which depending on the HCV genotype contains between 9024 to 9111 nucleotides (nt), that 
encode a single large polyprotein of circa 3000 amino acid residues; NH2-p22(C)-gp35(E1)-
gp7O(E2)-p21(NS2)-p70(NS3)-p4(NS4A)-p27(NS4B)-p2(NS5C)-p58/p56(NS5A)-p66(NS5B)-
COOH (76, 77). Structural genes are located at the 5’end of the viral genome followed by non-
structural genes on the 3’end (Figure 1.5B).  
 
The ORF is flanked by highly conserved untranslated regions (UTR) present at the 5’ and 3’ 
termini (Figure 1.5A) (76). The 5’end UTR, which is 341 nt in length, contains an internal 
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ribosome entry site (IRES) while the 3’end UTR contains a highly conserved pyrimidine-rich 
sequence, a polyU/UC tract of 80 nucleotides and an invariant 98 nucleotide long X-tail region 
(78, 79). The latter forms three stable and highly conserved stem-loop structures which are 
critical for replication. 
 
The large polyprotein encoded by the ORF is post-translationally processed by cellular signal 
peptidases and two viral proteinases. Post-translation modifications result in the generation of 
three structural proteins, six non-structural proteins (NS) and the proteins termed p7 and F 
(Figure 1.5C) (80). 
1.2.2 Untranslated regions 
The two UTRs located at the 5’ and 3’end of the HCV RNA genome play an important role in 
HCV translation and replication respectively. The 5 ’UTR is a highly conserved region of 341 
nucleotides that folds into a four-domain structure. The  IRES is composed of three of these 
structures (II-IV) and is involved in the recruitment of the ribosomal complex for cap-
independent translation of the ORF (discussed in detail in section 1.6) (81).  
 
The polypyrimidine tract of the 3’ UTR, which varies in length based on the virus genotype, 
consists of a poly(U) stretch and a C(U)n-repeat region while the X region consists of three stem-
loops (figure 1.6). It has a role in the regulation of viral translation and a similar function as 
poly(A) sequences in mRNAs of other RNA viruses (82).  
Both regions, the X region and poly (U/UC) stretch, have been shown to be involved in the 
replication, translation and packaging of HCV RNA (83, 84). Previous studies indicated that 
deletion of the X-tail and/or segments of the 3’ UTR inhibited the ability of viral RNA to 
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replicate in chimpanzees (85, 86). These results and recent experiments confirmed the essential 
requirement of the 3’ UTR, in particular the X-tail and poly(U/UC) tract, for viral replication 
(87). It has also been reported that the 3’ UTR interacts with cellular factors such as the 
polypyrimidine tract-binding protein (PTB), La autoantigen (La), heterogeneous nuclear 
ribonucleoprotein C (hnRNPC) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(discussed in detail in section 1.6.3) (88). 
 
Figure 1.5: HCV genome organisation, polyprotein processing and protein functions. 
A: HCV RNA genome containing a single ORF flanked by the two UTRs, the 5’ UTR 
containing the IRES and the 3’ UTR. B: Viral polyprotein. Arrows refer to cleavage sites by host 
signal peptidases (Blue arrows) and by the viral NS2–3 (red arrow) and NS3–4A proteases 
(Black arrows). C: Functions of the viral proteins. 
Figure adapted from Rehermann 2009 (80). 
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Figure 1.6: Predicted model of the HCV 3’ UTR secondary structure. 
The entire 3’ UTR of HCV RNA with a ΔG value of -34.9 kcal/mol consists of three stem-loop 
structures indicated as SL1, SL2, and SL3 a variable region, a poly U/polypyrimidine tract and 
the X region. Figure adapted from Ito 1997 (89). 
 
1.2.3 Structural proteins 
The HCV structural proteins, which are essential in forming viral particles, are the core protein 
and the two envelope glycoproteins (E1 and E2). The 191-residue precursor (23 kDa) of core 
proteinis processed to the predominant form of 21 kDa which has the essential role to form the 
viral nucleocapsid (78), while the envelope glycoproteins E1 and E2 interact with each other 
forming E1-E2 complexes, which are retained in the ER where HCV particles acquire their 
envelope (90). Another “structural” protein termed F is expressed by a translational ribosomal 
frameshift in the core gene in subtypes 1a and 1b, but it has not as yet been assigned a function. 
Additionally, this protein does not appear to be essential for viral RNA replication (91). 
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1.2.3.1 Core  
The core protein is the building block of the HCV nucleocapsid and the most conserved 
structural protein. Its detection by serologic assays is indicative of ongoing infection. The core 
protein consists of three domains. The 191-residue precursor of 23 kDa is processed to yield the 
predominant form of 21 kDa, which consists of a highly basic N-terminal domain named domain 
one (D1), a hydrophobic C-terminus domain termed domain two (D2) and a third domain (D3) 
containing a hydrophobic region that acts as a signal sequence for HCV envelope glycoprotein 
E1 (78, 92, 93).  
 
Post-translational modification of the core protein occurs via the ubiquitin-proteasome pathway, 
which regulates different cell functions and is the major system for protein degradation in 
eukaryotic cells (78). One of the ubiquitin ligases termed E6AP, a prototype of a family of 
ubiquitin ligases called HECT domain ubiquitin ligases, can bind to the core protein and enhance 
its ubiquitinylation and degradation (78, 94). In vitro studies indicated that the expression of 
E6AP decreased intracellular core protein levels while the knockdown of E6AP expression by a 
small interfering RNA (siRNA) increased HCV core protein levels leading to an increment of 
supernatant HCV infectivity titres (94). 
 
Core protein D1, which contains many positively charged amino acids, is involved in RNA 
binding and includes immunodominant antigenic sites, protein binding sites that can be displayed 
on the surface of the infected cell (95, 96). The hydrophobic D2 mediates interactions with lipids 
and membrane proteins. D3 interacts with the envelope glycoprotein E1 forming a hetero-
dimeric complex and it is involved in intracellular lipid accumulation (78, 92, 93). Recent studies 
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demonstrated that cells expressing HCV core protein exhibit an accumulation of lipid droplets 
(92, 97) and that the expression of D3 alone is sufficient for intracellular lipid containing droplet 
accumulation (98).  
 
Experimental evidence indicated that the core protein has multifunctional properties, different 
roles in HCV replication and possesses nucleic acid chaperone activity (92, 99). The core is also 
involved in pathogenesis as it can influence the functions of the tumour-suppressor 
transcriptional activator genes of the p53 family such as p53, p63 and p73 (100). In fact, the core 
possesses  different regulatory functions and can play an important role in cell transformation, 
apoptosis, and lipid metabolism (78). Reports also suggested the possibility of the core protein 
being involved in the activation or repression of the NF-kB pathway, which is involved in cell 
proliferation and the expression of many target genes implicated in the host immune response 
(101) (discussed in detail in section 1.4), and to interact with the 5’ and 3’ UTRs to inhibit IRES 
function and mediate genome dimerisation (discussed in detail in section 1.6) (102). The 
activation of NF-kB has been seen in other viruses including HIV and influenza virus as a 
mechanism to promote viral replication and prevent virus-induced apoptosis (55). NF-κB 
regulates cell survival in many viral infections and NF-kB activation by HCV core protein has 
been shown to result in an anti-apoptotic activity, a possible strategy to evade the host defence 
mechanisms that limit replication by killing infected cells. Additionally, this antiapoptotic 
response may lead to viral persistence and possibly to hepatocarcinogenesis in HCV-infected 
cells (55, 103, 104). 
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On the other hand, the suppression of NF-kB activation by HCV core protein via binding and 
inhibition of the IKKβ kinase activity have been shown to down-regulate the expression of an 
important inflammatory protein termed Cyclooxygenase-2 (COX-2) in antigen-presenting cells. 
Additionally, the suppression of COX-2 expression reduces the antiviral actions of prostanoids, 
molecules with anti-inflammatory and anti-viral activity with the ability to inhibit NF-κB-
mediated transcriptional activation. Thus, the regulation of NF-kB may be a mechanism of the 
virus to modulate immunnoregulatory molecules and evade the host defence mechanisms during 
HCV infection (101, 105, 106).  
1.2.3.2 F protein 
In the core region, the presence of an ORF that overlaps with the core coding sequences allows a 
-2/+1 frameshift of the ribosome in the N-terminal core-encoding region between codons nine 
and eleven. In this region, an A-rich sequence and an RNA pseudoknot at the 5’end of the core 
coding region make this programmed ribosomal frameshift possible, leading to the translation of 
a viral protein of 17 kDa termed frameshift (F) or alternate reading frame protein (ARFP) which 
associates with endoplasmic reticulum (ER) membranes in a similar way to the core and NS5A 
proteins suggesting that the F protein might be a component of the HCV replication complex (93, 
107, 108).  
 
The characteristic ribosomal frameshifting for gene expression has been seen in different 
families of RNA viruses including retroviruses, coronaviruses and astroviruses (91). The 
existence of initiation sites in the same frame has also been documented in vitro in 
encephalomyocarditis virus (EMCV), foot and mouth disease virus (FMDV), hepatitis A virus 
and Theiler's murine encephalomyelitis virus (TMEV) where the expressed ARFP had anti-
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apoptotic activity (109). Other examples include Influenza virus PB1 mRNA, which uses an 
alternative reading frame to produce PB1-F2 protein, the frameshifting between gag and pol 
genes in avian leukosis virus (ALV) and in morbilliviruses where the frameshift that produces 
the V protein has been shown to interact with interferon signalling (110).  
 
Thus, based on the examples of other viruses, the F protein might not play a role in viral 
replication but in host defence mechanisms. In fact, the protein is not involved in HCV RNA 
replication as the replication of the virus genome is not impaired when the F protein is not 
expressed (107) and ARFP expression is inversely linked to the level of viral replication as HCV 
core protein can suppress ARFP translation (109). On the other hand, HCV F protein has 
recently been shown to promote the development of chronic hepatitis by being involved in the 
inhibition of p21 and in disturbing the balance of cytokine secretion (111, 112).  
1.2.3.3 E1 and E2 
The HCV envelope consists of a lipid bilayer that contains the envelope proteins E1 (30 kDa) 
and E2 (70 kDa), which are type I transmembrane (TM) glycoproteins involved in host-cell entry 
and membrane fusion. They also participate in the assembly of the infectious particles (90).  
 
Previous studies indicated that E2 initiates viral attachment while E1 is believed to be involved 
in intra-cytoplasmic virus membrane fusion (113). The envelope glycoprotein E2 acts as the 
receptor binding protein and interacts with E1, which serves as the fusogenic subunit, to form 
oligomers. The E1-E2 complexes are retained in the ER where virus particles acquire their 
envelopes (90). The C-terminal domain of E1 and E2 consists of hairpin structures that cross the 
membrane twice. Moreover, cleavage by signal peptidases in the ER changes the orientation of 
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the C-terminal transmembrane domains (TMD) from luminal to cytosolic (114). This event leads 
to the orientation of the E1 and E2 C-terminus towards the cytosol.   
 
An ER chaperon protein termed Calnexin, which is involved in disulphide bond formation, 
associates with E1 and E2 for the complex process of glycoprotein maturation and folding (115). 
Studies with the use of retroviral particles with functional  HCV E1 and E2  indicated that 
hepatocytes are the major targets of infection in vitro, targeting low density lipoprotein receptor  
(LDLr) candidates and CD81, and that anti-E2 monoclonal antibodies and sera of HCV-infected 
patients  can neutralise  HCV pseudoparticles (116).  
 
A 27 amino acid long region located at the N-terminus of the E2 glycoprotein is targeted by anti-
HCV neutralising antibodies. This region termed hypervariable region 1 (HVR1) is the most 
variable region of the HCV genome (117). Another hypervariable region, HVR2, has been 
detected in E2 of HCV genotype 1 strains (118). Both regions, HVR1 and 2, contribute 
significally to the quasispecies nature of HCV. They can also regulate E2 receptor binding 
through intramolecular interactions (115). These regions have positively charged residues that 
can interact with negatively charged molecules located at the cell surface.  
1.2.4 Non-structural proteins 
NS proteins, located downstream from the structural protein E2, are essential components for the 
genomic replication of the virus. The first translated protein of the non-structural region is a 
small integral membrane protein termed p7, followed by a non-glycosylated transmembrane 
protein termed NS2, which is a cysteine autoprotease. The next NS protein to be processed is the 
NS3 serine protease, which also functions as an NTPase and a helicase (78, 119). The interaction 
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of NS2 with NS3 forms the NS2-3 cysteine proteinase, which results in the cleavage and release 
of the NS2 protein. The chymotrypsin-like serine protease domain residing in the N-terminal 180 
aa of NS3 requires for full activity NS4A as cofactor (119). The assembled NS3–4A protease 
generates the C terminus of NS3 and processes all downstream junctions in the polyprotein 
( NS3/4A, NS4A/B, NS4B/5A, and NS5A/B) (120).  
1.2.4.1 p7 
P7 is a small hydrophobic polypeptide (7 kDa) of 63 amino acids in length located between the 
E2 and NS2 genes. This protein has the capacity to form an ion channel that mediates cation 
passage across membranes (121). In fact, studies with recombinant p7 proteins demonstrated that 
the protein belongs to the viroporin family and forms ion channels in artificial lipid membranes 
(121, 122). This suggests that the protein transports ions from the ER into the cytoplasm as p7 is 
located mainly in ER membranes (123). 
 
Mutations on this cytoplasmic loop inhibited infectivity of transfected HCV cDNA in 
chimpanzees (122) suggesting that p7 is required for the production of infectious virions and not 
for HCV genome replication. In fact, P7 appears to promote virus particle production and to be 
essential for virus assembly and release in vitro (124). Similar results have been obtained with 
the p7 of BVDV (125).  
 
P7 has been extensively studied as a potential target for antiviral drug development. Recent 
studies indicated that overexpression of p7 in Huh7.5 cells induced apoptosis, a similar result 
seen in the viroporin protein termed M2 of influenza A virus (126). The inhibition of p7 by an 
antiviral drug termed Amantadine abrogated viral infectivity (123). This result suggested that p7 
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might be important in HCV replication. However, the use of subgenomic replicons indicated that 
p7 is not essential for genomic replication (123). 
1.2.4.2 NS2 
The first virally encoded protease needed for HCV polyprotein processing is the NS2 protein, 
which derives from the cleavage of the NS2/3 junction. NS2 is a non-glycosylated 
transmembrane protein of 21-23 kDa with hydrophobic N-terminal residues, which form 
transmembrane helices that insert into the membrane of the ER (78). The C-terminus has 
cysteine protease activity required for its cleavage from the HCV polyprotein. The formation of 
the NS2-3 cysteine proteinase complex catalyses the cis cleavage between NS2 and NS3 (85, 
127). After this event, NS3 is free to bind NS4A while NS2 loses its proteinase activity 
following degradation by the proteasome in a phosphorylation-dependent manner through the 
protein casein kinase II (CK2) (119, 128). 
 
Previous studies have shown that NS2 is not essential for viral RNA replication as the deletion of 
the protein did not disrupt RNA replication (78). However, NS2 has a role in the phosporylation 
of NS5A (p58) (129) and is essential for completion of the viral replication cycle as it has been 
shown to be important in virus assembly and release (130). Moreover, NS2 seems to play a role 
in regulating cellular genes (131). Additionally, NS2 and NS3 contain amino-terminus sequences 
that are characteristic for Zn2+-binding proteins, suggesting that both proteins are zinc-dependent 
metalloproteases (132).    
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1.2.4.3 NS3 & NS4A 
NS3 is a 70 kDa multifunctional protein essential for viral replication. The protein has two 
functional domains that act independently of each other. NS3 has a serine proteinase domain in 
its N-terminal end, whilst its C-terminal end functions as a helicase /NTPase (119, 133, 134).  
 
NS3 uses its C-terminal domain as an RNA helicase in order to unwind double-stranded nucleic 
acids (127). Adenosine triphosphate (ATP) triggers and coordinates the cyclic movement and 
unwinding of NS3, which behaves like a nucleic acid translocation motor (134). The C-terminal 
RNA helicase/NTPase allows translocation of NS3 along the nucleic acid substrate and unwinds 
RNA (135). On the other hand, the serine protease domain located at the N-terminal domain 
releases the NS3 in cis and produces the N-termini of NS4B, NS5A and NS5B in trans (136). 
 
NS3 requires the presence of NS4A in polyprotein processing. This protein of 8 kDa stabilises 
and activates NS3, acting as cofactor of NS3 (119). The binding and formation of the NS3-4A 
complex, controls the correct folding of the NS3 protease active site and it activates the 
proteinase to cleave at the NS3/4A, NS4A/B, NS4B/5A, and NS5A/B sites (78, 120).   
The NS3/4A protease has also been shown to counteract the host antiviral mechanisms by 
inhibiting type I interferon production and by disrupting signal pathways that lead to the 
activation of IRF3 (discussed in detail in section 1.4) (137).  
1.2.4.5 NS4B 
NS4B is a 27 kDa ER membrane-associated protein with  a major role in the formation and 
reorganisation of the ER membrane during viral replication (78), leading to the formation of a 
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membranous web. It is a multifunctional protein co-translationally associated with the ER, 
membrane lipid rafts and some HCV non-structural proteins (133).  
 
NS4B has the ability to oligomerise and to recruit other HCV non-structural proteins forming 
replication complexes where HCV-RNA replication takes place (discussed in detail in section 
1.3.3) (127, 138). Previous studies indicated NS4B as the only non-structural protein with the 
intrinsic ability to associate with lipid rafts. This association triggers the formation of vesicles, 
the “membranous web”, which contains the HCV replication complex and serves as a scaffold 
for HCV RNA replication (127, 138-140). 
 
The use of recombinant HCV NS4B constructs showed that NS4B localises to the ER. 
Additionally, NS4B is part of a multiprotein complex that seems to induce the 
hyperphosphorylation of NS5A, the formation of new ER-derived membrane structures, and is 
tightly coupled to the viral RNA polymerase NS5B during the HCV replication cycle (133, 141, 
142). In addition to the major role of NS4B to induce alteration of the ER membrane, NS4B 
possesses enzymatic activities that catalyse the synthesis of ATP and AMP from two ADP 
molecules and hydrolyse guanosine triphosphate (GTP) and ATP, and in addition interacts with 
cellular proteins (78, 143). 
1.2.4.6 NS5A 
NS5A is a 58 kDa phosphoprotein with three major domains and a zinc binding motif within the 
N-terminal domain, which has four cysteine residues (127). NS5A, first isolated in 1994, is an 
essential HCV protein that has many important roles such as modulating viral replication and 
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interacting with HCV non-structural proteins, host regulatory factors, microtubules and actin 
filaments (144, 145). It may also perturb the host immune response (146). 
 
HCV RNA replication requires the interaction of NS5A with the viral RdRp NS5B. In vitro 
studies on this interaction suggested the ability of NS5A to act as a positive modulator of HCV 
replication by interacting with NS5B (147, 148). NS5A modulates HCV RNA replication and 
co-localises with viral RNA in the ‘membranous web’, which is generated with the requirement 
of NS4B (149). This suggests that NS5A membrane association is required during HCV RNA 
replication.  
 
NS5A is recognised by a cellular vesicle membrane transport protein termed hVAP-33, the 
human homologue of the 33-kDa vesicle-associated membrane protein-associated protein. The C 
terminus of hVAP-33 binds to the N terminus of NS5A, only when it is in its 
hypophosphorylated form, while the hVAP-33 N terminus binds to the C terminus of NS5B. 
These interactions suggest a role for hVAP-33 in the formation of the HCV replication complex 
by binding to NS5A and NS5B, functioning as a docking site for the assembly of the replication 
complex (140).  
 
NS5A can also exert antiviral activity by interacting with the interferon-induced double-stranded 
RNA activated protein kinase R (PKR) (141, 148). Additionally, NS5A can also modulate the 
mitogen-activated protein kinase (MAPK) signalling pathway, which stimulates signalling 
molecules that activate regulatory molecules and initiate cell proliferation through the regulation 
of three classes of MAPK (149). 
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1.2.4.7 NS5B 
NS5B is a 68 kDa ER-membrane-associated protein with RdRp activity. It is the viral RdRp 
responsible for the synthesis of the complementary negative-strand RNA from the genomic 
template. NS5B is an integral membrane protein with the characteristic GDD motif in its 
catalytic site, which is required for RNA synthesis and genome replication (148).  
 
Protein Function 
Molecular weight 
(kDa) 
C 
Nucleocapsid assembly, binds 
to HCV RNA, genome 
encapsidation 
precursor: 23, 
mature: 21 
F Unknown 16-17 
E1 
Envelope glycoprotein, 
associates with E2 
33-35 
E2 
Envelope glycoprotein, receptor 
binding, associates with E1 
70-72 
p7 Calcium ion channel (viroporin) 7 
NS2 
Autoprotease, associates with 
NS3 
21-23 
NS3 
Component of NS2-3 and 
NS3/4A, Serine protease, 
NTPase/helicase domain. 
69 
NS4A Proteinase cofactor for NS3 6 
NS4B Membranous web induction 27 
NS5A 
Involved in the formation of 
replication complexes, RNA 
replication, manipulates host 
immune system 
basal form: 56, 
hyperphosphorylated 
form: 58 
NS5B 
RNA-dependent RNA 
polymerase 
68 
 
Table 1.1 Summary of the functions of the HCV proteins. 
Adapted and edited from Chevaliez 2006 (150). 
 
NS5B belongs to a class of membrane proteins termed tail-anchored proteins, which are 
membrane proteins targeted post-translationally via a carboxy-terminal insertion sequence (151). 
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Additionally, its structural conformation results in the formation of a hairpin loop structure into 
the active site of the protein that allows the positioning of the HCV 3’ UTR. This event initiates 
HCV RNA synthesis of the positive and negative RNA strands (152). NS5B is also involved in 
the formation of the membrane-associated replication complex (151). All these important 
functions of NS5B in viral replication make the protein a major target for the development of 
antiviral drugs. (152). Unfortunately, the poor fidelity rate of NS5B leads to the mutability of the 
HCV genome, which evolves rapidly and has extensive sequence diversity as NS5B is highly 
error prone, incorporating a wrong nucleotide at a rate of ca. 10-3 per generation (78, 153). 
 
1.3 HCV replication cycle 
1.3.1 Attachment and entry 
The HCV life cycle begins with the attachment of the virus particles to the target cells, usually 
hepatocytes, through the binding of HCV structural proteins to the target cell surface receptor 
molecules, which have been extensively studied. 
 
Different receptor molecules have been identified as candidate receptors that mediate the binding 
and internalisation of HCV. The discovered receptors are the human tetraspanin CD81, the 
scavenger receptor type B class I (SR-BI), claudin-1 (CLDN1) (154, 155) and LDLr (156). 
Previous studies suggested that HCV attachment requires also other cell surface molecules, 
which might be used in combination with these candidate protein receptors. In fact, it has been 
demonstrated that HCV can infect any cell as long as these receptors and other cell surface 
molecules are present (157, 158).   
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The first cell surface receptor to be considered as a potential receptor molecule involved in HCV 
entry was the human tetraspanin CD81, a widely expressed cell surface protein. In vitro studies 
indicated that CD81 functions as a post-attachment entry co-receptor and that the expression of 
only CD81 is not sufficient to allow viral entry (78, 159, 160). CD81 was shown to bind 
efficiently to E2 proteins from the HCV 1a genotype, but it weakly recognised E2 from genotype 
1b (154). These results clearly indicated that cellular factors other than CD81 could be required 
in the initial binding of HCV. In fact, a study of HCV binding to HepG2 cells, which do not 
express CD81, indicated that HCV was able to bind HepG2 by using SR-BI (154). SR-BI is a 
509 amino acid glycoprotein that belongs to the CD36 superfamily. SR-BI is highly expressed in 
hepatocytes and has been shown to bind to HCV E2 in viral isolates derived from genotypes 1a 
and 1b (154). Additionally, the use of an SR-BI ligand termed oxidised low-density lipoprotein 
(LDL), which binds to SR-BI, inhibited HCV entry in vitro (119). These studies indicated SR-BI 
as an essential component for HCV entry. However, the use of different antibodies against SR-BI 
did not inhibit completely the binding of HCV to the target cell, indicating that HCV binding to 
hepatocytes might require other cell surface receptors (119, 161). 
 
Another candidate receptor identified as an essential component for HCV entry was CLDN1, a 
co-receptor highly expressed in the liver where it forms the backbone of tight junctions through 
homo- and heterotypic interactions. Additionally, CLDN1 is a tight junction (TJ) protein that 
acts after the binding and interaction of HCV with the CD81 co-receptor during late stages in the 
entry process (162). 
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In addition to CLDN1 other co-receptors were suggested as putative HCV receptors. CD81 and 
SR-BI have been shown to be both required in HCV entry (155). However, cell lines that 
expressed CD81 and SR-BI were non-permissive for HCV pseudoparticle (HCVpp) infection 
suggesting that other cell surface molecules may be involved in HCV attachment (78). A recent 
study indicated that HCV infection does not require only cells that express SR-BI, CD81 and 
LDLr but additional liver specific co-factor(s) are necessary for HCV entry (155). Co-receptors 
such as glycosaminoglycans (GAG), heparan sulphate, epidermal growth factor receptor (EGFR), 
ephrin receptor A2 (EphA2) and cholesterol-uptake receptor Niemann-Pick C1-like 1 (NPC1L1) 
have been shown to be additional factors for HCV entry (163). 
 
It follows that HCV entry is a complex multistep process that requires different cellular entry 
factors, which are required for binding and travelling to tight junctions. HCV attachment to the 
host seems to adopt a natural route of cargo delivery into hepatocytes. Previous experiments 
indicated that HCV gets in contact with CLDN1 and another HCV entry factor termed human 
occludin (OCLN) (Figure 1.7). Additionally, these studies indicated that any cell can be infected 
with HCV as long as human CD81, SR-BI, claudin-1 and human occludin are present (157, 158). 
However, the binding of HCV can occur in the absence of CD81 receptor. In fact, a previous 
study has shown HCV binding to human promonocytic U937 cells and platelets where CD81 
was not expressed (164). 
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Figure 1.7: Model of hepatitis C virus entry. 
HCV virus particles associated with lipoproteins interact with co-receptor proteins located on the 
surface of hepatocytes. HCV enters via endocytosis and upon acidification the viral envelope 
fuses with the endosome membrane releasing the viral nucleocapsid into the cytoplasm. Figure 
adapted and edited from: http://www.sciencedaily.com/releases/2012/01/120124134429.htm 
 
HCV entry is also linked to the association of virus particles with lipids and very-low-density 
lipoproteins circulating in the bloodstream. Previous studies indicated that HCV circulates in 
patient sera in the form of triglyceride-rich particles and uses glycosaminoglycans and/or LDLr 
on host cells as initial attachment factors followed by HCV particle interaction with SR-BI and 
CD81 (165). This helps the re-localisation of the virus particle to the tight junction CLDN1 
protein (Figure 1.7) (162). However, cell entry of HCVpp suggests that HCV entry can be 
independent of lipoprotein association also as seen in cells not expressing CD81 (164, 165).  
 
These final steps lead to HCV entry which occurs via receptor mediated endocytosis and is pH 
dependent (119, 166). The acidification of the endosomal vesicles containing HCV virions 
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results in the fusion of the HCV envelope with the endosomal membrane and is followed by the 
disassembly of the viral nucleocapsid (155). The release of the HCV-RNA permits viral cap-
independent translation to take place (155). 
 
1.3.2 Translation and polyprotein processing 
After uncoating of the viral nucleocapsid and liberation of the viral genome in the cytosol, HCV 
RNA is translated at the rough ER. Translation initiation is controlled by the IRES, which 
modulates the cap-independent IRES-mediated process by initially recruiting cellular factors and 
ribosomal subunits (discussed in detail in section 1.6).  
 
Cap-independent translation begins with the binding of the 40S ribosomal subunit to the IRES. It 
follows the binding of the eukaryotic initiation factor 3 (eIF-3) to the IRES forming a complex, 
which joins with eukaryotic initiation factor 2 (eIF-2), the initiator transfer RNA (tRNA), GTP 
and other factors to form the 48S complex. The tRNA is positioned in the P site of the 40S 
subunit and base pairs with the start codon AUG of the mRNA (Figure 1.8) (78, 167).  
 
The hydrolysis of GTP allows eIF-2 to dissociate from the complex releasing the tRNA. On the 
other hand, the hydrolysis of GTP leads to the association and the binding of the 60S ribosomal 
subunit. This final event leads to the formation of a functional 80S ribosomal complex (Figure 
1.8). Subsequently, the initiation of HCV translation begins after the binding and activation of 
eIF2 and eukaryotic translation initiation factor 5B (eIF5B) (78, 119, 167). 
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Figure 1.8: Model of HCV IRES translation initiation. 
The HCV IRES binds to the 40S subunit and recruits eIF3 and a ternary complex forming the 
IRES-48S complex. GTP hydrolysis is followed by the binding of the 60S subunit to the IRES-
48S complex, leading to the formation of the IRES-80S complex.  
Figure adapted from Otto A. 2004 (167). 
 
Viral protein translation begins as PTB binds to the 5’ UTR and 3’ UTR on the X region 
(discussed in detail in section 1.6.3). This binding mediates the circularisation of HCV RNA 
further enhancing the translation initiation of viral RNA from the positive-sense RNA genome 
(79). Cap-independent translation results in the production of the aforementioned polyprotein 
(77).   
 
The translated polyprotein is subsequently co- and post-translationally processed by viral and 
cellular proteases. Structural proteins are processed at junctions between core/E1, E1/E2, E2/p7 
and p7/NS2 by cellular proteases such as the presenilin-type aspartic protease, which has 
protease activity within cellular membranes such as ER, or undergo conformational changes 
through several maturation steps (78, 119, 168). On the other end, non-structural proteins are 
processed by the viral proteases NS2 and NS3/4A as already mentioned. Initially, the NS2-3 
complex releases NS2 by cis-cleavage of NS2 from NS3. NS3 then assembles with its cofactor 
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NS4A and catalyses two different cleavage modes: the intramolecular cis-cleavage and the trans-
cleavage that takes place at all downstream junctions (77, 78, 119).  
 
1.3.3 RNA replication 
One of the most important steps in the HCV life cycle is RNA replication where non-structural 
proteins together with host proteins form membrane-associated RNA replication complexes (RCs) 
which contain most of the virus non-structural proteins and positive-strand RNA genome, a 
favourable condition for replication of viral RNA (169).  
 
HCV proteins and altered host intracellular membrane structures such as the ER, Golgi apparatus, 
endosomes and lysosomes organise into many RCs forming the membranous web, which 
consists of many small vesicles containing HCV non-structural proteins and host factors (Figure 
1.8). These RCs are lipid rafts derived from the ER or Golgi apparatus that form a lipid raft-
associated membrane complex (169). RCs protect and hide viral RNA from cellular nucleases 
and from host response proteins that could trigger the host antiviral response, providing thus a 
stable environment for HCV RNA synthesis (140). 
 
In the RCs the positive-strand RNA genome is used to synthesise a complementary negative-
strand RNA after the interaction of the RdRp subdomains with the HCV genome (170). This 
negative-strand RNA serves as a template to produce numerous positive-stranded genomes, 
which are used for polyprotein translation or packaging into new virus particles (Figure 1.9) 
(171). RNA synthesis requires the formation of a pseudoknot structure between domain I, 
located in the 5’ UTR that forms a G/C-rich stem loop, and the cis-acting replication element 
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termed 5BSL3.2, located at the 3’end of the viral genome (119). The pseudoknot structure 
triggered by the 3’ X region, the 5BSL3.2 and proteins of the replication complex initiate RNA 
replication in the RCs (88, 119).  
 
Previous studies indicated that the NS3-4A complex, NS4B, NS5A, and NS5B associate 
predominantly with ER membranes, interact with cellular host proteins and are essential in the 
formation of the lipid rafts, which are rich in cholesterol and sphingolipids (172). The association 
of the NS5A with lipid rafts through its binding to the C-terminal region of the human vesicle-
associated membrane protein-associated membrane protein (hVAP-A) has proved to be essential 
in the formation of RCs (140). Additionally, studies on RCs indicated that some RCs can 
associate with endoplasmic reticulum tubules and some are ER-independent and are transported 
by a microtubule (MT)-dependent transport (172). These results suggested that there are two 
populations of HCV RCs with distinct dynamic features and with possibly distinct functions as 
HCV RCs might be subject to intracellular transport processes that depend on the dynamic 
organisation of the ER and microtubule network (172).  
 
 Luca Mercuri 
61 
Imperial College London 
 
 
 
Figure 1.9: Schematic model of the HCV replication cycle. 
HCV binds to host cell receptors and gains entry by receptor-mediated endocytosis. Uncoating of 
the virus particle liberates the viral genome, which is translated at the rough ER (rER). HCV 
non-structural proteins induce the formation of a membranous web associated with rough ER 
small vesicles embedded in a membranous matrix (arrows in electron micrograph in the lower 
right), nucleus (N), rER and mitochondria (M). HCV genome replication takes place in the 
membranous web and newly produced virus particles containing S and NS-proteins assemble in 
association with the RNA genome. After virus assembly, virion particles are released. Adapted 
from Bartenschlager 2004 (171). 
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1.3.4 Viral assembly and release 
In the assembly of progeny viruses, the process called packaging is essential for a productive 
viral replication cycle. The incorporation of the intracellular viral genome into virus particles 
using a cis-acting RNA element present on the viral genome termed packaging signals (PSs) has 
been seen in positive-strand RNA viruses such as coronaviruses, retroviruses and flaviviruses. In 
these viruses, PSs have frequently been shown (but not always) to mediate the selective 
interaction between viral proteins, often nucleocapsid or envelope proteins, and viral RNA to 
drive the specific packaging of RNA into virus particles. Additionally, the location of PS varies 
among viruses but are often located on the terminal coding and/or noncoding regions of the 3' 
and 5' ends of the viral genome (173-176). 
 
In the case of HCV, different studies indicated the absence of cis-acting PS in the 5′ UTR and the 
core-NS2 region (177, 178). Thus, it is possible that the encapsidation of the viral genome occurs 
not on protein-RNA but on protein-protein interactions. However, a previous study indicated that 
the core protein  plays an important role in virus assembly as it can bind selectively to the 5’ 
UTR (179). In fact, the core’s domain  D1 binds to the viral RNA while domain D2 associates 
the core protein with host cellular membranes such as the ER and lipid droplets (LDs) (99). 
Additionally, core-RNA interaction switches RNA replication to packaging while core and 
E1/E2 interaction is thought to determine viral morphology (78, 119). Thus, in HCV the self-
assembling of the core protein and its interaction with the HCV genome switches RNA 
replication to packaging leading to viral nucleocapsid assembly (119, 180, 181).  
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Assembly of nucleocapsids occurs in the cytoplasm within intracellular vesicles consisting of 
LDs (180, 182). Previous studies reported the binding of HCV core to LDs, an event that takes 
place in the ER and favours the aggregation of LDs around the nucleus promoting thus the 
interaction between HCV RNA replication and virion assembly (180). However, other studies 
indicated that viral structural proteins can also associate with the Golgi apparatus (119). 
 
As the nucleocapsid buds from the lipid droplet surface or from the dilated ER lumen, where 
viral glycoproteins E1 and E2 are positioned, it acquires an envelope (180). It is possible that 
HCV utilises the viroporin p7 to prevent premature acid-induced inactivation of glycoproteins 
during transport of the virus through the secretory pathway. This could prevent the exposure of 
the mature virion to low pH that results in acidification of vesicles; thus p7 may behave in a 
similar way as the M2 protein of influenza virus (183, 184). 
 
The newly formed virus, of circa 60 nm in diameter, is then released from the cell through the 
secretory pathway or by being exported by very low density lipoproteins (VLDL),  which are 
produced and used by the liver to export triglycerides and cholesterol into plasma (92, 94, 185). 
Previous studies demonstrated the involvement of VLDL not only in the export of triglycerides 
and cholesterol but also in the secretion of virus particles (185). HCV particles bind or are 
incorporated into VLDL during their assembly, which initiates with the synthesis of 
apolipoprotein B (apoB) in the rough ER (Figure 1.10) (185, 186). This explains the association 
of HCV particles with the secreted form of VLDL and its components (apoB and apoA) detected 
in the plasma of infected patients (182).    
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Figure 1.10: Schematic representation of HCV assembly and secretion with VLDL. 
The formation of VLDL begins with the synthesis of apoB in the rough ER and terminates with 
the fusion of VLDL with lipid droplets, a fusion reaction mediated by the microsomal 
triglyceride protein (MTP) that generates nascent VLDL particles. HCV associates with VLDL 
particles containing ApoE and ApoB forming the VLDL-HCV complex, which is then secreted 
into the plasma through exocytosis. Adapted from Jin Ye 2007 (186). 
 
 
1.4 Host innate immune response to virus infection, NF-kB and IRF  
The activation of the innate immune response is critical for cells to recognise viruses and initiate 
a strong antiviral response. The innate immune response to virus infection is mediated by viral 
infection, in particular viral components such as single-, double-stranded RNA and DNA. Two 
major pathways are important in the early antiviral innate immune activation. These pathways 
are the nuclear factor-kappa B (NF-kB) and the interferon regulatory factor (IRF) transcription 
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factor pathway. Both signalling pathways activate IFN and inflammatory cytokines (Figure 1.10) 
(55). 
 
NF-kB is a transcriptional regulator that promotes the expression of a very large number of target 
genes encoding for chemokines, antigen presentation proteins and cytokines (55). Genes 
stimulated by NF-kB are involved in the host immune response, apoptosis, cell proliferation and 
inflammatory response.  The activation of the NF-kB signalling pathway can occur with the 
detection of generated dsRNA replicative intermediates during HCV replication, the protein-
protein interaction between HCV core protein with other factors, the death domain of the tumour 
necrosis factor receptor 1 (TNFR1), the cytoplasmic tail of the lymphotoxin receptor and in 
response to cytokines  such as TNF (55).  
 
NF-kB activation requires phosphorylation and ubiquitination of the inhibitory protein IkB by 
the two cytokine-inducible IkB kinases (IKK). This complex consists of the regulatory subunit 
NEMO and catalytic subunits IKKα and IKKβ (55, 187). The phosphorylation and/or 
modification of IkB followed by its degradation in the proteasome allow the NF-kB complex to 
translocate to the nucleus and induce transcription of the target genes (Figure 1.11) (188).  
Three classes of pattern-recognition receptors (PRRs) can detect viral components and activate 
intracellular signal cascades that lead to the expression of IFN-inducible genes, which encode for 
proteins that target viral components and induce cell death such as protein kinase R and 2’5’-
oligoadenylate synthase (189). Classes of PPRs are the Toll-like receptors (TLRs), nucleotide 
oligomerisation domain (NOD)-like receptors (NLRs) and retinoic acid-inducible gene I (RIG-I)-
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like receptors (RLRs). The induction of many type I IFNs and IFN-stimulated genes is also 
accomplished by members of the IRFs (190).  
 
HCV has developed different mechanisms to inhibit interferon production by blocking 
downstream signalling events. It is known that triggering of the IFN response limits HCV 
replication in hepatocytes (191). However, specific HCV structural proteins such as core and E2 
are able to inhibit production of cytokines by preventing signalling via TLR3 and the RIG-I 
pathway (187). The most immunosuppressive HCV protein is NS5A, which is able to regulate 
different host regulatory genes and together with E2 can inhibit IRF-1 activation by binding PKR 
(192). Additionally, recent studies demonstrated the ability of the viral serine protease NS3-4A 
to contribute to virus persistence and escape from the IFN response by inhibiting 
phosphorylation of IRF3 (Figure 1.11). This step inhibits the RIG-I signalling pathway as IRF3 
is an important transcriptional regulator of the IFN response (192).  
 
Another strategy evolved by HCV to evade the immune system is with targeting of Toll-IL-1 
receptor domain-containing adaptor inducing IFN-beta (TRIF). NS3-4A targets and mediates 
cleavage of TRIF. This event results in the reduction of TRIF and inhibition of the polyI:C 
(pIC)-activated signalling through the TLR3 pathway before its ramification to IRF-3 and NF-κB 
(Figure 1.11) (193). Another mechanism adopted by NS3-4A is to cleave a mitochondrial 
antiviral signalling protein (MAVS) also known as IPS-1, VISA, and CARDIF (Figure 1.11). 
Previous experiments indicated that NS3-4A cleaves MAVS at Cys-508. This event dislocates 
the N-terminal fragment of MAVS from the mitochondria and inhibits the induction of IFN-β 
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(Figure 1.11) (194). These mechanisms are remarkable examples of the ability of HCV to limit 
expression of multiple host defence genes. 
 
 
 
 
Figure 1.11: RNA virus recognition by RIG-I and TLR3 receptor. 
In the TLR3 dependent signalling pathway, detection of dsRNA by TLR3 recruits the TRIF 
adaptor that activates the IKKε and TBK1 kinases. Once activated, IKKε and TBK1 
phosphorylate IRF3 and IRF7 inducing IFN activation. Additionally, phosphorylation of IkBα by 
the IKKα/β NEMO complex releases the NF-kB DNA binding subunit, which can then activate 
cytokine production. In the RIG-I dependent signalling pathway, viral ribonucleoprotein 
complexes activate RIG-I through the C-terminal RNA helicase domain, which interacts with 
viral dsRNA and with CARD domains. CARD interacts with the MAVS/IPS/VISA/Cardif 
adaptor. The HCV NS3-4A can interact with TRIF and/or cleave the C-terminal domain of 
MAVS inhibiting IFN activation. Figure adapted from Hiscott et al 2006 (187). 
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1.5 Model systems to study HCV replication 
1.5.1 In Vivo models 
The chimpanzee has been the main immunocompetent animal model for HCV infection.   
For the  discovery of HCV in 1989, chimpanzees  proved invaluable in first demonstrating the 
existence of a transmissible agent and then for the collection of pooled  plasma for cloning 
attempts to take place (3).  Chimpanzees were also used in studies of intrahepatic injection with 
RNA transcripts obtained from HCV cDNA clones (86). However, they remain a non- 
conventional animal model as they are an endangered species. 
 
Another in vivo model is the monkeys of the genus Saguinus called tamarins, which have been 
used to study another flavivirus that replicates efficiently in tamarins, the GBV-B, which is 
phylogenetically related to human HCV (195). This virus was isolated from tamarins previously 
infected with serum from a human hepatitis patient (196, 197). Chimeric viruses, between GBV-
B and HCV (198), have been used to infect tamarins and study viral replication (199). However, 
in contrast with HCV, GBV-B causes protective immunity after resolution of the virus and does 
not cause chronic hepatitis in the animals, except in rare cases (9, 200).  
 
 Smaller animals such as transgenic mice have been used to study the replication of the virus. 
Mice with human/murine chimeric livers have been infected with HCV positive human serum. 
Results indicated that viral proteins were produced during the replication of the virus within the 
human portion of the mouse liver with viraemia detected up to 35 weeks post-infection (47, 201). 
Additionally, the virus produced was passaged and infected naïve transgenic mice. Scientists also 
produced a human hepatocyte-transplanted chimeric mouse with the transplantation of human 
 Luca Mercuri 
69 
Imperial College London 
hepatocytes into urokinase-type plasminogen activator transgenic/severe combined 
immunodeficiency mice (uPA+/+/SCID) (202). Unfortunately, these HCV infected chimeric mice 
were not able to spontaneously clear the virus as they lack a functional adaptive immune system. 
However, activation of the innate immune system of the hepatocyte occurred after infection 
(203). Nowadays mice remain a better option to the other in vivo model systems, which are 
commonly restricted by high costs, limited availability and ethical issues.  
1.5.2 In Vitro models 
Development of a reliable and efficient cell culture system to study HCV replication has been 
difficult. Scientists have been trying to develop immortalised human hepatoma cell lines as  
primary cultures have limited passage capacity. HCV infected primary hepatocytes from humans 
or chimpanzees have been shown to support low levels of HCV replication (204). Additionally, 
cDNA clones derived from HCV infected patients could infect chimpanzees but could not be 
cultured in vitro (86).   
 
The first breakthrough in in vitro models came in 1999 with the development of a subgenomic 
replicon system (205), which helped to identify permissive hepatoma cell lines able to support 
efficient HCV replication. The subgenomic replicon consists of the authentic HCV UTRs, a 
neomycin phosphotransferase gene (NEO), which is a selectable marker driven by the HCV 
IRES, the IRES from EMCV and the HCV non-structural proteins from NS3 to NS5B (Figure 
1.12) (205, 206). Due to the absence of structural proteins in the subgenomic replicons, virus  
assembly and budding do not occur during viral replication (207). Translation of the HCV non-
structural proteins is directed by the IRES of EMCV while the HCV IRES directs translation of 
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the NEO gene that confers resistance to the cytotoxic drug neomycin  sulphate (G418) (120, 205, 
208).  
 
 
 
Figure 1.12: Diagram of the HCV genome and subgenomic replicon. 
A: HCV genome regions that encode structural proteins (shown in dark blue) and non-structural 
proteins (shown in red). Arrows indicate cleavages mediated by the NS2–NS3 and the NS3 
proteases. B: Subgenomic replicon. The HCV 5' UTR is maintained while the region that 
encodes the structural proteins is replaced with NEO. EMCV IRES directs the synthesis of the 
non-structural proteins (shown in red). Adapted from Bartenschlager 2002 (209). 
 
Cells maintained under the use of a selective antibiotic that were able to support efficient 
subgenomic HCV replication were identified using the Huh-7 hepatoma cell line.  Clonal cell 
lines of Huh-7 such as Huh7.5 support HCV replication at a much higher level than Huh7 due to 
a mutation in RIG-I, an interferon-inducible cellular DExD/H box RNA helicase (210, 211). 
Mutational inactivation of RIG-I results in the non-expression of a cytoplasmic protein that 
recognises intracellular structured RNA and induces IRF-3 and NF-κΒ to produce type I 
interferons (210). Huh7.5 cells are considered the most permissive subline capable of supporting 
high level replication of HCV.  
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In 2002, the replicon system was improved with the generation of a full-length HCV genome 
replicon to study the full replication cycle of HCV in Huh7 cells. Unfortunately, viral particles 
were not produced possibly due to the lack in Huh7 of certain host cell factors essential for virus 
assembly (212). Then came the discovery and development of a full length HCV replicon 
isolated from a Japanese patient with fulminant hepatitis. This HCV strain termed JFH-1 was 
able to replicate in human hepatoma cell lines and to produce infectious virus particles (118, 
206). JFH-1 particles were infectious for chimeric mice, UpA-SCID, transplanted human 
hepatocytes and for chimpanzees. This virus strain allowed the study of the full replication cycle 
of the virus from cell entry to egress.  
 
In recent years, studies on HCV in vitro models led to the development of infectious HCVpp 
harbouring E1 and E2 glycoproteins. Pseudoparticles have helped in the study of HCV cell entry, 
identification of potential host receptors, host-range studies and antibody neutralisation attempts 
(116).  The production of HCVpp has been possible due to the ability of retrovirus particles to 
incorporate into their envelope foreign proteins as the particles bud from cell membranes. In a 
study, human embryo kidney cells termed 293T were transfected with three vectors encoding 
unmodified HCV glycoproteins E1 and E2, the retroviral core proteins and an MLV-derived 
genome encoding the green fluorescent protein (GFP) as a marker. The released virus particles 
collected from the culture medium were capable in infecting naïve hepatocytes (213). This 
system mimics the early steps of HCV infection and helped in the study of candidate receptors 
used by HCV envelope glycoproteins in viral entry. 
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Scientists have also been trying to propagate HCV in cells of non-hepatic origin. The first 
success was obtained in 2003 with the replication of a subgenomic replicon in HeLa cells (214). 
The ability of HCV to replicate in HeLa cells suggested that host factors required for the 
replication of the virus are not hepatocyte specific (215). A lymphotropic HCV strain isolated 
from an HCV-infected non-Hodgkin’s B-cell lymphoma was reported to infect B and T cells 
(216, 217) but with much lower virus titres than those of JFH-1 in Huh 7 cells. The results 
obtained from the infection studies of HCV in T cell lines (Molt-4 and Jurkat cells) indicated that 
the HCV polyprotein was efficiently processed as demonstrated with luciferase assays. However, 
replication of the virus was impaired possibly due to the lack of host factors in these 
lymphocytes (discussed in detail in section 1.6.5) (218).  
 
1.6 The Internal ribosome entry site 
1.6.1 IRES structure  
The 5’ UTR which consists of 341 nt and the first few nucleotides from the core encoding region 
are the most conserved regions of the HCV genome. This region includes the IRES that functions 
as a translation regulator of HCV genomic RNA. The IRES has extensive secondary structure 
formed by palindromic complementary sequences with several stem-loops and four structural 
domains (Figure 1.13) (219).  
 
RNA structure can be determined by difficult experimental methods such as X-ray 
crystallography, nuclear magnetic resonance (NMR) spectroscopy and cryoelectron microscopy 
or predicted by using computational approaches such as the phylogenetic comparative, the 
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thermodynamic energy minimization and the stochastic context-free grammar methods (SCFG) 
(220, 221). These computational methods can be divided in two major groups; the single 
sequence with use of thermodynamic and the comparative sequence analysis with the use of 
phylogenetic analyses. 
 
The single sequence analysis method is used to determine RNA secondary structure with the 
minimum free energy (MFE) when only one or a few RNA sequences are available using  
dynamic programming (DP) algorithms such as mfold (222) and RNAfold (223). The MFE 
method uses the Turner energy model (224) taking into account thermodynamics, particularly the 
thermodynamic hypothesis, which states that the conformation with the lowest free-energy is the 
native RNA structure (220). This method allows the generation of  pseudoknotted-free RNA 
structures as free energy of RNA loops in pseudoknots remains difficult to evaluate and requires 
other computational methods such as IPknot (225). 
 
The comparative sequence analysis does not rely on thermodynamic approaches but involves 
phylogenetic analysis to generate an alignment of many RNA sequences and computational 
methods such as the RNAalifold (226) and Pfold (227). The use of a set of homologous 
sequences, although not always feasible, allows a higher prediction accuracy than the single 
sequence analysis methods as it takes evolutionary information into consideration and can be 
used to apply covariance models, statistical representations of related RNAs based on pairwise 
covariations in multiple alignments (225, 228). Comparative sequence analysis has been useful 
in revealing RNA secondary structure from multiple RNA sequences of for example tRNA, 
RNaseP and snRNAs (229).  
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Figure 1.13: Sequence and secondary structure of the HCV IRES within the 5’ UTR. 
Nucleotide sequence (1-383) and secondary structure of the HCV IRES of genotype 1b (shown 
in grey) with the four structural domains (I to IV) and subdomains. The AUG translation 
initiation codon is located at position 342. Nucleotide numbers and positions refer to the HCV 
Con1 isolate (GenBank N. AJ238799). Adapted from Romero-Lopez 2012 (230). 
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The prediction of RNA secondary structures through comparative sequence analysis and 
thermodynamic modelling has been extensively used to predict RNA secondary structures in the 
genome of different virus families including the Hepadnaviridae (231), Picornaviridae (232) and 
Flaviviridae (233), where the secondary structure of the HCV genome has been predicted from 
the core- to the NS5B-encoding regions (234), including the 5’ and 3’ UTRs (235). 
 
RNA structures obtained from comparative sequence analysis can be validated experimentally 
using probing approaches, which involve the use of chemical reagents and/or nucleases. This 
type of analysis can also provide complementary results to the information obtained from X-ray 
crystallography and NMR methods, both of which have limitations on either the type or length of 
the RNA molecules that can be investigated (236, 237). 
 
In structure probing analysis, the treatment of RNA with organic molecules, RNase enzymes or 
metal ions result either in cleavage of the RNA or in formation of a covalent chemical adduct 
between the RNA and probe molecule (238). The chemical probes used to modify specific RNA 
bases at certain sites are base-specific probes, which react with unpaired nucleotides, the 
Watson-Crick face of the nucleobases, and sugar-phosphate backbone probes, which react with 
base-paired residues by cleaving the sugar-phosphate backbone (238). 
RNA modifications are then detected by transcribing the RNA and examining different lengths 
of cDNA fragments that terminate at the adduct or cleavage site. cDNAs can also be 
radioactively labelled and separated by gel electrophoresis alongside a sequencing ladder, 
otherwise RNAs can be end-labelled and separated by electrophoresis (239, 240). 
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Common chemical reagents used that form stable covalent adducts with one or more of the four 
RNA base groups are 3-ethoxy-a-ketobutyraldehyde (kethoxal), 1-cyclohexyl-3-(2-
morpholinoethyl) carbodiimide metho-p-toluene sulfonate (CMCT) and dimethyl sulfate (DMS) 
(238, 241), which has been used in previous experiments to determine structures of HCV IRES 
domains IIId and IIIe (242).  
 
Beside chemical reagents, enzymes that react with double-stranded regions or specific single-
stranded ribonucleotides have largely been used on their own or in combination with chemical 
probes (237). For example, the endoribonuclease RNase P has been used to cleave 5’-UTR 
IRES-containing regions near the AUG initiator triplet of HCV, BVDV, EMCV, CSFV and 
cricket paralysis virus (CrPV) in order to determine the presence of a tRNA-like structure in the 
IRES (243). Another example is the Escherichia coli RNase I, which has been used to develop 
structural models for RNA regulatory elements (244).  
 
The secondary structure of RNA has been also examined at single nucleotide resolution using a 
quantitative approach involving selective 2’-hydroxyl acylation analysed by primer extension 
(SHAPE) (245). This method involves acylation of the ribose in the sugar-phosphate backbone 
where it is flexible, in single-stranded rather than canonically base-paired regions (239).  
Acylation generates a bulky ester adduct that blocks the progress of RT. Thus, the reaction with 
functional groups in the RNA backbone allows RNA structural information at single nucleotide 
resolution, whether RNA is single- or double-stranded (238, 239, 241). cDNA products can then 
be quantified by labelling with fluorophores followed by capillary electrophoresis analysis, a 
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method termed high-throughput SHAPE, which has been used to reveal structures in HIV-1 
genomic RNA (239, 246).  
 
RNAs have also been probed with SHAPE reagents in a native acrylamide gel to separate and 
analyse conformers with differing electrophoretic mobilities. This method termed in-gel SHAPE, 
has allowed the probing and confirmation of the structure of HIV-1 monomeric and dimeric 
packaging signal RNAs (247). SHAPE has also been used to map the structure of biologically 
important RNAs such as tRNAAsp transcripts (248), to examine organisation of structural 
domains of FMDV IRES (249-251) and to develop a secondary structure model of an entire 
HIV-1 RNA genome (252). 
 
Hydroxyl radical probing (HRP) has also been used to modify and examine RNA structures. 
Hydroxyl radicals, which consist of an OH group with an unpaired electron (•OH) and are 
generated in solution from hydrogen peroxide or molecular oxygen using an Fe(II)–EDTA 
catalyst, cleave the RNA backbone by abstracting a hydrogen atom from the sugar-phosphate 
backbone with no sequence or secondary structure specificity (238, 253).  
 
RNA structures have also been modified without the use of any type of chemicals or reagents 
using a method termed in-line probing, which involves the incubation of RNA with and without 
a ligand to then examine any RNA structural changes in response to ligand binding (254). 
Additionally, nucleotide analogues tagged with a phosphorothioate have also been inserted into a 
unique site of the RNA during DNA templated in vitro transcription. In this technique termed 
nucleotide analogue interference mapping (NAIM) the phosphorothioate tag marks the site of 
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substitution and identifies sites at which the modification affects the structure or function of the 
RNA molecule (255).  
 
All the different chemical and enzymatic structural probing technologies have helped scientists 
to gain information regarding RNA structures in virus and other biologically important RNAs. 
For example, structural analysis by chemical probing has confirmed the presence of an internal 
loop on subdmain IIIb of the HCV IRES (256), identified IRES structural components of CSFV 
(257), determined RNA secondary structure model of the 5’ NC region of poliovirus type 3 (258), 
evaluated the susceptibility to alkylating reagents displayed by RNA hairpins of the HIV-1 
packaging signal and their complexes (240). Thus, RNA structure studies have helped to identify 
important RNA structures such as IRES domains and possible binding sites of host proteins.  
 
In the case of the HCV IRES which is recognised by ribosome initiation factors along with 
ribosomal subunits, their binding to IRES domains has been determined by chemical and 
enzymatic foot-printing studies (259) while the secondary structure of the HCV IRES, which 
resembles closely that of the recently isolated GBV-B, has been examined by various methods 
such as computer folding software and with the use of biochemical probing.  
In addition, IRES function has been examined by functional analysis of the IRES in vitro and in 
vivo in the context of expression vectors (260, 261). Research into the structure and function of 
the IRES revealed that its structure, which requires residues 40 through 372 with all stem-loop 
structures within this region, determines its function, i.e. the initiation of cap-independent 
translation of the viral polyprotein (76, 262). 
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1.6.2 IRES domains and their functional importance 
The HCV IRES consists of two major domains, domain II and III, which contain sequence 
elements essential for initiation of translation. Domain I contains the mir-122 recognition sites 
while domain IV contains the start codon AUG, residues 342-344, and part of the core coding 
region. Dicistronic reporter assays clearly mapped the HCV IRES region, which spans residues 
40 through 372 (81). Additionally, the position of these domains has proved to be essential for 
initiation of viral protein translation. 
1.6.2.1 Domain I 
Domain I consists of a hairpin structure in subdomain 1a, nucleotides 5 to 20, and a sub domain 
1b region from nucleotide 29 to 43. This region incorporates the two recognition binding sites of 
miR122 (discussed in detail in section 1.6.3) (263). The binding of the liver-specific human miR-
122 at these two sites has been shown to increase the production of infectious virions (264). 
Although the mechanisms by which miR-122 increase virus production remain unknown, in 
some studies domain I has been shown to be important for IRES function, whereas, in other 
studies, domain I has been shown not only to be dispensable but also inhibitory in translational 
experiments (260, 265). In fact, deletion of domain I enhanced HCV IRES mediated initiation 
(266). Additionally, domain I appears to be necessary in stabilizing the formation of the correct 
secondary structure of the IRES (262). 
1.6.2.2 Domain II 
Domain II consists of a less conserved region than domain III and is organised into two 
subdomains, IIa and IIb. At the base of sub domain IIa, there is a 90 degree bend, which is a 
conserved feature that might be essential in positioning domain IIb into the mRNA exit site on 
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the 40S subunit. Deletion of domain IIa has been shown to reduce HCV RNA translational 
activity five-fold as it blocks 80S formation. Similar results were obtained with the deletion of 
the entire domain II (81, 267, 268). 
 
It is domain IIb that interacts with the 40S ribosomal subunit forming the IRES-40S complex, 
where after eIF3 binding, the IRES recruits subunits eIF3a, eIF3b, eIF3d and eIF3f within a 
binary 40S–eIF3 complex (81, 261). The apical loop contains a polypyrimidine sequence, the 
binding site of protein p87. Previous studies have shown that the binding of the 40S ribosomal 
unit to subdomain IIb causes conformational changes in the 40S subunit (267).  
 
Domains II and III are the most important in IRES function as they are involved in the 
recruitment of different cellular factors involved in the regulation of HCV RNA translation such 
as La antigen and the heterogeneous nuclear ribonucleoprotein L (hnRNP L) (discussed in detail 
in section 1.6.3) (269) 
1.6.2.3 Domain III 
Domain III consists of five hairpin stem-loops (IIIa, b, c, d, e, f) with conserved regions, and 
contains the binding sites, at the apical loop segment, for protein p120, and at the stem loop 
segment, for protein p170. These proteins are subunits of eIF3, which consists also of protein 
subunits p110 and p116 (261). In fact, in previous experiments domain III was shown to be 
involved in eIF3 binding to the HCV IRES (270). Subdomains IIIc, d, e and f together with domain 
VI bind to the 40S ribosomal subunit while subdomains IIIa and IIIb offer a binding site for 
eIF3(259).  
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It has been shown that the deletion of IIIa and IIIb domains affected 40S binding and that mutations 
in subdomain IIIc reduced  40S binding up to 10-fold. On the other hand, mutations in subdomain 
IIIb reduced eIF3 binding, stopping the progression steps of the 40S-IRES complex (81, 259, 271). 
Subdomain IIId consists of a helical stem with non-canonical pairings and a hexanucleotide loop 
region, which is highly conserved in all HCV isolates (272). Mutations in this region, the guanine 
bases at position 266 to 268 on the hairpin loop (U264UGGGU269), have been shown to reduce 40S 
binding  affinity to the IRES (259, 271) and to cause structural reorganisation of the IRES that leads 
to the disruption of IRES translation initiation (273, 274). 
Subdomain IIIe and IIIf are involved in 40S binding and RNA translation activity. Subdomain IIIe 
is a direct contact point with the 40S subunit. This subdomain contains a G295, which comes in 
contact with the 40S major groove. Additionally, the hairpin loop located in subdomain IIIe 
containing the GAUA motif is also involved in 40S binding and previous experiments indicated that 
a U297A mutation reduced the binding affinity to the 40S subunit and RNA translation activity  
(242). The introduction of mutations and the disruption of the pseudoknot in subdomain IIIf  had no 
effect on 40S binding but stopped  IRES activity (81). This might suggest that the pseudoknot 
located in subdomain IIIf might help the positioning of the start codon AUG in domain IV in the 
ribosomal P site (81, 242).  
 
Thus Domain III has binding affinity with eIF3 through the IIIb stem-loop and the 40S ribosomal 
subunit with the three stem-loops located in subdomains IIIc, IIId, IIIe, and the pseudoknot  of 
subdomain IIIf. Additionally, studies on binding affinity of domain III revealed that this domain is 
the only domain of the IRES able to interact efficiently with all other domains (242).  
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1.6.2.4 Domain IV 
Domain IV, located downstream from domain III, contains the start codon AUG and ten 
nucleotides (nt 345-354) of the core-encoding gene (275). This domain contains a pseudoknot 
and the start codon region, which is essential in internal initiation of translation (276). The La 
antigen (p52) has been shown to bind to domain IV and to play a key role in the initiation of HCV 
RNA translation (discussed in detail in section 1.6.3) (277). Several reports indicated that Domain 
IV regulates translation initiation by sequestering the initiation codon (278-280). Additionally, 
changes in the sequence upstream of the initiator AUG can have a profound negative effect in 
IRES activity as the initial sequence of the core coding region located at the 5’end from 
nucleotide 4 to 33 is required for internal initiation of translation (1, 281, 282). 
 
1.6.3 Viral and cellular factors influencing IRES efficiency 
1.6.3.1 HCV core protein 
The core protein, which is located downstream from the IRES from nucleotide 342 to 874, has 
been considered in many cases to act as a transactivator of HCV RNA translation. Previous 
studies indicated specific interactions of HCV core protein with positive-strand RNAs. In these 
interactions,  HCV core protein had the ability to suppress HCV translation by interacting 
independently with the 5’ UTR (nt 1 to 341) and/or other regions of viral RNA (102). In vitro 
studies indicated the ability of the first 20 amino acids at the N-terminus of the HCV core protein 
to bind and inhibit HCV IRES-dependent translation (283). It is possible that HCV might use the 
core protein to directly reduce the level of HCV replication. 
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1.6.3.2 Cellular factors 
Besides the virus-encoded factors, host cellular factors play an essential role in the replication of 
positive-strand RNA viruses (284). Previous experiments indicated that these factors such as 
PTB (285), the heterogeneous nuclear ribonucleoprotein L (269), the LA autoantigen (286) and 
poly-C binding protein (287) are implicated in IRES-regulated translation as they bind to the 5’ 
UTR and modulate viral translation.  
 
One of these proteins is PTB, especially its p57 complex. This protein has been shown to interact 
directly with the 5’ UTR at three distinct sites and to be functionally required for translation 
initiation (288). PTB has also been shown to bind the 3’ UTR, an  event that could potentially 
mediate HCV RNA circularisation as PTB can interact with itself (84). PTB belongs to hnRNP I, 
which are nuclear proteins that interact with heterogeneous nuclear RNAs (hnRNAs), such as 
transcripts formed in the eukaryotic nucleus before being processed to mRNA molecules by 
splicing (289). A member of this protein family termed hnRNP L has been shown to bind to the 
5’ UTR when also present in the cytoplasm, as hnRNP L localises mainly in the nucleus.  hnRNP 
L binds to the region immediately downstream of the AUG codon (Figure 1.14) (84). It is 
believed that the binding of hnRNP L near the initiation codon could facilitate recruitment of the 
ribosome and/or translational initiation factors.  
 
Another cellular factor that plays a role in RNA translation  is an autoantigen of 50 kDa in size 
with RNA helicase activity termed La antigen or  p52 (277).  The La antigen is able to target 
many RNA viruses such as influenza and the picornaviruses. In HCV, the La antigen interacts 
with the initiator codon AUG located at nucleotide 342 towards the 3’end of the 5’ UTR (277). 
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The La antigen has been shown to play an important role in enhancing RNA translation as 
recognition and binding of La to the AUG have been shown to enhance translation (277). 
 
Another protein able to bind to the 5’ UTR is the Poly(rC)-binding protein 2(PCBP2), also 
known as  hnRNP E. This protein recognises the entire 5'UTR (Figure 1.14), in particular stem-
loop I, and can also associate with the sites of the HCV replication complex. Down-regulation of 
PCBP2 by the use of a short hairpin RNA diminished the amounts of HCV RNA and non-
structural proteins produced during viral replication (284). Additionally, electron microscopy 
revealed the interaction of PCBP2 with the 5’ and 3’ UTRs. This interaction induced 
circularisation of the HCV RNA (290). 
 
Eukaryotic translation initiation factors (eIF), in particular eIF2 and eIF3, are also involved in 
IRES binding. eIF3 stabilises the binding of the 40S ribosome subunit with eIF2, which is 
attached to GTP-Met-tRNA, and supports dissociation of 80S ribosomes (291). Both proteins 
have RNA-binding capacity and are required with the 40S subunit to assemble the 48S initiation 
complex. Additionally, purification of the 40S ribosomal subunit revealed P25 as one of the 
subunit components of the 40S protein complex (292). HCV RNA translation studies and UV 
cross-linking competition analyses indicated P25 as a binding protein to the 5’ UTR especially in 
the regions of nucleotides 47-74 or 279-331. This correlates with the involvement of P25 in HCV 
RNA translation initiation. Additionally, P25 binding is specific to the HCV IRES as it has not 
been observed in poliovirus and the encephalomyocarditis virus (293).  
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IRES stem-loops II, III and the pseudoknot are ribosomal binding sites (RBS) of the 40S 
ribosomal subunits (294). The 40S ribosomal subunits protect stem-loop II, part of the stem-loop 
III and the pseudoknot region. In fact, previous studies revealed that the IRES stem-loop III and 
the pseudoknot domain were protected and not digested by pancreatic RNase while residues 192 
to 199, which comprise the apical loop of stem-loop III, were not protected (Figure 1.14) (270, 
294). 
 
The transition from HCV-40S to 48S complex and the protected domain change in a 3’ direction 
in stem-loop IV exposes stem-loop II, which remains unprotected. On the other hand, during this 
shift, the start codon AUG and part of the coding sequence become protected. Thus, the IRES 
undergoes a structural transition from the 40S binary complex, where stem-loop II promotes 40S 
subunit binding, to the 48S and 80S complexes, where stem-loop II lacks protection while  the 3’ 
sequence of the IRES becomes more protected (Figure 1.14 C) (294). In fact, stem-loop II was 
always degraded by pancreatic RNase while the AUG codon was only minimally protected.  
 
These studies identified nucleotide regions that are protected by ribosomes. The 40S subunit 
protected fragments within nucleotides 49 to 353 while the 48S protected fragments within bases 
124 to 355. The 80S protected a region between nucleotide 124 to 392. Unprotected regions were 
detected between bases 192 and 199 for the 40S ribosomal complex (Figure 1.14A & B) (294). 
These results indicated that ribosomes or ribosomal subunits bind to ribosomal binding sites 
protecting thus IRES sequences.  
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Figure 1.14:  HCV IRES regions protected by ribosomes. 
A: Regions of the HCV RNA genome (thick black line) between bases 1 and 400 protected by 
the 40S subunit (green lines), by the 48S complex (red lines) and by the 80S ribosomal complex 
(blue lines). Protected fragments fall between bases 49 and 355 while unprotected fragments are 
located between bases 192 and 199. B: IRES regions protected by the 40S (green lines) and 
“core” protected regions recovered from HCV-40S complexes (purple lines). C: Schematic 
representation of unprotected IRES regions during IRES translation initiation.  
Figure adapted and edited from Lytle 2002 (294). 
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The complex secondary structure adopted by the HCV RNA genome has also an impact on the 
binding sites, whether or not these sites remain accessible, for  microRNAs (miRNAs), which are 
regulators of gene expression (295). When expressed in liver cells, such as microRNA-122 
(miR-122), they have been shown in many cases to bind the 5’ UTR and facilitate HCV RNA 
replication (296, 297). There are two miR-122 binding sites located in the 5’ UTR and one in the 
3’ UTR. In the 5’ UTR, the first binding site is located between nucleotide 17 to 28 while the 
second binding site is between nucleotide 29 to 42 (Figure 1.15) (298). 
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Figure 1.15: Schematic representation of viral and cellular factors that interact with HCV 
5’ UTR. 
The HCV 5’ UTR region consists of the secondary structure of the IRES (grey coloured region), 
which includes four domains (I-IV) and subdomains a to f within domain III. Coloured boxes 
and circles indicate the binding site of viral and cellular factors: Eukaryotic translation initiation 
factors (eIF2 and eIF3), La antigen, Poly (C)-binding proteins (PCBP), miR-122, and PTB that 
binds to three distinct sites (nt regions 1 to 84, 126 to 134, 135 to 291 and 315 to 323 (84)). 
hnRNP L interacts with a region immediately downstream of the AUG codon. 
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The binding of miR-122 to recognition sites may lead to RNA folding or RNA sequestration in 
replication complexes, an event that may facilitate viral RNA replication (299). Recent 
experiments indicated that translation activation via the 5’ UTR requires sequence features of the 
miR-122 3 end (300). Direct analysis by mass spectrometry of liver-specific miR-122 indicated 
that the 3’ end of miR-122 has a function in the stability of miR-122 in the liver and might 
undergo 3’ end modification (301). It is possible that miR-122 might recruit specific microRNA-
induced silencing complex (miRISC) proteins or cofactors involved in translation activation. 
Additionally, miR-122 binding to the HCV 5’ UTR may help to mediate a better conformation of 
the IRES that could increase and stimulate translation. 
 
There are many other cellular proteins such as RNA helicase A, PCBP2, elongation factor 1A, 
GAPDH and interleukin enhancer-binding factor 3 (ILF3) that can bind to the 5’ UTR, interact 
with cellular factors and have an impact on the efficient translation of mRNAs (290). 
Unfortunately, the implications of many cellular factors in the interaction with the HCV IRES 
for initiation of translation remain unclear. 
 
 
1.6.4 IRES mutations 
A single nucleotide change could disrupt the overall stacking geometry of the IRES, in other 
words change the RNA secondary structure, and change junctions held by inter-nucleotide bonds, 
which involve a complex network of hydrogen bonds, non-canonical base-base and base-sugar 
interactions. The 5’ UTR is highly conserved and one of the most conserved regions of the viral 
genome with a complex secondary structure, however, HCV RNA isolated from patients displays 
heterogeneity in the 5’ UTR region from PBMC, liver tissue and serum samples (302, 303) (304).  
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Previous experiments indicated that IRES sequence variations can increase or inhibit IRES 
translational activity. For example, multiple silent mutations within the first 42 nucleotides of the 
IRES inhibited translation (305). The same result occurred with the in frame insertion of 12 
nucleotides within the coding region, just downstream from the start codon AUG (278). A 
nucleotide insertion (T) at position 207 detected in a Japanese HCV1b-positive patient enhanced cap-
independent translation. This T insertion might enhance the affinity of eIF3, which binds to the IRES 
domain III. In fact, enzymatic foot-printing analyses results showed that eIF3 bound to the IRES 
apical region of domain III and protected nucleotides at positions 204, 214 to 216, and 212 from 
cleavage by RNase V1 (306, 307). Point mutation A/C at position 119 also enhanced cap-
independent translation (307). 
 
Studies conducted with RLuc/FLuc bicistronic RNAs and/or dicistronic reporter system 
assays pointed out the importance of the location of mutations within the RNA structure of 
the IRES and indicated the impact of nucleotide changes in the 5’ UTR IRES activity. 
Studies with HCV genotype 3a and 4a indicated that point mutations U/C at position 175 
and G/A at position 224 destabilised the IRES secondary structure and that three changes 
between nucleotide 247 to 249 (between stem-loops IIIc and IIId) in genotype 3a altered the 
stem-loop structure (278, 308). This was later confirmed by a recent study indicating that the 
primary sequence of subdomain IIId is required for optimal HCV IRES-mediated translation 
(309). Mutations in the loop region of subdomain IIIe have been shown to diminish the 
activity of the HCV IRES (278, 308, 309).  
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Beside the different mutations detected in the IRES region, the presence of dominant 
quasispecies with similar nucleotide substitutions in the IRES region was detected in HCV 
infected Daudi and Human T-cell lines (310). These HCV quasispecies had a restricted number 
of point mutations, distinct from liver and serum, and identical nucleotide substitutions in the 
IRES region; G107→A, C204→A and G243→A, commonly known as the A-A-A variant (Fig.3) 
(310). These variants had increased translational activity in lymphoid cell lines compared to wild 
type G-C-G variants but not in cell lines derived from monocytes, granulocytes and hepatocytes 
(311). In fact, translational activity increased 2- to 2.5-fold in three of five human 
lymphoblastoid cell lines used (Raji, Bjab, and Molt4 but not Jurkat or HPBMa10-2 cells) but  
not in hepatocytes (Huh-7), monocytes and granulocyte cell lines such as HL-60, KG-1, or THP-
1 (311).   
 
The translation activity of the IRES with different mutations detected in lymphotropic quasispecies 
has been examined in many experiments (table 1.2). The results obtained in these studies 
suggested the involvement of host factors in IRES function that may be differentially expressed 
in different cell lineages. However, the effect of these mutations on the replication of the virus 
has not yet been investigated. 
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Reference Substitution  
Stem-
loop  
Relative IRES activity  
TNT  Huh7  HepG2  CHME3  Jurkat  
DG
75  
(272) T61→C II ↓ ↔  ↔  ↓ ↔  ↔  
(312) T91→C II ↔  ↓ ↔ ↓ ↑ ↔  
(20, 272) A107→G II ↑ ↑   ↑ ↑   ↔ ↔  
(272, 274) 
T116→C 
G118→C  
II ↓ ↓ ↓ ↓ ↔  ↑  
(312, 313) 126
C127 
insertion 
II ↓ ↔ ↓   ↔ ↑   ↔  
(272) C213→T III ↓ ↓ ↓ ↔ ↔ ↓ 
(309) G271→A IIId ↓ ↔ ↔ ↔ ↓ ↔ 
(303) C334→T IV ↓ ↓   ↔ ↔ ↔ ↔ 
(275) G350→A IV ↑   ↑ ↔ ↔ ↔ ↔ 
 
Table 1.2: IRES mutations and translational activity of lymphotropic quasispecies. 
Nucleotide substitutions and their translational efficiency in lymphocytic cell lines (shown by 
arrows). Green arrows indicate down-regulation, red arrows up-regulation while horizontal 
arrows indicate no changes in IRES translation activity.  
 
The A-A-A variants have also been detected in the brain suggesting the central nervous system 
(CNS) as a candidate site of extrahepatic replication, as cognitive dysfunctions have been seen in 
patients with chronic HCV infection (303, 314). The ability of HCV to replicate in the CNS was 
suggested in a previous study where the HCV negative strand was detected and HCV-RNA 
extracted from brain tissue was shown to be different from serum-derived viral sequences. 
Additionally, HCV RNA derived from a lymph node of another patient had identical sequences 
to the brain-derived ones of another patient. Moreover, these sequences differed from serum-
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derived sequences from the same patients. In the same study, the A204 and A243 mutations from 
HCV RNA present in the cerebellum were absent from serum-derived HCV RNA of the same 
patient (315). These studies demonstrated that adenine substitutions at positions 204 and 243 
together with G-to-A mutation at position 107 (Figure 1.16) have been associated with lymphoid 
compartment infection (303), detected in monocyte-derived dendritic cells (316), 
monocytes/macrophages (317) and in peripheral blood mononuclear cells (PBMCs) (302). These 
specific nucleotide substitutions associated with lymphoid cells have also been confirmed by 
several other groups (310, 311, 318). One group used site directed mutagenesis of a wt strain (G-
C-G IRES) to determine whether nucleotide substitutions at position 107, 204 and 243 could 
enhance translation in lymphoblastoid cells (311). 
 
All these results reassert the rigorous structure/function relationship exhibited by the HCV IRES, 
which might need to conserve its structural features to perform its functional activity including 
the binding of different cellular factors to the IRES regions. This could explain why HCV IRES 
regions are highly conserved among isolates with several structural similarities among related 
viruses from the Flaviviridae family, such as CSFV, BVDV, and GBV-B (81, 319). However, 
the mechanisms and effects of the mutations/structural changes on the IRES-driven translation 
and ultimately virus replication are not yet well understood. 
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Figure 1.16: Sequence and secondary structure of HCV IRES RNA. 
HCV genotype 1b CNS-derived HCV sequence mutations (indicated by the arrows) detected in a 
patient. Circles in red are the common AAA mutations at positions 107, 204 and 243.  
Figure adapted and modified from Forton 2004 (303). 
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1.6.5 Extrahepatic replication 
Hepatitis C virus infection has been associated with many extrahepatic conditions such as 
autoimmune thyroid dysfunction, non-Hodgkin’s lymphoma (NHL) and cryoglobulinaemia 
(320). In order to explain these conditions, the presence of the virus has been investigated in 
tissues and body compartments, other than the liver. Previous studies indicated that although 
HCV is mainly hepatotropic, the presence of HCV-RNA has been detected in lymph nodes, brain 
tissue and PBMCs especially macrophages, B-cells and T-cells (CD8+). Additionally, a study 
conducted with the use of cell markers to identify infected cells, revealed the presence of NS5A 
in PBMCs, in particular  dendritic cells (DC) and monocytes/macrophages (321, 322).  
 
The use of reverse transcription polymerase chain reaction (RT-PCR) has helped enormously the 
detection of HCV RNA positive and negative strands within cells. Initially, the presence of HCV 
RNA in PBMCs was considered as contamination or as passive adsorption due to the circulating 
virus in infected patients. However, this theory was excluded after demonstrating the presence of 
HCV- encoded proteins and negative-strand HCV RNA in PBMCs (323), first reported in 1993 
(324).  
 
In recent years it has been demonstrated that the virus persists in the PBMCs of patients who 
have received antiviral treatments. In these patients, who were successfully treated with Peg-
IFNα in combination with RBV, HCV RNA was detected in PBMCs but not in the serum (325-
327) and that the replication of HCV RNA in PBMC influenced the response to IFN therapy 
(328).  
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Many other reports have detected HCV replication in fibroblasts, in established human B cell 
lines (e.g. Rajii and Daudi), T cell lines (e.g. Molt-4 and Jurkat) and PBMC subpopulations 
(CD4+, CD8+, CD19+)  of HCV infected patients (discussed in detail in section 1.6.5) (217, 329, 
330). HCV infected Epstein-Barr Virus (EBV)-immortalized B cells with cell culture-produced 
HCV (HCVcc) strain JFH-1 have been shown to infect hepatoma cells but failed to establish a 
productive viral infection (331), while monocytes/macrophages have been shown to support 
HCV infection (332).  
  
Previous studies have found a strong association between chronic HCV infection and B cell non-
Hodgkin’s lymphoma (B-NHL) occurrence. Human B cells infected and immortalized with EBV 
have been used to study HCV replication (333). Studies on HCV infection of B cells indicated 
that HCV entry is mediated by the binding of HCV E2 protein to the CD81 receptor and possibly 
other receptors except CLDN1 and SR-BI as they are not expressed in B cells. HCV receptor 
CD81 was found to be highly expressed on CD14+, CD16++ and CD14++, CD16++ cells but not 
on monocytes (CD14++, CD16−). Additionally, even in B cells, type I IFN production was 
impaired by HCV infection (334). However, specific steps in the life cycle of the virus such as 
assembly, vesicle fusion and virion release remain unknown in B cells.  
 
HCV infects and may replicate in the peripheral CD19+ B cells of CHC patients. C19+ and 
CD27+ cells, which express a large amount of chemokine receptor CXCR3, are recruited to the 
inflammatory site in the liver of CHC patients (335, 336). At this site and in the plasma of CHC, 
a CXCR3 ligand termed IFN-gamma-inducible protein-10 (IP-10) is largely produced and this 
fact might suggest a strategy by HCV to ensure persistent infection by using the B cell 
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population to move from peripheral blood to the inflammatory site of the liver where IP-10 is 
produced (337). Quasispecies analysis of the HCV cultured in B cells, showed variants not seen 
in the initial serum used to produce the B cell line after 4 months of culture (338). 
 
The presence of HCV RNA in extrahepatic sites has also been detected in HIV-HCV co-infected 
individuals. In these patients, HCV negative strands have been detected in PBMC, CD4+, CD8+, 
CD19+, T cells, monocytes and macrophages. Additionally, serum- and monocyte/macrophage- 
derived viral sequences differed in their 5’ UTR sequences. (317). It has been reported in several 
studies that HIV infection may facilitate replication of HCV in monocytes/macrophages possibly 
by rendering cells more susceptible to HCV infection or by increasing HCV replication (339). 
However, a more recent study indicated the opposite, that HCV facilitates HIV-1 infection of 
macrophages (334). This could be explained as HCV-infected macrophages increase the 
production of TNF-α and IL-8, which can increase HIV-1 replication (315). Additionally, results 
of a study where HCV uninfected patients have been compared to HIV-HCV co-infected patients 
indicated that HCV had longer half-life and ten times higher HCV RNA levels in serum of co-
infected individuals (340, 341). It is possible that the increased HCV RNA levels in HIV-HCV 
co-infected patients might not be caused by longer half-life but by a slower clearance of HCV 
possibly caused by the loss of immune function due to HIV-1 infection.  
 
The infection and possible replication of HCV in extra-hepatic sites is obvious but it has been 
difficult to study as it remains challenging to in vitro culture HCV in non-hepatic cells. A recent 
long term culture system has been developed for PBMCs. This system involves the infection of 
macrophages with serum or plasma carrying HCV. After one week incubation, a cell-free extract 
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of HCV is used to infect other cell types (Figure 1.17) (338, 342). The same system has 
previously been used to culture HCV in EBV infected B cells (338) and to co-infect T cells with 
HCV, HIV and Human Herpesvirus 6 (HHV-6) (341).  
 
 
 
Figure 1.17: Flow chart for long term in vitro culturing of HCV isolated from patient serum 
or plasma. 
Figure adopted from Revie 2011 (338) 
 
It is still unknown how HCV infects B cells or T cells and whether HCV genotype is relevant for 
extrahepatic replication. It is possible that hematopoietic reservoirs of HCV infection such as B 
cells, T cells, other lymphocytes and/or monocytes may become infected by a particular HCV 
quasispecies population during circulation in the blood or passage through the liver, which also 
contains B cells, T cells, Kupffer cells (macrophages) and endothelial cells (343). Unique 
quasispecies populations have been detected in PBMCs compared to liver (330, 344-346). These 
populations may be HCV treatment-resistant quasispecies indicated in previous studies of non-
responder patients (347). Although HCV spontaneous recovery and disappearance can often 
occur, a previous study detected the replicative HCV RNA negative strand in PBMC samples 
collected 5 years after HCV recovery. These results indicated that HCV RNA can persist at very 
 Luca Mercuri 
99 
Imperial College London 
low levels for many years after apparently complete spontaneous or antiviral therapy-induced 
resolution of chronic hepatitis C (348). Thus, it is possible that the detected trace amounts of 
HCV RNA may lead to reactivation of hepatitis C as different groups reported HCV recurrence 
and reappearance of serum HCV RNA, after successful antiviral therapy (349, 350). However, it 
is often uncertain and remains to be established whether cases of late relapse are actually cases of 
reactivation or reinfection, in particularly in the liver transplantation setting and intravenous drug 
users (IVDU) (351, 352) and the hypothesis of individuals with HCV RNA present only in 
extrahepatic compartments should not be excluded.  
 
In vitro studies in extrahepatic cells have helped in acquiring a much broader knowledge of 
infection and spread of HCV. However, even if HCV RNA (plus-strand) and replicative 
intermediate (minus-strand) sequences have been detected within these cells, this is not complete 
proof of successful replication of HCV in these cells.  
 
1.7 Hypothesis and aims  
The finding of distinctive mutations detected in extrahepatic sites strongly supports the 
lymphotropic nature of HCV and points to mutations that may be responsible for such 
adaptations. We still don’t know whether HCV IRES mutations, the A-A-A substitutions, 
together and in combination, have an effect on the efficiency of virus replication. We know that 
PBMCs can serve as a virus reservoir (350) and that HCV reactivation, which has been clearly 
seen in cancer patients during immunosuppressive therapy (353) and after liver transplantation 
(354), is part of the natural course of chronic HCV infection (355) and often related to virus 
genotype (355). Thus, it is possible that the distinctive IRES mutations detected in extrahepatic 
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sites might allow the virus to maintain a latent state in extrahepatic reservoirs without inducing 
an antiviral response or attracting the attention of the immune system. This may explain the re-
infection of the liver after antiviral treatment or liver transplantation due to the persistence of the 
virus in extrahepatic sites, which could also occur due to the development of cirrhosis or 
hepatocellular carcinoma, when the liver becomes unsuitable for HCV replication.  
 
The presence of point mutations in the HCV 5’ UTRs derived from PBMCs, microglial cells and 
in the central nervous system may allow the virus to increase its translation activity in 
hepatocytes while reducing such activity in the brain (303), suggesting that virus polymorphisms 
at these three sites (107, 204 and 243) may be responsible for the persistence of the infection and 
a viral strategy for latency and immune escape. 
 
The advent of nucleic acid amplification assays allowed the detection of HCV infection. 
Additionally, the isolation of the JFH-1 HCV strain, which is capable of replication and infection 
of new cell cultures, enables the study of the full virus replication cycle. With the construction of 
mutant variants using the JFH-1 strain, it will be possible to examine whether or not these point 
mutations have an effect on the replication of the virus and/or allow the virus to maintain a 
“latent state” avoiding thus any antiviral response. In other words, these mutations may play a 
crucial part in viral persistence, pathogenesis and reinfection of the liver.  
 
The aims of this thesis were to examine the replication efficiency of HCV with 5’ UTR point 
mutations, obtained by site-directed mutagenesis, as detected in HCV strains isolated from 
PBMCs of infected patients, by using the following steps:  
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1. Analyse and compare nucleotide sequences of the IRES obtained from PBMC-derived HCV 
RNA from infected patients with serum-derived HCV RNA.  
2. Introduce the treble adenine substitution, together and in combination, in the JFH-1 clone and 
the HCV 1b replicon at nucleotide positions 107, 204 and 243.  
3. Introduce the mutated IRES region of HCV genotype 1b in the JFH-1 clone creating thus a 
hybrid between genotype 2a (JFH-1) and 1b. 
4. Examine the replication capacity of the HCV mutant constructs by transfecting the mutants 
into Huh7.5 cells.  
5.  Determine whether virus from successfully transfected cultures reverts to wild type 
sequences with long term culture.  
6. Study the replication of the same HCV constructs in microglial and lymphocyte cell-lines 
such as Jurkat, B-lymphocytes and PBMCs. 
7. Analyse factors that may affect HCV mutant replication using siRNA against NF-kB and/or 
IRF3. Additionally, the expression of IFNα, IFNγ, IRF3, IRF7 and NF-kB will be detected 
with the use of quantitative real-time PCR, which will also be used to quantify viral mutant 
genomic RNA expressed in different cell lines after transfection and viral passage. 
 
We know that HCV targets cells of the immune system, especially peripheral monocytes, and 
that infection and replication in these cells differ from those in hepatocytes.  Thus, understanding 
the mechanisms underlying HCV infection of immune cells will help us have a clearer view of 
the pathogenesis and natural progression of HCV infection. Nucleotide mutations of the HCV 
IRES and analysis of their effect on replication in the infectious JFH-1 cell culture system may 
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provide clues on the possible role of these mutations in the HCV life cycle. It may also help us to 
clarify the possibility of HCV latency in immune privileged sites and to understand if the 
elimination of the virus from non-hepatic host cells can prevent the relapsing of HCV infection 
and improve the success of anti-viral therapy, a major unresolved issue in HCV viral persistence. 
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MATERIALS and METHODS 
CHAPTER 2 
 
2.1 Patient HCV-RNA studies 
2.1.1 Ethics statement 
All work covering patient material was carried out after obtaining informed consent. Moreover, 
all such work received approval from the local Ethics committee. 
2.1.2 Patient profile 
Fifty-nine samples in total from twenty-four patients (both male and female, 24-62 years old), 
(table 2.1), positive for anti-HCV and HCV-RNA by RT-PCR, were included in this study. None 
of the patients was co-infected with Hepatitis B virus (HBV) or had other causes of liver disease. 
The HCV genotypes involved were 1a, 1b, 3a and 4d. These genotypes were previously 
determined in a clinical virology laboratory and by sequencing analysis of the core region. Most 
patients, except patient numbers 1, 2, 11, 16, 17 and 19, received combination therapy with Peg-
IFNα-2b (100 µg/wk) plus ribavirin (800-1000 mg/d). All patients were HIV positive and had 
abnormal values for blood counts and liver function tests. Patient details, and biochemical (ALT) 
and viral markers (quantitative HCV RNA load) are given in table 2.1. Full recovery after acute 
infection occurred in a few patients as shown in table 2.1. 
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Table 2.1 Information on clinical samples investigated. 
A total of 59 samples from 24 HCV infected patients were investigated. 21 samples were 
PBMCs and the rest plasma. 
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2.1.3 Storage of clinical samples 
PBMCs and plasma samples were obtained from Dr. Emma Thomson in EDTA-containing 
vaccutainer tubes. The samples were processed in a designated containment level III laboratory 
and stored at -20°C (plasma) or -80°C/liquid nitrogen (PBMCs). 
2.1.4 PBMC isolation from peripheral blood 
Five millilitres of non-infectious peripheral blood obtained from volunteers was transferred to a 
15 ml conical tube containing an equal volume (5ml) of PBS, pH7.4. The sample was mixed and 
layered on 3 ml of Ficoll-1077 (Sigma-Aldrich) in a new 15 ml conical tube without breaking 
through the Ficoll layer.  The sample was centrifuged at 400 g for 20 min at room temperature. 
PBMCs located between the plasma and Ficoll layers were transferred into a new tube, 
suspended with 10 ml PBS and recentrifuged at 100 g for 10 min at room temperature. The PBS 
was removed and the cell pellet was resuspended in 10 ml PBS once again and recentrifuged at 
100 g for 10 min. The PBS was finally removed and the PBMCs were used to extract RNA (see 
2.1.5) or resuspended in 2 ml Roswell Park Memorial Institute (RPMI) medium (Invitrogen) 
supplemented with 10% Foetal bovine serum (FBS) and the mitogen phytohaemagglutinin-P 
(PHA-P) (5 μg/mL) (Sigma-Aldrich) (see 2.6.1). 
2.1.5 RNA extraction from PBMCs 
The extraction of RNA from PBMCs was carried out using the QIAgen RNA blood minikit 
(Qiagen). After centrifugation of 2 x 106 cells at 1300 rpm, the supernatant was removed and 350 
µl of buffer RLT containing 10 µl/ml of β-mercaptoethanol was added to each sample. Each 
sample was then vortexed and added to a QIAshredder spin column with a 2 ml collection tube. 
The sample was centrifuged at 13000 rpm for 2 min. The column was then discarded and 350 μl 
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of 70% ethanol was added to the lysate. The latter was added into a new QIAamp spin column, 
which was then centrifuged for 15 seconds at 5000 rpm. The lysate was discarded and 700 μl of 
buffer RW1 was added to the QIAshredder spin column, which was next inverted and then 
centrifuged for 15 seconds at 5000 rpm. After removing the flow-through from the collection 
tube, 500 μl of buffer RPE was added to the spin column and centrifuged for 15 seconds at 5000 
rpm. 500 μl of buffer RPE was added again to the column, which was recentrifuged at 7500 rpm 
for 2 min. After removing the flow-through from the collection tube, a further centrifugation step 
of 1 min was carried out to remove any residual ethanol prior to elution with 30 μl of RNase-free 
water. RNA concentration, purity and quality were assessed using a nanodrop 1000 
spectrophotometer and by running RNA samples on non-denaturing agarose gels stained with 
ethidium bromide (see 2.9.3). RNA samples were stored at -80°C.  
2.1.6 RNA extraction from Plasma 
RNA was extracted from plasma using the QIAamp MinElute virus spin kit (Qiagen). Two 
hundred microlitres of plasma was mixed with 25µl QIAGEN protease to reach a total volume of 
225 µl, otherwise 0.9% of sodium chloride was added to the solution to reach the desired volume. 
Cells were lysed with the addition of 200 µl buffer AL, which contained 28 µg/ml of carrier 
RNA. The sample was incubated at 56°C for 15 min. The lysate was added to the QIAamp 
MinElute column and centrifuged at 8000 rpm for 1 min. After discarding the flow-through, 500 
µl of buffer AW1 was added to the column, which was next centrifuged at 8000 rpm for 1 min. 
The flow-through was discarded and the column centrifuged at the same speed after the addition 
of 500 µl buffer AW2. The column was centrifuged again at 8000 rpm for 1 min after the 
addition of 500 µl of 96-100% Ethanol. The column was centrifuged once again at 14,000 rpm 
for 3 min following incubation at 56°C for 3 min to evaporate any possible left-over ethanol.  
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The QIAmp MinElute column was placed in a clean 1.5 ml Eppendorf tube and 50 µl of buffer 
AVE or RNA was added to the column, which was then incubated at room temperature for 1 min 
followed by a final centrifugation at 13000 rpm for 1 min. The flow-through containing the 
extracted RNA was stored at -80°C. RNA concentration, purity and quality were assessed as 
described below (see 2.9.2). 
2.1.7 Generation of cDNA 
HCV RNA was transcribed into complementary DNA (cDNA) using 2 µl of the reverse primer 
27 (0.5 µM) (Appendix 8.1.1) and 50 Units of Moloney Murine Leukaemia Virus reverse 
transcriptase (MMLV RT) (RETROscript kit, Ambion) in a volume of 20 µl following the 
manufacturer’s protocol. For each sample, 5 µl of RNA (2 µg), 2µl of primer 27 (0.5 µM) and 5 
µl of RNAse-free water were mixed and incubated at 85°C for 3 min. Samples were then cooled 
on ice for 2 min to prevent secondary structures from reforming. The following components 
were then added to each sample: 2 µl 10XRT buffer, 4 µl dNTPs (10 mM), 1 µl RNAse Inhibitor 
(100 U/ µl) and 1 µl MMLV-RT (100 U/ µl) to reach a final volume of 20 µl of mixture. 
Samples were then mixed and incubated at the extension temperature of 42°C for 60 min for the 
reverse transcription (RT) step followed by a 10 min step at 92°C for heat inactivation. Two 
negative controls were also included in the experiment, a no template control (NTC) and a no 
enzyme control (NEC). Subsequent PCR steps were considered valid only if the negative 
controls did not produce any amplicons. cDNA samples were stored at -20°C. 
2.1.8 HCV 5’ UTR Amplification  
PCR was carried out using the Fast Start High Fidelity PCR System (Roche) with inner primers 
26 and 27 (Invitrogen). Two microliters of cDNA were amplified in a 50 µl PCR reaction 
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mixture. Each PCR reaction contained: 5 µl of 10X PCR buffer, 1 µl of 10 mM dNTPs, 1µl of 
forward primer 26 (0.5 µM ) and 1 µl of reverse primer 27 (0.5 µM), 2 µl of cDNA and 0.5 µl of 
enzyme (5 U/µl). The sequences of the PCR primers used can be found in appendix 8.1.1.  
The reaction components were mixed in a 0.2ml thin wall PCR tube and placed in a GeneAmp 
9700 (Applied Biosystems) thermal cycler. Thermal cycling conditions used  were: pre-
amplification denaturation (one cycle), 95°C for 2 min; amplification (35 cycles) included 
denaturation at 95°C for 30 sec, annealing at 56°C for 30 sec and elongation at 72°C for 40 sec. 
A final elongation step (1 cycle) was carried out at 72°C for 7 min. Each sample was examined 
and visualised in a 2% agarose gel following electrophoresis using all 50 µl of the PCR product 
mixed with 5 µl SYBRsafe DNA gel stain (Invitrogen). An NTC and a positive control of a 
plasmid containing the HCV 5’ UTR were included in the experiment.  
 
The PCR was considered valid only if the negative controls did not reveal any amplicons and if 
positive controls yielded the expected amplicon length. The expected product size was 243 base 
pairs (bp) in length. The correct PCR amplicons were gel extracted and cloned. The sequences of 
the PCR primers used can be found in appendix 8.1.1.   
2.2 Cloning 
2.2.1 Media preparation  
Luria-Bertani (LB) broth: 
LB broth was prepared by dissolving 10 g of LB powder (Sigma) in 500 ml of distilled water in a 
sterile 500 ml glass bottle. The entire mixture was autoclaved at 121ºC for 40 min. After cooling, 
500 µl of Ampicillin (50 µg/ml) (Serva) was added to the 500 ml LB broth. 
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LB agar: 
The following components were dissolved in 1 litre of distilled water.  
Agar   15 g 
NaCl    10 g  
Tryptone   10 g 
Yeast Extract      5 g 
After autoclaving, the agar was allowed to cool and poured into plates under aseptic conditions, 
before setting. 
2.2.2 DNA plasmids  
Plasmid DNA templates used for PCR and cloning were pGEM-T easy vector (Promega), the 
pJFH-1 (donated by Dr A. Baillie) and pHCVrep1bBB7 (donated by Dr Y. Ho). The mutant 
amplicon constructs flanked by restriction sites and ligated into these plasmid vectors were used 
for transformation of competent DH5α bacteria. Recombinant colonies were detected by 
white/blue selection when using pGEM-T easy as vector.  
2.2.3 Ligation 
The ligation reaction mixture, which had a final volume of 20 µl, contained: 100 ng of vector 
DNA (pGEM-T easy or pJFH-1), 17 ng of insert DNA, 2 µl of 10XLigase buffer and 1µl of T4 
DNA Ligase (3 u/µl). The reaction mixture was incubated overnight at 4°C and a volume of 3 µl 
was used for transformation. 
2.2.4 Bacterial transformation 
Transformation with high efficiency was obtained by transferring 3 µl of the ligation reaction 
(circa 50 ng of circular DNA) to 50 µl of DH5α competent cells (Invitrogen). The reaction 
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mixture was incubated on ice for 30 min. The sample was then heat-shocked at 42ºC for 50 sec 
followed by a second incubation on ice for 2 min. A volume of 500 µl of LB broth containing no 
antibiotics was added to the sample, which was then incubated for 1 hour at 37ºC in an orbital 
shaker at 225-250 rpm. In the bacterial transformation of large plasmids such as pJFH-1, SOC 
medium (New England BioLabs) was used instead of LB broth. After one hour, the sample was 
centrifuged for 30 sec at 13000 rpm to pellet the bacteria and remove 250 µl of supernatant. The 
presence of insert was detected by restriction digestion of extracted plasmid and sequence 
analysis. For blue/white colony selection, to identify clones that contained a plasmid with an 
insert and clones containing a plasmid with no insert, 5-bromo-4-chloro-3-indolyl-beta-D-
galacto-pyranoside (X-Gal) (20 mg/ml) (Promega) to a final concentration of 40 mg/ml (a 1:500 
dilution of the stock solution) was added to the sample, which was then mixed and poured on an 
agar plate containing Ampicillin (125 µg/ml). The plate was incubated overnight (16-20 hours) 
at 37ºC. The next day, an isolated white bacterial colony was aseptically “picked off” from the 
plate and incubated overnight in 5 ml LB broth containing 5 µl Ampicillin (125 µg/ml) at 37°C 
in an orbital shaker at a speed of 220 rpm.  
2.2.5 Mini-preparations 
The extraction of plasmid DNA was conducted using the GenElute Plasmid Miniprep Kit 
(Sigma). After overnight incubation of bacteria in 5 ml LB broth, 500 μl of bacterial sample was 
mixed with 500 µl of 80% sterile glycerol and stored at -800C. The remaining bacterial culture 
was centrifuged at 13000 rpm for 5 min. The pellet was resuspended in 200 µl of resuspension 
solution. The sample was then lysed with 200 µl of lysis solution for 4 min followed by 
inactivation with 350 µl of neutralisation solution. Meanwhile, 500 µl of column preparation 
solution was added to the binding column, which was placed in a collection tube. After 
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centrifugation at 13000 rpm for 1 min, the flow-through was discarded and the clear lysate was 
transferred into the binding column, which was then centrifuged at 13000 rpm for 1 min. The 
flow-through was discarded and 700 µl of wash solution containing ethanol was added to the 
column. The flow-through obtained after centrifugation at 13000 rpm for 1 min was discarded 
again and the column was re-centrifuged at the same speed and time to remove residual wash 
solution. The column was transferred to a new collection tube and allowed to stand for 2 min 
after the addition of 50 µl elution solution, followed by a final centrifugation at 13000 rpm. The 
collection tube containing the purified plasmid DNA was stored at -20ºC for further analysis.  
2.2.6 Restriction digestion 
A total of 50 µl reaction mixture was made by adding the following reagents into a sterile 1.5 ml 
microfuge tube: 5 µl of 10X of the appropriate restriction endonuclease buffer, 5 µl of plasmid 
DNA, 1 µl of restriction endonuclease and sterile deionised water to 50 µl. The reaction mixture 
was incubated at 37ºC for 1 hour. For double restriction digestions two restriction enzymes were 
added together if both enzymes had similar restriction endonuclease buffer compatibility, 
otherwise after the first digestion, the DNA sample was gel extracted and used for a second 
restriction digestion. In some cases, after the first restriction digestion, the enzyme was 
inactivated by thermal inactivation for 20 min at 65ºC followed by cooling for 30 min at room 
temperature. No-enzyme containing “mock” digests were included and run in parallel with all 
restriction digestion experiments. DNA fragments that resulted from the restriction digestions 
were examined together with untreated DNA controls using agarose gel electrophoresis. 
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2.2.7 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to detect PCR amplicons, plasmids, vectors and inserts. To 
produce a 1% agarose gel, 0.5 g of ultrapure agarose (Invitrogen) was dissolved in 50 ml of 1X 
TBE buffer using a standard microwave. 5 µl of SYBRsafe stain (Invitrogen) or 2 µl of Ethidium 
Bromide (10 mg/ml) (Promega) were added to the molten agarose, which was then poured into 
the gel tank for solidification. In certain cases, different percentage of agarose gel (0.7% to 
1.5%) was produced for better DNA band separation. Once the gel had set, 50 ml of 1X TBE 
buffer was used to flood the gel. One to two µl  of DNA sample was mixed with 3 µl of 6X 
blue/orange loading dye (Promega), pipetted into the wells of the gel and run along with the 
100bp and/or 1 kb DNA ladder (Promega) or HyperLadder (Bioline) (Appendix 8.3.1). The 
voltage used to run the gel was 70 volts for 45 min using the electrophoresis power supply EPS 
3500 (Pharmacia Biotech). DNA bands were visualised and photographed using a UV trans-
illuminator (BioDoc-It UVP). 
2.2.8 DNA extraction from agarose gel   
The gel bands containing the PCR products or plasmid inserts, which were previously restriction 
digested, were extracted from the agarose gel using the QIAquick Gel Extraction Kit (Qiagen) 
according to the manufacturer’s instructions. After excising a piece of agarose gel containing the 
required DNA fragment, three volumes of buffer QG were added to 1 volume of gel and 
incubated at 50ºC for 10 min followed by the addition of 1 gel volume of isopropanol. The 
sample was then loaded onto the QIAquick column, which was placed in a collection tube. After 
centrifugation of the column at 13000 rpm for 1 min, 500 l of buffer QG was added to the 
column followed by another centrifugation. 750 µl of buffer PE was then added into the column, 
which was centrifuged twice to remove any residual ethanol from buffer PE and to dry the 
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column. To elute bound DNA from the membrane into a clean 1.5 ml microcentrifuge tube, 50 µl 
of buffer EB was added to the membrane followed by a final centrifugation at 13000 rpm for 1 
min. The purified DNA was then analysed in an agarose gel and stored at -20°C. 
 
2.3 Construction of HCV and inter-genotypic chimeric mutants  
2.3.1 Primer design 
Primers for PCR, RT-PCR, site-directed mutagenesis, SYBR green qPCR and qRT-PCR were 
designed using online resources. HCV sequences were obtained from the national centre for 
biotechnology information website (http://www.ncbi.nlm.nih.gov/).  Mutagenic primers were 
designed using the online software PrimerX (http://www.bioinformatics.org/primerx/) while 
primers for SYBR green PCR were designed with the online software Primer3 
(http://frodo.wi.mit.edu/). Additionally, NetPrimer software (Premier Biosoft) was used to 
analyse all designed primers for primer melting temperature and primer secondary structures. All 
oligonucleotide DNA primers were synthesised by Invitrogen and were diluted to the appropriate 
concentrations of 10 ng/µl from the original stock of 100 ng/µl. 
2.3.2 Site-directed mutagenesis 
The IRES region of the pJFH-1 and pHCVrep1bBB7 strains was amplified in a 50 µl reaction 
mixture using the Fast Start High Fidelity PCR System (Roche) as previously described (see 
2.1.8). Site-directed mutagenesis was employed to introduce the desired mutations by using 
splice extension PCR targeting the 3 nucleotides within the IRES at positions 107, 204 and 243. 
All PCRs were performed in 50 µl reaction mixtures. The reaction conditions for both rounds of 
PCR were the same to the conditions used for PCR amplification. The first round of PCR was 
 Luca Mercuri 
115 
Imperial College London 
mutagenic, using flanking primers containing restriction sites, for JFH-1(EcoRI JFH-1 and 
BstZ17I JFH-1), for HCV1b (EcoRI HCV1b and BstZ17I HCV1b), and the mutagenic primers 
for JFH-1(C107A, A204C, A243G) or for HCV1b (G107A, C204A, G243A). 
 
After the synthesis of two mutagenic DNA fragments, both fragments were added together in the 
reaction mixture for the second round PCR, which involved the use of only outer primers except 
during the first 10 cycles to allow extension of overlapping fragments. The PCR reactions were 
carried out as described before. The sequences of the mutagenic primers and outer primers can 
be found in appendices 8.1.2 and 8.1.3.   
2.3.3 PCR purification 
PCR products were purified with a QIAquick PCR Purification Kit (Qiagen). In each PCR 
sample, 5 volumes of buffer PB were added and the mixture was applied for 1 min to the 
QIAquick spin column provided with the kit. The sample was centrifuged at 1500 rpm for 1 min 
to allow binding of DNA to the column, which was then washed with 750 µl of buffer PE. The 
column was centrifuged at 1500 rpm for 1 min followed by a second wash with 750 µl of buffer 
PE and a final centrifugation without any buffer to remove any residual ethanol present in buffer 
PE. The column was placed in a clean 1.5 ml microcentrifuge tube and incubated for 2 min after 
the addition of 30 µl elution buffer EB. The sample was centrifuged at 1500 rpm for 2 min and 
the flow-through containing the purified PCR product was stored at -20°C. One µl of purified 
DNA was analysed on a 1% (w/v) agarose gel stained using SYBRsafe (Invitrogen). 
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2.3.4 Cloning strategies  
Four different clones were created to construct seven mutagenic JFH-1 plasmids and eight inter-
genotypic chimeric ones between HCV genotype 1b and 2a. The first clone consisted of the 
mutagenic IRES insert, which contained the restriction sites EcoRI / BstZ17I and the bacterial 
expression vector pGEM-T easy (figure 2.1, clone 1). The second clone consisted of the pGEM- 
T easy vector with an insert of 2516bp upstream of the 2a IRES, which was removed from pJFH-
1 by BstZ17I / NotI digestion. Another second clone with a smaller insert of 904bp removed 
from pJFH-1 by BstZ17I / BsiWI digestion (figure 2.1, clone 2) was constructed to obtain a 
better restriction fragment separation after BstZ17I / BsiWI digestion than with BstZ17I / NotI 
digestion (see 4.2.3). The third clone was constructed by removing and replacing from the 
second clone the WT IRES fragment, by an AaTII / BstZ17I digestion, with the mutagenic IRES 
insert from the first clone (figure 2.1, clone 3). From this third clone, the mutagenised IRES and 
JFH-1 region downstream of the 5’ UTR was removed by EcoRI / NotI or EcoRI / BsiWI 
digestion and sub-cloned into pJFH-1 after the removal of the EcoRI / NotI or EcoRI / BsiWI 
WT fragment (figure 2.1, clone 4).  
Correct sequence and orientation (5’-3’) of plasmid inserts was confirmed by nucleotide 
sequence analysis. A total of 16 recombinant plasmids were needed to obtain the different 
sequence combinations at positions 107, 204 and 243 (table 2.2). Mutations were introduced by 
site-directed mutagenesis (see 4.2.1).  
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Table 2.2 Full range of nucleotide substitutions that were introduced in the 5’ UTR of the 
infectious HCV clone, pJFH-1.  
 
The WT and JFH-1 clones containing the mutagenised IRES were then linearised by XbaI 
digestion and transcribed in vitro (see 2.5.1). The plasmid maps can be found in appendix 8.2.1 
and the cloning strategy in appendix 8.2.2.   
2.3.5 Generation of an inter-genotypic chimeric virus between HCV genotype 1b 
and 2a. 
Genotype 1b mutagenised IRES sequences generated by splice-extension PCR of pHCVrep1b as 
template and released by EcoRI and BstZ17I digestion were subcloned into pJFH-1, which was 
obtained by double restriction digestion with EcoRI and BstZ17I to remove the genotype 2a 
IRES sequence. The inter-genotypic chimeric virus contained the IRES and part of the core 
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coding region of genotype 1b in frame with the remaining genotype 2a coding region and 3’ 
UTR.  
 
2.4 Nucleotide sequence analyses 
Sequence analysis of plasmid clones was used to ensure that the correct nucleotide/fragment 
substitution/replacement had taken place, at desired positions, and to analyse sequence 
polymorphisms of 5’ UTR regions and the inter-genotypic chimeric constructs.  
2.4.1 Direct sequencing 
Clones and PCR products were sequenced using the same forward or reverse primers as for 
amplification or T7 targeting the plasmid. The full sequence of pJFH-1 was also analysed using 
PCR primers that covered most of the HCV genome to determine the right plasmid and genotype. 
In a total reaction volume of 10 µl, 1 µl of primer (27 or T7) at 3.2 pmol, 6 µl water, 5 µl of 
plasmid or 2 µl of amplicon DNA were sent for sequencing to the Imperial Genomics Core 
facility at the Hammersmith Hospital Campus. The primers used for sequence analysis of pJFH-1 
can be found in appendix 8.1.4. 
 
The sequences were compared and analysed using BioEdit (Ibis Biosciences) and Molecular 
Evolutionary Genetics Analysis (MEGA) software (356). The consensus sequence subtype 1a was 
used for multiple sequence alignments.  
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2.4.2 Single nucleotide polymorphism detection by SYBR green PCR 
To investigate single nucleotide polymorphisms, the SYBR green PCR kit (Qiagen) was used 
with appropriately designed primers. A master mix of the ingredients common to each reaction 
was created to perform multiple reactions. For a total reaction volume of 20 μl, approximately 1 
ng of template DNA was mixed with 10 µl of 2X QuantiTect SYBR green PCR master mix 
(Qiagen). This master mix was aliquoted into capillary tubes, which were centrifuged at 6000 
rpm for 15 sec, with DNA template, 1µl of reverse primer 2 (10 µM) and either 1µl of primer 1 
(10 µM) to detect the 107A or primer 3 (10 µM) to detect the 107G substitution. Additionally, 
negative controls were included in each run. The running protocol was programmed in the 
computer using the LightCycler Software Version 3 (Roche). Melt-curve analysis was used to 
identify true amplicons and reject those due to primer-dimer formation. The sequences of the 
primers used can be found in Appendix 8.1.6.   
2.4.3 Construction of phylogenetic trees 
The analysis of the patient IRES sequences (10-15 clones for each patient sample) was 
performed using the MEGA version 5 computer program. The sequences of the 5’ UTR were 
aligned and genetic diversity was calculated. Additionally, to compare variability of IRES 
sequences, entropy values (Hx) along the IRES nucleotides were calculated using the BioEdit 
software (Ibis Biosciences).   
The evolutionary history of rooted trees was inferred using the Neighbor-Joining method and the 
sequence of HCV genotype 5 (GenBank accession number L29612.1) was used as out-group   
while the evolutionary distances were computed using the Jukes-Cantor method (16). 
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The evolutionary history of unrooted tree was inferred by using the Maximum Likelihood 
method based on the Kimura 2-parameter model (357) and phylogenies were estimated using the 
neighbor-joining method.  
2.4.4 RNA secondary structure studies 
RNA sequences obtained from 10-15 5’ UTR clones from each patient and from in vitro 
infectious studies were analysed using the MFold 3.2 web server software to predict stem-loop 
secondary structure and thermodynamic stability with Turner energies and selected constraints 
on base pairing (222). Multiple RNA sequence alignment to compute the consensus 2D RNA 
structure within aligned RNAs was performed using the RNAalifold program (226), which 
predicted a minimal energy structure conserved across all variants. Additionally, predicted 
consensus structures were also compared with predicted structures of previous publications and 
RNA secondary structures predicted with Mfold and IPknot software (222, 225) and visualised 
with VARNA software (358). Predicted consensus secondary structures were also represented in 
mountain plots. Tertiary RNA structures were predicted using the  3dRNA and MC-Fold & Mc-
Sym web servers (http://biophy.hust.edu.cn/3dRNA/ & http://www.major.iric.ca/MC-Pipeline/) 
and visualised with the PyMOL molecular graphics system, version 1.3 software (Schrödinger, 
LLC) (359, 360). 
2.4.5 Sequence analysis of JFH-1 
The JFH-1 plasmid containing the full-length cDNA of the JFH-1 isolate subtype 2a (GenBank 
accession no. AB047639) was analysed to confirm HCV sequence and genotype. Different 
primers that annealed with the plasmid and covered most of the JFH-1 region were used for 
 Luca Mercuri 
122 
Imperial College London 
sequencing. Each sample was prepared with a specific primer (see 2.4.1) and sent for sequencing. 
The sequences of the primers used can be found in appendix 8.1.4.   
 
2.5 Generation of viral RNA 
2.5.1 In Vitro HCV RNA Transcription  
2.5.1.1 Digestion and purification of pJFH-1 
In order to generate genomic HCV RNA and transfect cells, pJFH-1 WT or mutant plasmid 
constructs were linearised at the 3’ end with XbaI restriction digestion. The restriction digestion 
reaction was assembled with 15-20 µg/µl of plasmid DNA, 1-2 µl XbaI (100 U/µl) (Promega, 
NEB), 5 µl 10x buffer D (Promega) or buffer 2 (NEB) and 0.5 µl of bovine serum albumin (BSA) 
(10 mg/ml) in a final volume of 50 µl. A no-enzyme “mock” digest was included and run in 
parallel with the experiment. The digest was incubated at 37ºC for 2-3 hours followed by the 
analysis of 1 µl of the digested and untreated samples on a 1% (w/v) agarose gel to confirm 
complete plasmid digestion.  
 
Digested samples were next mixed with 50 µl TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) 
and with 100 µl phenol–chloroform–isoamyl alcohol (25:24:1) (Sigma). The mixture was shaken 
and centrifuged at 13000 rpm for 15 min at room temperature. The aqueous phase was 
transferred into a new 1.5 ml microcentrifuge tube, which was centrifuged for 5 min at 13000 
rpm after the addition of an equal volume of chloroform. The aqueous phase was then transferred 
into a new 1.5 ml tube followed by ethanol precipitation with the addition of 1/10 volume of 3M 
sodium acetate, 2.5 volume of 99.5% ethanol and 1/100 volume of glycogen. After storing the 
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mixture at -80ºC for 20 min or at -20ºC for 12 hours, the DNA was pelleted after centrifugation 
at 4°C for 20 min at 13000 rpm. The pellet was next washed with 500 µl of 70% ethanol, 
centrifuged for 15 min at 13000 rpm at 4ºC, air-dried and resuspended in 43 µl RNase-free water.  
 
The purified DNA was mixed with 5 µl of 10X Mung bean nuclease buffer and 2 µl of Mung 
Bean nuclease (10 U/µl ) (New England Biolabs)  to remove the four terminal nucleotides and 
ensure the correct 3’ end of the HCV cDNA at  5′ overhangs. The reaction mixture was 
incubated at 30ºC for 30 min. To remove any contamination from preparations of nucleic acid, 
the sample was then treated with 10 µl of 10% (wt/vol) SDS, 2 µl of Proteinase K solution (20 
µg/µl) (Invitrogen) and 138 µl of RNase-free water making a total volume of 200 µl. The 
reaction mixture was incubated for one hour at 50ºC followed by DNA extraction and 
purification with 200 µl of phenol–chloroform–isoamyl alcohol (25:24:1) as previously 
described.  
2.5.1.2 Reverse transcription 
The linear template DNA was transcribed in a total volume of 20 µl using the MEGAscript T7 
Kit (Ambion, Austin, TX). The reaction mixture contained 2 µl of 10X reaction buffer, 3 µl of 
linear template DNA (500 ng to 1 µg) and 2 µl of ATP, CTP, GTP and UTP. The reaction 
mixture was first incubated at 37ºC for 3 hours and then for 15 min at 37ºC after the addition of 1 
µl TURBO DNase (2 U/µl) to degrade any remaining DNA template. After incubation, 115 µl of 
RNase-free water and 15 µl of stop solution were added to the sample, which was then diluted 
with 100 µl of RNase-free water.   
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2.5.1.3 RNA purification 
The total volume of in vitro transcribed RNA was purified to remove any unincorporated NTPs, 
enzymes, and buffer components with 200 µl Trizol reagent (Invitrogen) (see 2.9.1) or with the 
MEGAclear kit (Ambion), which enabled quicker recovery of higher-quality and quantity of 
transcribed RNA compared to the Trizol reagent. 
 
A volume of 350 µl of binding solution provided with the MEGAclear kit was added to the in 
vitro transcribed RNA sample followed by the addition of 250 µl of 100% Ethanol. The sample 
was mixed, added onto the filter cartridge and centrifuged at 12000 rpm for 1 min at room 
temperature. The flow-through was discharged and 500 µl of wash solution were added to the 
cartridge. The sample was centrifuged at 12000 rpm for 1 min. This step was repeated with the 
addition of a second 500 µl aliquot of wash solution. The flow through was removed each time 
and a final centrifugation at 12000 rpm for 1 min was applied to remove any traces of wash 
solution. A volume of 50 µl elution solution pre-heated to 70C° was added to the filter cartridge, 
which was then transferred to a new collection tube and incubated in a heat block at 70C° for 10 
min followed by a final centrifugation at 12000 rpm for 1 min.  
 
The concentration and purity of the RNA sample was determined with a Nanodrop 1000 
spectrophotometer. Additionally, to assess RNA quality, samples were run on a non-denaturing 1% 
agarose gel (see 2.9.2). RNA samples were stored at -80°C. 
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2.6 Cell culture systems 
2.6.1 Cell cultures 
Huh7.5 cells donated by Dr. Nadia Sifennasr, Jurkat donated by Dr. Marco Purbhoo, and 
Lymphoblastoid cell lines (LCL) carrying the Epstein-Barr Virus (EBV) donated by Dr. Keith 
Gould were grown in Dulbecco’s modified Eagles Medium (DMEM) supplemented with 10% 
heat-inactivated FBS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C in a 5% CO2 
atmosphere. All the solutions used were first warmed to 37°C and cells were passaged every 3 
days at a split ratio of 1:4. For each passage, the cells were washed with 5ml Phosphate Buffered 
Saline (PBS) while adherent Huh7.5 cells were first treated with 1 ml of 0.05% Trypsin-EDTA 
(Invitrogen) followed by incubation for 2-5 min at 37°C in 5% CO2 and resuspension in 5ml 
medium. The cells were centrifuged at 1300 rpm for 5 min. The supernatant was removed and 
the pellets resuspended in 10 ml complete medium. 2 ml of cell suspension was added in a 75cm2 
flask containing 13 ml complete DMEM medium. The flasks were then incubated at 37°C in 5% 
CO2. Different volumes of growth medium were used to culture the cells; 15 ml for 75 cm
2 
flasks, 2 ml for 25 cm2 flasks and 2 ml for 6-well plates. 
PBMCs, isolated by Ficoll-hypaque density gradient (see 2.1.4) from healthy donors with no 
history or molecular evidence of HCV exposure, were donated by Dr. Khaleel Jamil, Dr Wafa 
Khamri and Dr. Robert Tidswell. PBMCs were cultured in 6 well plates at 1 x 106 cells per well 
in 2 ml RPMI medium (Invitrogen) supplemented with 10% FBS at 37 °C in 5% CO2. PBMCs 
were stimulated with PHA-P (5 μg/mL) (Sigma-Aldrich) for 24-72 hours. Cultured PBMCs were 
then exposed to patients HCV infected plasma (see 2.7.4), electroporated with in vitro 
transcribed JFH-1RNA (see 2.7.2) and siRNAs (see 2.11). 
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2.6.2 Storage of cell cultures 
The cells were washed with 5ml PBS and centrifuged at 1300 rpm for 5 min. The supernatant 
was discarded and the cells were resuspended in DMEM containing 90% FBS and 10% DMSO 
to give a final concentration of 5x106 cells/mL in cryogenic vials. The cells were stored for 12 
hours at -70°C in a "Mr. Frosty" Freezing Container (Nalgene) before being transferred to liquid 
nitrogen for long-term storage. 
 
2.7 HCV Infection and Transfection 
2.7.1 In vitro liposome-mediated transfection of HCV mutants in Huh7.5 
In vitro transcribed genomic JFH-1 RNA and JFH-1 mutant RNAs were transfected into Huh7.5 
cells using lipofectin transfection reagent (Invitrogen) at an RNA/lipofectin ratio of 1:2 (5 
µg/well of transcribed HCV RNA and 10 µl/well of Lipofectin) for 72 hours. 
One day before transfection, Huh7.5 cells were first washed once with PBS, trypsinised and 
resuspended in growth medium (see below). The cells were then seeded in a 6-well plate (9.6cm2 
per well) at a density of 6x105 cells/ml in 500 µl DMEM medium (Invitrogen) supplemented with 
10% FBS without antibiotics and incubated at 37°C in 5% CO2. The concentration of cells was 
calculated using the Glasstic slide 10 with grids (KOVA, Hycor Biomedical Inc) or a 
haemocytometer after mixing an equal volume of cell suspension with 0.4% trypan blue stain 
solution (Sigma). 
 
The next day, at the time of transfection, cells were 30-50% confluent. The medium was 
removed, the cells were washed with PBS and 500 µl of Opti-MEM medium (Invitrogen) were 
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added to each well. Cells were incubated at 37°C in 5% CO2 for 2 hours. After one hour and a 
half, for each transfection reaction, 5-10 µg HCV RNA were mixed with 100 µl OPTI-MEM 
medium while in a separate Eppendorf tube 10 μl stock Lipofectin was diluted in 90 μl Opti-
MEM medium, mixed gently and incubated for 5 min. The lipofectin/OptiMEM mixture was 
combined with diluted RNA/Opti-MEM solution and incubated for 20 min at room temperature 
to allow the formation of HCV RNA–Lipofectin lipocomplexes. After 30 min, the growth 
medium was removed from the cells and washed with 1 ml Opti-MEM. The 200 µl 
RNA/Lipofectin/OPTI-MEM transfection mixture and 800 µl Opti-MEM medium was then added 
to each well. The plate containing the wells was gently rocked back and forth to mix the content 
of the wells. The cells were incubated at 37°C in 5% CO2 for 72 hours. However, after eight 
hours incubation, the transfection medium was replaced with 2 ml DMEM medium (Invitrogen) 
supplemented with 10% FBS. Different volumes of RNA concentration were used based on the 
cell culture vessel used (table 2.3). 
 
At the end of the 72 hours incubation period, the medium was removed, filtered through a 0.20 
µm filter (Merck Millipore) followed by a second filtration through an Amicon ultra-15 
centrifugal filter unit (Merck Millipore) (see 2.8.1). The concentrated medium was used to infect 
naïve Huh7.5 cells at 50% confluency in 25 cm2 flasks. Three days p.i., the infected cells were 
washed with ice cold PBS and intracellular RNA was extracted with Trizol reagent (Invitrogen) 
(see 2.9.1). RNA was stored at -80°C for quantification and gene expression analysis (see 2.10.3). 
The experiments were performed in duplicate. Non-infected Huh7.5 cells were used in the 
experiment as negative control while naïve cells infected with live JFH-1virus were used as 
positive control. Transfection efficiency was also checked by transfecting cells with a plasmid 
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encoding the GFP (appendix 8.2.1) obtained from Dr. Lemonica Koumbi for analysis by flow 
cytometry. 
 
Culture 
Vessel 
Surface area 
per well (cm2) 
Volume 
plating 
Medium 
Cells per well 
RNA (µg/µL) and 
Opti-MEM 
volume (µl) 
Lipofectin(µL) 
and Opti-MEM 
volume (µl) 
6-well 10  2 ml 0.25-1 x 106 5-10 in 100  10 in 90 
12-well 4  1 ml 2.5 x 106 5 in 100 4 in 96 
24-well 2  500 µl  0.5-2 x 106 1 in 50 2 in 48 
 
 
Table 2.3 Transfection conditions for Huh7.5 cells. 
 
2.7.2 Electroporation 
In vitro transcribed genomic JFH-1 RNA and JFH-1 mutant RNAs were transfected into Huh7.5, 
Jurkat, B-LCLs and PBMCs by electroporation. Huh7.5 cells were first grown in culture media 
without antibiotics for 48 hours to reach circa 70% confluence followed by trypsinisation of 
monolayers and subsequent resuspension in growth medium. Jurkat, B-LCLs and PBMCs were 
passaged 24-30 hours before electroporation to achieve an active cell growth phase on the day of 
transfection.  
Prior to electroporation, the cells were first washed in PBS without Ca2+ and Mg2+, counted and 
centrifuged for 5 min at 1300 rpm. Suspension cell viability was determined by Trypan blue 
staining. The supernatant was removed and for each reaction, the cells were resuspended in 400 
µl resuspension buffer R or T. Buffer R was used for adherent cells (Huh7.5) and suspension 
cells (Jurkat) while buffer T was used for primary blood-derived suspension cells (B-LCLs and 
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PBMCs). Ten µg of full length in vitro transcribed HCV RNA were added to the cells/buffer 
mixture prior to transfection by electroporation using the Neon apparatus (Invitrogen). 
 
The samples were stored on ice while the Neon polystyrene tube was inserted into the pipette 
station and filled with 3 ml electrolytic buffer. An electrode pipette and gold plated 100 µl tips 
(Invitrogen) were used to pipette and introduce the RNA/cell mixture into the electroporation 
chamber containing the electroporation buffer. The neon tips and electroporation buffer were 
changed for each electroporation. The conditions for optimal electroporation efficiency varied 
between different cell types (table 2.4). These conditions based on cell types were obtained from 
the Neon cell online database (Invitrogen).  
 
After the voltage pulse, the cells were placed on ice for 5 min, transferred to 8ml complete 
DMEM, or RPMI medium for PBMCs, and seeded at a density of 3 x 105 cells/cm2, circa 2 ml of 
cell suspension per well in a 6 well plate. 
 
Cells 
Cell density 
(cells/ml) 
RNA 
(µg/µL) 
Pulse 
voltage 
(V) 
Pulse 
width (ms) 
Pulse 
number 
Transfection 
efficiency (%) 
Viability 
(%) 
HUH7.5 2 x 107 10 1200 20 2 n/a n/a 
JURKAT 2 x 107 10 1325 10 3 93.7 97.8 
B-LCLs 2 x 107 10 1350 30 1 80 80 
PBMCs 2 x 107 10 2150 20 1 23 95 
 
Table 2.4 Electroporation parameters for different cell types using the Neon apparatus. 
 
The cells were incubated at 37°C in 5% CO2 for 72 hours. The experiments were performed in 
duplicate.  The negative control for every cell type was mock transfected cells, which were 
electroporated without template RNA. The cells were also electroporated with the GFP plasmid 
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to examine by fluorescent microscopy electroporation transfection efficiency. HCV replication 
was confirmed by immunostaining and qPCR while the presence of HCV in the supernatants was 
determined by qRT-PCR at the indicated time points. Additionally, sequence studies were 
conducted on HCV RNA extracted 72 h post-electroporation.  Supernatant from electroporated 
cells was filtered through a 0.20 µm filter (Merck Millipore) following a second filtration 
through an Amicon ultra-15 centrifugal filter unit (Merck Millipore) (see 2.8.2). 
2.7.3 Passage of HCV mutants 
Mutant constructs were passaged up to ten times. Intracellular RNA was extracted with Trizol 
(Invitrogen). RNA was analysed by RT-PCR and sequence analysis of HCV RNA was 
performed to detect possible nucleotide sequence variability of the IRES at different viral 
passages. 
2.7.4 Inoculation with patient-derived HCV infected plasma  
Plasma from four HCV infected patients (patient number 21 to 24) (table 2.1) was used as 
inoculum  to infect naïve Huh7.5, Jurkat, B-LCLs and PBMCs. Prior to infection, the cells were 
washed with PBS, centrifuged at 700 rpm for 5 min to pellet the cells and remove the supernatant. 
The concentrated cells were resuspended by flicking the tube, placed in a 48-well cell culture 
plate at a concentration of 1 x 105 cells/ml-1 per well and exposed to serum samples containing 
HCV with viral loads ranging between 1 x 105 to 3 x 107 virus genome equivalents (vge) ml-1 as 
previously determined by real-time RT-PCR.  
 
To induce viral adsorption the cells were exposed to circa 250 µl HCV-infected plasma for 1 
hour at room temperature.  For mock infections, the cells were exposed to 250 µl of uninfected 
 Luca Mercuri 
131 
Imperial College London 
negative-control plasma. After one hour incubation, the samples were transferred to 24-well 
plates and culture medium was added to reach a final volume of 500 µl per well. Inocula were 
removed after 24 hours, the cells were washed with PBS and centrifuged at 1000 rpm for 5 min. 
After removal of the supernatant, the cells were resuspended in 500 µl growth medium and 
cultured for 72 hours at 37°C in a 5% CO2 atmosphere. Huh7.5, Jurkat and B-LCLs cells were 
cultured with DMEM supplemented with 10% heat-inactivated FBS and 100 µg/ml streptomycin. 
PBMCs were cultured in RPMI medium (Invitrogen) supplemented with 10% FBS and with 
PHA-P (5 μg/mL) (Sigma-Aldrich). All infections were performed in duplicate. 
 
At seven days p.i. for PBMCs and four days for Huh7.5, Jurkat and B-LCLs, RT-PCR was used 
to detect extracellular and intracellular HCV RNA using primers 26 and 27. HCV RNA was 
reverse transcribed, amplified by PCR, and cloned amplicons were sent for sequencing (see 2.2 
and 2.4). Additionally, the presence of intracellular HCV core protein was detected by confocal 
microscopy (see 2.12.1). 
 
2.8 Production of infectious virus 
2.8.1 HCV Production by Media Passage  
Growth media collected from 25 cm2 flasks of Huh7.5 cells infected with JFH-1 wild type virus or 
JFH-1 mutant constructs were centrifuged in a Mistral 3000 Benchtop Centrifuge (MSE) at 1500 
rpm for 5 min to remove cell debris. The supernatant was filtered through a 0.20 µm syringe-top 
filter unit (Merck Millipore). The concentrated medium was then filtered through an Amicon 
Ultra-15 filtration unit (Millipore) by centrifugation at 3000 g for 30-60 min at 4°C to retain any 
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virus particles. The concentrated medium was used to infect naïve Huh7.5 cells cultured in 
complete DMEM. Supernatants of uninfected Huh7.5 cells were also collected and treated 
similarly to generate mock medium for mock infected controls in infection experiments.  
Viral passage was carried out every 4 days for several weeks to obtain a high titre JFH-1 stock. 
Concentrated viral stocks and unfiltered concentrated medium were stored at -20°C.  
2.8.2 Titration of JFH-1 virus stocks  
Huh7.5 cells were seeded into 12-well cell culture plates (Millipore) at a density of 6 x 105 
cells/cm2 per well. Before seeding cells, plastic square coverslips (Ted Pella, Inc.) were 
introduced into each well. The concentrated JFH-1 virus stock obtained from concentrated cell 
supernatants of infected Huh7.5 cells was serially diluted 1 in 10 (0.1 µl), 1 in 100 (0.01 µl) 
and 1 in 1000  (0.001 µl)  in  DMEM  growth  medium and  used  to  infect  naïve  Huh7.5  cells in 
duplicate.  
 
The cells were incubated with serially diluted virus stock at 37°C in 5% CO2 for 4 hours and the 
inoculum was then removed. The cells were washed twice with PBS and then supplemented with 
fresh complete DMEM.  At 72 hours p.i., the level of HCV infection was determined by 
immunofluorescence using anti-HCV core antibody (see 2.12.1) and foci were counted using a 
Nikon Eclipse TE2000S fluorescence microscope to determine the level of HCV infection. The 
viral titre expressed as focus forming units per milliliter of supernatant (ffu/ml-1) of virus stock 
was calculated from the number of HCV core protein-positive cells, counted as a single 
infectious focus, detected at the highest dilution. Additionally, RNA was extracted from the 
supernatant of infected cells to quantify HCV RNA by qRT-PCR (see 2.10.3). 
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2.9 RNA analysis 
2.9.1 RNA extraction and purification  
Total cellular RNA was isolated from infected and mock-infected Huh7.5 cells and from culture 
medium using Trizol reagent (Invitrogen). In the procedure, Trizol reagent was used to 
homogenise samples, chloroform for phase separation and isopropyl alcohol for RNA 
precipitation.  The quantity of Trizol reagent used for different cell flasks was: 3 ml for a 75 cm2 
flask, 750 µl for each well of a 6-well plate. The Trizol-cell mixture was then homogenised by 
pipetting up and down. The RNA was then purified using 0.2 ml of chloroform per 1 ml of Trizol 
reagent used. Each sample was centrifuged at 4ºC for 15 min at 11200 rpm to separate the 
solution into an organic phase and an aqueous phase, which contained RNA. The aqueous phase 
was isolated and 0.5 ml of isopropyl alcohol per 1 ml of Trizol reagent was added to precipitate 
the RNA. The solution was incubated for 10 min at room temperature and centrifuged at 11200 
rpm for 10 min at 4°C. The supernatant was removed and the RNA pellet was washed by adding 
750 µl of 75% ethanol followed by centrifugation at 11200 rpm for 5 min at 4°C. This step was 
repeated twice. The supernatant was removed and the pellet was air-dried and resuspended in 6-
12 µl RNase free water. RNA samples were stored at -80°C. Mock extractions were also 
performed as contamination controls. All centrifugations were carried out using the Sorval 
Biofuge Fresco microcentrifuge (Heraeus instruments). 
 
Genomic DNA was removed from total RNA with Turbo DNA-free Dnase treatment (Ambion). 
The reaction mixture contained 12 µl RNA, 2 µl 10X TURBO Dnase buffer, 2 µl TURBO Dnase 
enzyme (2 U/µl) and 4 µl of Nuclease-free water to reach a final volume of 20 µl per reaction. 
The sample was incubated for 30 min at 37°C with 1 µl TURBO DNase enzyme. After 
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incubation for 30 min, 4 µl of DNase inactivation reagent was added to the sample, which was 
incubated for 2 min at room temperature followed by centrifugation at 10000 rpm. The 
supernatant containing the purified RNA was transferred into a new Eppendorf tube and stored at 
-80°C.  
2.9.2 RNA concentration and quality  
The concentration and purity of RNA was determined with a Nanodrop 1000 spectrophotometer. 
Additionally, to assess RNA quality, samples were run on non-denaturing 1% agarose gels. PCR 
was also performed for each RNA sample to test for the presence of contaminating genomic 
DNA.  
2.9.3 RNA analysis on non-denaturing agarose gel electrophoresis 
Total RNA isolated from the cells was analysed by non-denaturing agarose gel electrophoresis. 
Prior to running a gel, the gel tank, comb and metal plates were treated with RNase ZAP spray 
(Ambion) and then rinsed with nuclease-free water.  To produce a 1% agarose gel, 0.50 g of 
ultrapure agarose (Invitrogen) was dissolved in 50 ml of 1x TAE buffer using a standard 
microwave. Six µl of ethidium bromide (Invitrogen) were added to the molten agarose, which 
was then poured into the gel tank. Once the gel had set, 50 ml of 1x TBE buffer was used to 
submerge the gel. 2 µl of Gel Loading Buffer II (Ambion) and 6 µl of formamide were added to 
a 2 µg RNA sample. Before loading the sample into the well of the gel, each RNA sample was 
incubated for 5-10 min at 70°C and placed on ice for 5 min. The voltage used to run the gel was 
5-10 V/cm (cm of space between the electrodes in electrophoretic chamber), 70 volts for 30 min    
using the electrophoresis power supply EPS 3500 (Pharmacia Biotech). Four µl of RNA ladder 
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(Biolabs) (appendix 8.3.2) with 2 µl of Gel Loading Buffer II were included alongside the RNA 
samples. RNA bands were visualised using a UV trans-illuminator (UVP).   
 
2.10 HCV RNA detection and sequence analysis 
2.10.1 Detection of Intracellular JFH-1 genome RNA by RT-PCR 
Intracellular and extracelullar JFH-1 RNA were detected by semi-nested PCR, semi-quantitative 
RT-PCR or by one step RT-PCR. cDNA synthesis was first performed by mixing 2 µg of 
extracted and purified RNA with 0.5 µM primer 27 and Nuclease-free water to a total volume of 
15 µl. The mixture was heated for 5 min at 70˚C and cooled on ice. The reaction mixture was 
prepared with 1 µl MMLV RT (Ambion RETROscript) (100 units/μL), 5 µl MMLV 5 x buffer, 5 
µl dNTPs (10 µM each), 0.6 µl RNase Inhibitor (10 units/μL) and 13.4 µl of Nuclease-free water 
reaching a total volume of 25 µl. This reaction mixture was added to the RNA sample followed 
by a 60 min incubation at 42°C. The resulting cDNAs were used for PCRs with HCV 5’ UTR 
specific primers 26 and 27 (see 2.1.8) (appendix 8.1.1). PCR amplicon products were used to 
perform second PCRs with the same conditions and primers or with inner primers 27 and 28 
under the same cycling conditions except for the change of the annealing temperature to 64˚C. 
PCR products were analysed by electrophoresis on 0.6% agarose gels. In all PCRs, negative 
control samples were prepared by replacing cDNA template with Nuclease-free water. Positive 
controls were also included with the addition of pJFH-1 or pGEM-T+IRES instead of cDNA as 
template. 
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In some cases, cDNA synthesis and PCR were performed in a single one-step RT-PCR reaction 
using the SuperScript III One-Step RT-PCR system with platinum Taq high fidelity polymerase 
(Invitrogen). For each reaction, 1 µg RNA, 25 µl 2 x reaction buffer, 1µl primer 26 (10 µM), 1µl 
primer 27 (10 µM) and 1 µl of SuperScript III RT/ Platinum Taq high fidelity enzyme mix were 
mixed in a 0.2 ml thin wall PCR tube . The sample was placed in the thermal cycler GeneAmp 
PCR system 9700 (Applied Biosystems) under the following cycling conditions: 1 cycle at 55˚C 
for 30 min followed by 1 cycle at 94˚C for 2 min; 40 cycles at: 15 seconds at 94˚C, 30 seconds at 
55˚C and 35 seconds at 68˚C. One final cycle at 68°C for 5 min.  
 
Negative control (no template) and positive control (pJFH-1 as template) reactions were 
performed in parallel with each experiment. PCR amplicon products were analysed by gel 
electrophoresis, gel extracted with the QIAquick gel extraction kit (Qiagen) (see 2.3.8) and 
cloned for sequence analysis (see 2.2 and 2.4.1) 
 
2.10.2 Detection and quantification of virus production by qPCR and qRT-PCR 
qPCR or qRT-PCR were used to detect and measure levels of extracellular or intracellular JFH-1 
RNA. qPCR was performed using cDNA and the QuantiTect PCR SYBR green kit (Qiagen). 
qRT-PCR was performed with extracted RNA using the iScript one-step RT-PCR kit with SYBR 
green (Bio-Rad). The reactions were placed in a LightCycler Carousel-Based System (Roche) 
using a total reaction volume of 10 µl for each sample. However, different RNA and cDNA 
concentrations were used based on the kit manufacturer’s instructions. RNA samples were 
diluted prior to analysis to 100 ng/µl. The master mix was already prepared according to the 
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manufacturer’s protocol. However, a master mix of the ingredients common to each reaction was 
created to perform multiple reactions. 
 
For q-PCR the reaction mixture consisted of 250 ng of cDNA, 10 µl of 2x Quantitect SYBR 
green PCR mastermix, 1 µl primer 26 (10 µM), 1 µl primer 27 (10 µM), 0.2 µl of RT enzyme 
and nuclease-free water to a final volume of 20 µl.For qRT-PCR the reaction mixture consisted 
of 100 ng of RNA, 10 µl of 2x SYBR green RT-PCR mastermix, 1 µl primer 26 (10 µM), 1 µl 
primer 27 (10 µM), 0.2 µl of iScript RT enzyme and nuclease-free water to a final volume of 20 
µl. 
Master mixes were aliquoted into capillary tubes (Roche) with primers and cDNA or RNA 
templates. Capillary tubes were well sealed and centrifuged at 9000 rpm for 3 sec. Experiments 
were carried out in duplicate for each cDNA and RNA sample. The annealing temperature for 
primers 26 and 27 was set to 56°C while for primers 28 and 29 was set to 64°C. The temperatures 
and cycles were programmed in the computer using the LightCycler Software Version 3 (Roche) 
according to the kit manufacturer’s instructions.  Additionally, in each experiment, a reaction 
with no enzyme, a reaction with HCV RNA or cDNA and a reaction with water as template were 
included as negative and positive controls. 
2.10.3 HCV quantification and gene expression analysis 
The threshold cycle results obtained from qPCR and qRT-PCR were used to quantify intracellular 
HCV RNA by absolute quantification and to determine fold change in gene expression using the 
relative quantification method.  
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2.10.3.1 Absolute quantification 
To calculate the absolute amount of intracellular or extracellular JFH-1 RNA, qPCR or qRT-PCR 
were performed by including 10-fold serial dilutions of a standard of known concentration from 4 
ng to 40 fg.  The standard used for qRT-PCR was wild type HCV RNA JFH-1 generated by in 
vitro transcription, while for qPCR was 5’ UTR PCR amplicons amplified from pJFH-1.  The CT 
results obtained were used to generate a standard curve and calculate the genomic copies of JFH-1 
RNA. 
2.10.3.2 Relative quantification 
Relative quantification was performed to calculate fold change in cellular-gene expression using 
the comparative CT values with the ΔΔCT formula. qRT-PCR CT values of the target gene and 
reference gene were used to calculate the fold change in IRF-3, IRF-7, IFNα, IFNγ, miR-122 and 
NF-kB genes. GAPDH and β-Actin housekeeping genes were used as reference genes.   
2.10.3.3 Statistical analyses 
Statistical analysis was performed by using one-way analysis of variance (ANOVA) to examine 
statistically significant differences between mutant and wild-type infections followed by a 
Dunnett's post test for multiple comparisons. P values of less than 0.05 were considered 
significant. Two-tailed unpaired T test for pairwise comparisons was also used. Statistical 
analysis was only performed with a minimum of three biological replicates. 
 
2.11 siRNA and HCV RNA transfection by electroporation  
To study the effect of gene silencing on HCV replication, the cells were transfected with siRNA 
and full length in vitro transcribed HCV RNA by electroporation as previously described (see 
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2.7.2). The only difference in the protocol was the addition of siRNAs. siRNA molecules were 
purchased from Qiagen and targeted IRF3 and NF-kB. siRNAs added to each transfection 
mixture were 20 µl of 1.3 µM Flexitube IRF3 siRNA stock (20 µM), 20 µl of 1.3 µM Flexitube 
NF-kB siRNA stock (20 µM) and 20 µl of 1.3 µM AllStars negative control siRNA stock (20 
µM).  
Electroporation of a single HCV RNA mutant and targeting or non-targeting siRNA was done in 
duplicate and performed two times. Negative control samples were electroporated with negative 
control non-targeting siRNA. After 72 hours post-transfection, the efficiency of gene silencing 
and HCV RNA load was assessed by harvesting intracellular RNA to perform qRT-PCR. 
Additionally, the transfection efficiency was also evaluated by one step RT-PCR (2.10.3) using 
primers specific to IRF3 and NF-kB. siRNA sequences can be found in the appendix 8.1.7. 
2.12 HCV protein studies  
2.12.1 HCV Anti-Core Immunofluorescent staining  
JFH-1 infected cells were seeded onto a 12-well tissue culture plate at a density of 1x105 cells 
per well.  Huh7.5 were cultured on plastic square coverslips (Ted Pella, Inc.) added to wells 
before plating the cells. For suspension cells (Jurkat, B-LCLs and PBMCs), the coverslips were 
first coated with 1:10 Poly-L-lysine solution (Sigma), air dried, washed twice with PBS and air 
dried once again. The suspensions of cells were incubated on top of the coated coverslips for 
one hour to induce cell adhesion.  The cells were then washed twice with PBS and fixed with 
0.5% Saponin (Sigma)/PBS for 15 min while Huh7.5 cells were fixed in 4% (w/v) 
paraformaldehyde/PBS for 30 min. All the cells were then washed in PBS for 10 min, and 
permeabilised in 0.1% (v/v) Triton X-100 (Sigma) in PBS for 15 min. The cells were then 
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covered with blocking buffer (1% BSA in PBS) for 30 min at 37°C to minimize non-specific 
absorption of the antibodies to the coverslip. The blocking buffer was removed and the cells 
were incubated for 1 hour at room temperature in a humidity chamber with mouse anti-core 
monoclonal antibody C7-50 (Abcam, AB2740) at a dilution of 1 in 400 in PBS supplemented 
with 1% (w/v) BSA. After incubation, the cells were washed three times in PBS for 5 min and 
incubated for 1 hour at room temperature in a humidity  chamber  with  goat polyclonal 
secondary antibody to mouse IgG-H&L (Cy3®) (Abcam, AB97035) at a dilution of 1 in 1000 in 
PBS in 1% (w/v) BSA. After incubation, the cells were washed in PBS for 5 min, three times, 
and once with water to remove excess salts. The water was removed and the coverslips were 
mounted on glass slides after applying  15 µl of Mowiol 4-88(Sigma)  mounting medium (2.4 g 
Mowiol 4-88, 6 g Glycerol, 6 ml distilled water and 12 ml of. 0.2 M Tris pH 8.5) containing 1 µl 
of 4,6-diamidino-2-phenylindole (DAPI) (Invitrogen) nuclear stain.  
Core protein staining was observed using a Nikon Eclipse TE2000S fluorescence microscope and 
Axiovision 4.6 software for image acquisition. 
2.12.2 Western blot analysis of HCV core protein  
2.12.2 .1 Protein preparation and quantification 
The cells were washed in PBS and harvested in 150 µl lysis buffer (50 mM Tris/HCl (pH 7.5), 150 
mM NaCl, 5 mM EDTA, 0.5%  (v/v)  Igepal)  and 1x protease inhibitor cocktail (Sigma).  
The cells were incubated on ice for 30 min to one hour on a rotary shaker. The mixture sample was 
centrifuged for 20 min at 13000 rpm at 4°C and the supernatant containing the proteins was 
transferred into a new Eppendorf tube and stored at -20°C.     
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The Bradford protein quantification assay was used to quantify protein samples. Standards of 
known concentration of BSA were mixed with Bradford Assay Reagent (Sigma) to measure 
absorbance at 595 nm using a Biotech Ultrospec 2000 Spectrophotometer (Pharmacia). Five µl of 
cell lysate were diluted in RNase free water (1 in 10) and mixed with 250 µl of Bradford Assay 
Reagent in a 96-well flat bottom microplate. Protein concentrations were calculated after 5 min 
incubation at room temperature by measuring absorbance at 595 nm using a Versamax Plus 
microplate reader. The results were compared with a curve generated from the BSA standards (1.5, 
1.25, 1, 0.75, 0.5 and 0.25 mg/ml) to estimate protein concentration. 
2.12.2 .2 Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Each loading protein sample consisted of 6 µl NuPAGE LDS (4X) buffer, 50-100 µg of protein 
lysate and deionized water to reach a final volume of 20 µl. The protein samples were denatured 
at 90°C for 5 min, placed on ice and loaded into a precast polyacrylamide NuPAGE Tris-acetate 
mini gel (Invitrogen), which was previously washed and placed into a XCell SureLock mini-cell 
electrophoresis system (Invitrogen) filled with 1x SDS running buffer (50 mL 20X NuPAGE 
Tris-Acetate running buffer and 950 mL deionized water). Fifteen µl of SeeBlue pre-stained 
protein standard (Invitrogen) (appendix 8.3.3) was included on each protein gel alongside 50-100 
µg of each protein lysate sample. The mini gel unit was connected to the Mini-Protean Tetra 
powerpac apparatus (Bio-Rad) and run for one hour at 150 V and 50 mA.  
 
2.12.2 .3 Western Immuno-blotting of Polyacrylamide Gels 
After the run, a Hybond ECL nitrocellulose membrane (Amersham Life Science) was first pre-
soaked in water and then in the transfer buffer (25 mM Tris, 192 mM Glycine, 20% (v/v) 
 Luca Mercuri 
142 
Imperial College London 
Methanol). A mini Trans-Blot cell apparatus (Bio-Rad) filled with transfer buffer at 4°C and 
with a Bio-Ice cooling unit was used to perform the blot. The gel holder cassette was filled from 
the anode metal plate in the following order after being soaked in transfer buffer: pre-wet filter 
sponge, pre-wetted 3 mm chromatography filter paper (Whatman), pre-wetted blocking 
membrane, SDS PAGE gel, two pre-wetted chromatography filter papers and pre-wetted filter 
sponge. 
 
The Mini Trans-Blot cell apparatus was connected to the Mini-Protean Tetra powerpac apparatus 
(Bio-Rad). The blot was run at 4°C for 80 min at 100 V and 400 mA. After transferring, the 
membrane was washed three times in 5 ml PBS-T (PBS with 0.1% Tween 20) for 5 min on a gel 
shaker at room temperature. The membrane was then blocked with 5 ml 4% milk in PBS for 1 
hour. After incubation, the following antibodies were used: Anti-core monoclonal antibody C7-
50 (Abcam, AB2740) diluted 1:1000 in 4% milk in PBS or anti-actin antibody produced in 
rabbits (Abcam, A2066) diluted 1:1000 in 4% milk in PBS. The membrane was incubated 
overnight on a gel rocking shaker at 4°C. The membrane was then washed twice in 5 ml PBS-T 
for 15 min followed by incubation in 4% BSA with secondary antibody; 1:1000 anti-Mouse IgG 
(whole molecule)–Peroxidase conjugated antibody produced in goats (Abcam, A4416) to detect 
HCV core or 1:1000 anti-Rabbit IgG (whole molecule)–peroxidase conjugated antibody 
produced in goats (Abcam, A6154) to detect β-Actin. 
 
The membrane was incubated with secondary antibody in a dark humid chamber at room 
temperature for 1 hour on a gel rocking shaker followed by a final wash in 5 ml PBS-T three 
times for 5 min to remove excess unbound secondary antibody. The membrane was incubated for 
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5 min with 3 ml SuperSignal West Pico detection reagent 1 and 3 ml of reagent 2 (Thermo 
Scientific). After incubation, the excess SuperSignal West Pico detection reagents were removed 
and the membrane was covered with transparent foil, placed side up in an x-ray film cassette and 
exposed to a sheet of autoradiography Hyperfilm ECL (Amersham Biosciences) in a dark room. 
The cassette was closed and the autoradiography sheet exposure times varied depending on the 
antibody, less than 30 sec for core and circa 60 sec for β-Actin. The X-ray film was developed 
using the Optimax X-Ray Film Processor (Protec).  
 
2.12.2 .4 Primary antibody stripping 
To investigate more than one protein on the same western blot, the membrane was stripped to 
remove primary and secondary antibody using the western blot recycling kit (Alpha Diagnostic). 
The western blot membrane was first washed with water and incubated with 5 ml of 1:10 
antibody stripping solution for 20 min on a gel rocking shaker at room temperature. The 
membrane was washed twice in water for five min and incubated twice for five min with 5 ml of 
1x blocking buffer. The membrane was washed three times in 5 ml PBS-T and blocked with 5 ml 
4% milk in PBS for 1 hour on a gel rocking shaker at room temperature. The blot was then 
reprobed with different antibodies. 
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CHAPTER 3 
HCV 5’ UTR POLYMORPHISMS 
 
3.1 Introduction 
The initial aim of the project was to confirm and extend the findings relating to the presence of 
single nucleotide polymorphisms (SNPs) in the IRES region of HCV-RNA extracted from 
PBMCs and plasma of HCV infected patients. The extracted RNA was reverse transcribed and 
the 5’ UTR was amplified using primers 26 and 27. PCR amplicons were purified, ligated into 
pGEM-T easy vector and cloned. The plasmids containing the IRES inserts were extracted from 
bacterial colonies and sequence analysis was used to detect point mutations in the IRES region. 
The nucleotide sequences were compared and secondary RNA structure was predicted to identify 
nucleotide differences between PBMC and plasma-derived IRESes, which may possibly be 
associated with functional differences between the two compartments.  
3.2 Results 
3.2.1 Cloning HCV 5’ UTRs from infected patients. 
 In order to assess the presence of nucleotide substitutions in the 5’ UTR of HCV RNA, 57 
samples collected from 23 patients were investigated. HCV-RNA extracted from PBMCs and 
plasma was reverse transcribed using MMLV-RT and reverse primer 27. After cDNA synthesis, 
a PCR mixture containing the forward primer 26 and the reverse primer 27 was used in the 
amplification of a 243bp in length fragment from the HCV IRES region. To detect the molecular 
weight of the amplicons and contaminants, all PCR products were run on a 2% agarose gel and 
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the size of amplified products was assessed using the 100bp molecular weight (mol. wt.) marker 
(figure 3.1 and 3.2).  
 
 
Figure 3.1 2% agarose gel of a 5’ UTR amplicon from PBMC-derived HCV-RNA 
obtained by RT-PCR. 
Amplicon bands were visualised following staining with 5µl SYBR Safe (Invitrogen) after 
separation on a 2% agarose gel. The size of amplicons was assessed using the 100bp mol. wt. 
marker (Lane 1). Lane 2, a PCR amplicon of 243bp in length. Lane 3, negative control.  
 
The agarose gel electrophoresis revealed amplicons of approximately 243bp in length obtained 
from PBMC-derived HCV RNA. The absence of products in the negative control lane (lane 3) 
confirmed the absence of contamination while the presence of a band in the positive control lane 
(lane 2) confirmed that the basic conditions of the experiment produced the expected positive 
result (figure 3.1). Similar results were obtained with plasma-derived HCV RNA (Figure 3.2).  
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Figure 3.2 5’ UTR amplicons of plasma-derived HCV-RNA obtained by RT-PCR. 
Amplicon bands were visualised following staining with 5µl SYBRSafe (Invitrogen) after 
separation on a 2% agarose gel. The size of amplicons was assessed using the 100bp mol. wt. 
marker (Lane 1). Lanes 2 to 5, PCR amplicons of 243bp in size. 
 
3.2.2 Nucleotide Sequence variation detected in 5’-UTRs. 
To further validate the results and confirm the presence of SNPs in the 5’ UTR, in particular at 
positions 107, 204 and 243, all the amplicons of the 5’ UTR of HCV-RNA extracted from 
PBMCs and plasma were subjected to direct sequencing. Nucleotide sequences were aligned to 
identify mutations and regions of similarity. As the majority of patients were infected with HCV 
subtype 1a (table 2.1) the genomic sequences of 438 HCV subtype 1a isolates obtained from the 
Viral Bioinformatics Resource Centre database (http://www.hcvdb.org) and GenBank were 
aligned with BioEdit software to obtain the consensus sequence, which was used for multiple 
sequence alignments of PBMC and plasma-derived IRES amplicons (figure 3.3). The list of 438 
HCV subtype 1a isolates and consensus sequence can be found in appendix 8.5. 
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Figure 3.3 Nucleotide sequence alignment of the 5’ UTR amplicons obtained from PBMC 
and plasma samples. 
The alignment included sequences from PBMC- (n=38) and plasma-derived (n=16) samples. The 
nucleotide differences among the sequences are highlighted. Nucleotides that were invariant 
among all sequences are indicated by a dot in the alignment. Numbers in the figure indicate 
IRES nucleotide positions relative to the consensus sequence. Nucleotides at position 107, 204 
and 243 are presented in boxes. Names of sequences on the left side of the figure are shown as 
sample origin followed by patient and sample number. The alignment was performed using 
BioEdit 7.1.3 software. 
 
 
 Luca Mercuri 
149 
Imperial College London 
Nucleotide sequence alignment results were used to calculate nucleotide frequency at positions 
107, 204 and 243, and identify differences between PBMC and plasma samples. The results 
revealed similarities between plasma and PBMC samples at positions 204 and 243 (figure 3.4). 
However, at position 107, PBMC samples had the highest frequency of As while plasma samples 
had the highest frequency of Gs (figure 3.4). In PBMC and plasma samples, nucleotide T/U was 
not detected at any nucleotide position (107, 204 and 243), C was not detected at position 107 
and 243, while G was not detected at position 204 (figure 3.4). 
 
 
Figure 3.4 Stacked bar chart of percent frequencies of nucleotide substitutions in PBMC 
and plasma-derived HCV IRESes at positions 107, 204 and 243. 
Data represent the percent frequencies of nucleotide substitutions at indicated nucleotide 
positions (107, 204 and 243) in PBMC and plasma-derived HCV IRESes. Colour bars 
correspond to percentage of; As (blue), Cs (green) and Gs (purple). Nucleotide frequency was 
calculated from 16 plasma-derived IRES samples and 38 PBMC-derived IRES samples. 
Frequency analyses were conducted by using SPSS Statistics software. 
 
The analysis of the possible nucleotide combinations at positions 107, 204 and 243 revealed that 
the majority of the PBMC samples examined had the A-A-A variant, which was absent from 
plasma samples (figure 3.5).  The dominant strain in plasma-derived samples had G-A-A at these 
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positions, which was not encountered in PBMC-derived samples (figure 3.5). These results 
matched with the nucleotide frequency variations between Gs and As at position 107 (figure 3.4).  
 
A G-A-G variant was not present in any of the samples examined while a G-C-A variant was 
only present in PBMC-derived samples (figure 3.5). A higher frequency of A-A-G and A-C-G 
variants was found in PBMC-derived samples (figure 3.5), probably due to the higher frequency 
of As at position 107 in such samples (figure 3.4), while, a higher frequency of A-C-A and G-C-
G variants was present in plasma-derived samples (figure 3.5). Overall the frequency results 
suggested that nucleotide variation at position 107 was the main cause of divergence between 
PBMC and plasma-derived IRESes (figure 3.4 and 3.5). 
 
 
Figure 3.5 Stacked bar chart of percent frequencies of combined nucleotide substitutions at 
positions 107, 204 and 243 (variants) in PBMC and plasma-derived HCV IRESes. 
Data represent the percent frequencies of all possible nucleotide combinations of substitutions at 
positions 107, 204 and 243 detected in IRES amplicons derived from PBMCs (n=38, blue) and 
plasma (n=16, green). Frequency analyses were conducted by using SPSS Statistics software.  
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3.2.3 PBMC versus Plasma derived HCV 5’-UTRs. 
The presence of double peaks in the chromatogram of some of the 5’ UTR amplicon sequences 
suggested polymorphisms at a few positions. Thus, to examine in more depth sequence variation 
of the 5’ UTR, amplicons were cloned into pGEM-T easy vector and for each sample 15 clones 
were randomly selected and sequenced (table 3.1). The plasmids containing the IRES inserts 
were extracted from different individual bacterial colonies. The samples chosen for cloning were 
derived from patients 1, 3, 4, 7, 10, 15 and 17, as more samples were available from these 
patients to study sequence variation at different time points (see 3.2.5). 
 
Table 3.1 5’ UTR consensus nucleotide substitutions detected at positions 107, 204 and 243 
in PBMCs and plasma. 
Nucleotide bases detected at positions 107, 204 and 243 of HCV IRESes derived from clinical 
samples. 5’ UTR nucleotide substitutions relative to consensus sequence. Selected samples 
indicated by arrows were cloned into pGEM-T easy vector and for each 15 clones were 
sequenced. Blue colour indicates cloned samples derived from PBMCs while red colour 
indicates cloned samples derived from plasma. 
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Nucleotide sequences obtained from sequence analysis of clones were aligned and compared to 
the consensus subtype 1a sequence. The nucleotide differences among 263 PBMC-derived 
sequences (38 from amplicons and 225 from clones) and 241 plasma-derived sequences (16 from 
amplicons and 225 from clones) are highlighted on the secondary RNA structure of the 5’ UTR 
HCV (nt. 1-383 genotype 1b (GenBank, AJ238799.1) adapted from Honda et al (1) where 
numbers indicate IRES nucleotide positions relative to the consensus sequence (figure 3.6 A and 
B).  
 
PBMC-derived IRES sequences had more nucleotide substitution sites (27) than plasma-derived 
ones with only 20 nucleotide substitution sites (figure 3.6 A and B). Between PBMC and 
plasma-derived IRESes, nucleotide substitutions present at positions 108, 113, 115, 124, 130, 
198, 200, 216, 234 and 255, were only detected in PBMC-derived IRESes (figure 3.6 A). On the 
other hand, nucleotide substitutions A152 and A207 were only present in Plasma-derived IRESes 
(figure 3.6 B). Nucleotide substitutions at positions 107, 119, 179, 183, 187, 204, 205, 210, 214, 
220, 223, 224, 243, 247, 248, 262 and 270 were detected in both PBMC and Plasma-derived 
IRESes (figure 3.6 A and B).  
 
As the HCV genotype 1b 5’ UTR two dimensional structure was used to position the nucleotide 
substitutions detected in the patient HCV IRESes which were mainly genotype 1a (figure 3.6 A 
and B), the HCV genotype 1b IRES sequence(GenBank, AJ238799.1) was aligned with the 
consensus genotype 1a sequence to pinpoint any differences between the two IRESes. The only 
differences were substitutions 11T, 12G, 13A, 34G, 35A, 204A and 243A present in genotype 1a.  
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Nucleotide frequencies helped to identify the nucleotide positions where nucleotide frequency 
differences occurred between PBMC and plasma-derived HCV IRESes.  The majority of the 
IRES motifs were conserved between PBMC and plasma samples as similar nucleotide 
frequencies were obtained along the IRES sequence (table 3.2). Nucleotide positions 179, 183, 
187, 205, 210, 220, 223, 224, 234, 247, 248, 262 and 270 (highlighted in green) contained two 
nucleotide frequency changes common in both PBMC and plasma-derived samples (table 3.2). 
However positions 107, 119, 124, 152, 200, 204, 207, 214, 216 and 243 had different nucleotide 
frequencies between PBMC and plasma-derived samples (table 3.2, highlighted in yellow). 
These nucleotide positions are annotated graphically on the IRES (Figure 3.7). 
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Table 3.2 Nucleotide frequency summary at the positions indicated in HCV IRESes derived 
from PBMCs and plasma. Comparison of nucleotide frequencies between PBMC- (n=263) and 
plasma-derived IRESes (n=241). Pink columns indicate nucleotide position on the IRES, white 
columns the number of clones with the nucleotide shown and blue colour the frequency as a 
percentage. Those highlighted in green indicate two nucleotide frequency changes for each 
position similar between PBMCs and plasma. Nucleotide frequency changes different between 
PBMCs and plasma are highlighted in yellow.  Single nucleotide frequency similarities between 
PBMCs and plasma are not highlighted. The consensus sequence was not included in this study. 
Data analyses were conducted using MEGA 5.1 and BioEdit software. 
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Figure 3.7 Nucleotide position changes in PBMC and plasma-derived HCV IRESes. 
Positions of nucleotide frequency changes in PBMC- (n=263) and plasma-derived (n=241) 
IRESes; similar nucleotide frequency variation between PBMC and plasma-derived samples in 
green dots and different ones in yellow dots. Structural domains are indicated in Roman letters 
(I-IV). The start codon AUG is highlighted in stem-loop domain IV. The nucleotide sequence 
and putative secondary RNA structure of the 5’ UTR [nt. 1-383 genotype 1b (GenBank, 
AJ238799.1)] was adapted from Honda et al (1). 
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Overall the majority of changes occurred between nucleotide positions 179 to 187, 200 to 224 
and occasionally from 234 and 270 (table 3.2). These results were also confirmed by entropy plot 
analysis (figure 3.8). The entropy values (Hx) along the 200 nucleotides (positions 100 to 300) 
measured nucleotide variation at a given position in 504 aligned sequences (263 from PBMCs 
and 241 from plasma). The positional entry plot indicated that overall the IRES sequences 
derived from PBMCs and plasma were mainly conserved with no variation (Hx=0), particularly 
between regions 120 to 151, 153 to 178, 188 to 198 and 225 to 233 (figure 3.8). Regions between 
179 to 187, 203 to 224, 242 to 249 and at positions 107, 119, 152, 180, 183, 188, 204, 210, 215, 
221, 223 to 225, 243, 247 and 248 were more highly variable (figure 3.8). 
 
 
Figure 3.8 Positional entropy plot of the IRES for the PBMC and plasma-derived samples. 
Entropy plot of IRES sequence alignment of 504 sequences derived from PBMCs (n=263) and 
plasma (n=241). Included nucleotides were from position 100 to 300 of the HCV IRES. The X 
axis indicates the nucleotide position, while the Y axis the entropy (lack of information) at that 
position. Each bar represents the variability at a single nucleotide position. The entropy (Hx) was 
calculated by using BioEdit 7.1.3 software. 
 
The positional entropy data was analysed statistically (figure 3.9). The dataset was randomised 
with replacement 100 times and the difference in entropy was calculated for each of these 
random sets. This difference was compared to the difference between PBMC and Plasma in the 
real set to determine whether the difference in entropy was higher than you would expect based 
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on randomly sampling the sequences. A positive value indicated that the entropy was higher in 
PBMC than in Plasma while a negative value indicated that the PBMC had a lower entropy than 
the plasma. A significant entropy difference according to the randomisation was detected in 
specific nucleotide positions. High entropy in PBMCs was detected at nucleotide positions 104, 
108, 119, 124, 200, 205, 216, 221, 243, 245 and 282, whilst high entropy in plasma (lower in 
PBMC), was detected at nucleotide positions 107, 152, 163, 207, 210, 211, 214, 220, 223, 224, 
262 and 270 (figure 3.9). 
 
 
 
 
Figure 3.9 Entropy differences between the PBMC and plasma.  
Entropy differences between sequences (nt 100 to 300 of the HCV IRES) derived from PBMCs 
(n=263) and plasma (n=241). The X axis indicates the nucleotide position, while the Y axis is the 
entropy difference between sequences derived from PBMCs and plasma. Each bar represents the 
entropy difference at a single nucleotide position. Significant differences between the entropy of 
PBMC and plasma are indicated by orange bars while no significant differences by blue bars. 
The results were generated using a perl script and the figure was produced in R software 
programming language. 
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. 
The Maximum Composite Likelihood analysis of aligned sequences established the pattern of 
nucleotide substitution, particularly the transitional (A to G, T to C, C to T and G to A) and the 
transversional substitutions (A to T, A to C, T to A, T to G, C to A, C to G, G to T and G to C) 
(table 3.3). The transition/transversion bias of the HCV IRES was more in PBMC-derived 
samples than in plasma ones (table 3.3). This suggested that plasma-derived IRES sequences had 
a reduced rate of substitutions in the selected nucleotide bases than PBMC-derived IRES 
sequences.   
 
 
1 PBMCs 
 
2 Plasma 
 
A T C G 
  
A T C G 
A - 3.43 3.43 18.14 
 
A - 4.15 4.15 16.71 
T 3.43 - 18.14 3.43 
 
T 4.15 - 16.71 4.15 
C 3.43 18.14 - 3.43 
 
C 4.15 16.71 - 4.15 
G 18.14 3.43 3.43 - 
 
G 16.71 4.15 4.15 - 
 
 
 
Table 3.3 Maximum Likelihood Estimate of the Substitution Matrix in HCV IRES 
sequences derived from PBMCs and plasma. 
Each entry shows the probability of substitution (r) from one base (row) to another base 
(column). The substitution pattern and rates were estimated under the Kimura (1980) 2-
parameter model (+G) (361). A discrete Gamma distribution was used to model evolutionary rate 
differences among sites (5 categories, [+G]), parameter =0.2283 in PBMCs and parameter 
=0.1411 in plasma derived samples. Rates of different transitional substitutions are shown 
in bold and those of transversional substitutions are shown in italics. The sum of r values was 
made equal to 100. For estimating ML values, a tree topology was automatically computed. The 
maximum Log likelihood for this computation was -676.433 for PBMC sequences and -783.603 
for plasma derived sequences. The analysis involved 504 nucleotide sequences, 263 for PBMCs 
and 241 for plasma. All positions containing gaps and missing data were eliminated. There were 
a total of 200 positions in the final dataset of PBMC and 200 positions in the final dataset of 
plasma samples. Evolutionary analyses were conducted using MEGA 5.1 software. 
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The Maximum Composite Likelihood estimate of the pattern of nucleotide substitutions in HCV 
IRES sequences suggested the probability of nucleotide substitution from one base to another 
base (table 3.4). The analysis of the rates of transitional substitutions (patterns A-G, G-A, C-T, 
T-C) indicated that the T-C substitution was greater than the rest of the substitution patterns in 
PBMC- (35.48) and in plasma-derived (25.66) samples (table 3.4). 
Rates of different transversional substitutions indicated that in PBMC- (5.82) and in plasma-
derived samples (5.98) T-G and C-G was greater than the rest of the substitution patterns (table 
3.4). Thus, PBMC- and plasma-derived samples were T + G and C + G rich. 
 
1 PBMCs 
 
2 Plasma 
 
A T C G 
  
A T C G 
A - 3.8 5.45 1.84 
 
A - 3.91 5.58 11.74 
T 3.35 - 35.48 5.82 
 
T 3.46 - 25.66 5.98 
C 3.35 24.77 - 5.82 
 
C 3.46 17.96 - 5.98 
G 1.06 3.8 5.45 - 
 
G 6.79 3.91 5.58 - 
 
Table 3.4 Maximum Composite Likelihood Estimate of the pattern of nucleotide 
substitutions in HCV IRES sequences derived from PBMCs and plasma. 
Each entry shows the probability of substitution (r) from one base (row) to another base 
(column). For simplicity, the sum of r values was made equal to 100. Rates of different 
transitional substitutions are shown in bold and those of transversional substitutions are shown in 
italics. In PBMCs (table 1), the nucleotide frequencies were 18.20% (A), 20.64% (T/U), 31.60% 
(C), and 29.56% (G). In plasma (table 2), the nucleotide frequencies were 18.28% (A), 20.64% 
(T/U), 31.59% (C), and 29.49% (G). The analysis involved 504 nucleotide sequences, 263 for 
PBMCs and 241 for plasma. All positions containing gaps and missing data were eliminated. The 
consensus sequence was not included in this study. There were a total of 200 positions in the 
final dataset. Evolutionary analyses were conducted using MEGA 5.1software. 
 
The aligned sequences for PBMCs and plasma samples were scanned and the results were 
included in a graph to visualize nucleotide variation at specific positions between PBMCs and 
plasma-derived aligned IRES sequences (figure 3.10). The information scan analysis and 
sequence divergence between PBMC- and plasma-derived IRESes, detected a higher number of 
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nucleotide variations at 40 different positions in PBMC-derived samples compared to 36 in 
plasma-derived samples (figure 3.10). Nucleotide variations detected in PBMC and not in 
plasma-derived IRESes were located at positions 103, 108, 112, 115, 124, 130, 135, 147, 194, 
200, 209, 216, 221, 244, 245, 255, 269, 282 and 299. Among these, the highest nucleotide 
variation was detected at positions 124 and 282 (figure 3.10, PBMCs, yellow circles). On the 
other hand, nucleotide variations detected only in plasma and not in PBMC-derived IRESes were 
located at positions 101, 136, 148, 152, 155, 163, 177, 186, 199, 201, 207, 211, 241, 272 and 273. 
Among these, the highest nucleotide variation was detected at position 152 (figure 3.10, plasma, 
yellow circle).  
The strongest nucleotide variations that occurred in both PBMC- and plasma-derived samples 
were located at positions 107, 179, 183, 187, 204, 210, 214, 220, 223, 224, 243, 262 and 270. At 
position 107, the nucleotide variation was higher in plasma samples than in PBMCs, while the 
opposite occurred at positions 204 and 243 where the nucleotide variation was higher in PBMCs 
than in plasma-derived IRESes (figure 3.10).  The highest nucleotide variation in PBMC-derived 
samples occurred at positions 204 and at position 214 in plasma-derived samples (figure 3.10, 
black circles).  
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Figure 3.10 Information scan of PBMC and plasma-derived sequences. 
The analysis involved 504 nucleotide sequences derived from PBMCs (n=263) and from plasma 
(n=241). There were a total of 200 positions in the final dataset (nt. 100 to 300). White spaces 
indicate nucleotide variation on the alignment at specific positions. Black circles indicate the 
highest nucleotide variable position in PBMCs and plasma-derived samples. Yellow circles 
indicate the highest nucleotide variation present only in PBMCs or plasma-derived samples. All 
positions containing gaps and missing data were eliminated. The reference sequence was not 
included in this study. Data analyses were conducted with BioEdit software. 
 
Conserved nucleotide sequences were identified among PBMCs and plasma- derived IRES 
sequences (figure 3.11). Two conserved regions were identified in PBMC-derived IRES 
sequences. These conserved regions were located on the IRES at positions 120 to 178 and 271 to 
300 (figure 3.11 A). In plasma-derived IRES sequences, five conserved regions were detected at 
positions 120 to 151, 153 to 178, 188 to 203, 225 to 242 and 271 to 300 (figure 3.11 B). The 
conserved region observed at positions 271 to 300 was detected in both PBMCs- and plasma- 
derived IRESes (figure 3.11 A and B). 
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3.2.4 Mutation combinations at positions 107, 204 and 243.  
Nucleotide sequence variation at positions 107, 204 and 243 was examined in all samples, not 
only in the amplicons (figure 3.5) but also in all the clones (figure 3.12).  
The A-A-A variant occurred more frequently in PBMCs (26%) than in plasma-derived samples 
(10%). In PBMC-derived IRESes, the A-C-A variant was dominant with a frequency percentage 
of 31% while the majority of plasma-derived IRESes had the G-A-A variant with a frequency 
percentage of 34%. The G-A-A variant was not present in any of the PBMC samples (figure 
3.12). Another significant difference between PBMC- and plasma-derived samples was the 
higher frequency of the A-A-G variant in PBMC-derived IRESes (21%) compared to plasma-
derived ones with a percentage frequency of only 7%. The frequencies of A-C-G, G-A-G, G-C-A 
and G-C-G variants were similar in both PBMC- and plasma-derived IRESes (figure 3.12).  
 
 
Figure 3.12 Stacked bar chart of percent frequencies of combined nucleotide substitutions 
at positions 107, 204 and 243 in all PBMC- and plasma-derived HCV IRESes. 
Data represent the frequencies in percent of all different possible nucleotide combinations at 
positions 107, 204 and 243 detected in PBMC- and plasma-derived HCV IRES. The combination 
frequency was calculated from all IRES samples, clones and amplicons, derived from PBMCs 
(n=263, blue) and plasma (n=241, green). Frequency analyses were conducted by using the SPSS 
Statistics software. 
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In order to determine in which compartment (PBMCs or plasma) the distribution of each 
nucleotide combination at position 107, 204 and 243 was more variable, PBMC- and plasma-
derived samples were analysed in each patient (figure 3.13). Plasma-derived samples had more 
variation in the population of variants than PBMC-derived samples except in patient 3 and 7 
where only one specific variant was present in plasma samples. In each patient, the GAA and 
GAG variants were present in plasma- but not in PBMC-derived samples.  
 
Figure 3.13 Distribution of each nucleotide combinations at positions 107, 204 and 243 in 
PBMC- and plasma-derived IRES samples in different patients. 
Data represent the frequencies in percent of all possible nucleotide combinations at positions 107, 
204 and 243 detected in PBMC- and plasma-derived HCV IRES samples from different patients 
and at different times as shown in table 3.1. The combination frequency was calculated from the 
total number of clones derived from PBMCs (n=225) and plasma (n=225) samples and 
represented in a stacked bar chart. Frequency analyses were conducted by using the SPSS 
Statistics software. 
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The percentage frequency of the A-A-A variant detected in each patient (figure 3.13) is 
represented graphically in figure 3.14 to show that overall the frequency of the A-A-A variant 
was much higher in PBMCs than in plasma, where some patients (patient number 3, 7 and 15) 
did not have the A-A-A variant (figure 3.14). Most of the patients with high percentage 
frequency of the  A-A-A variant in PBMCs had a lower frequency of the A-A-A variant in 
plasma-derived samples, except for patient number 1 who had similar frequency of the A-A-A 
(33%) variant in PBMC- and plasma-derived samples. The only presence of the A-A-A variant 
in plasma and not in PBMCs was detected in patient number 17 while patient number 15 had no 
A-A-A variant in any samples (figure 3.14). 
 
 
Figure 3.14 Frequency of the A-A-A variant in plasma- and PBMC-derived IRESes from 
different patients. 
Data represent the frequencies in percent of the A-A-A variant at positions 107, 204 and 243 
detected in PBMC- and plasma-derived IRESes in different patients (n=7). A-A-A frequency 
was calculated from the total number of clones from PBMC- (n=225, blue) and plasma-derived 
IRES samples (n=225, red). Frequency analyses were conducted by using the SPSS Statistics 
software. 
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3.2.5 Nucleotide variation over time and Phylogenetic analysis of the HCV 5’ 
UTR population 
 
The changes for each variant over time were analysed in different patients to determine whether 
nucleotide changes occurred at the same time or different time points in PBMCs and plasma. 
This could give information on whether there is separation or connection between the two 
compartments. Among all the different patient samples, only patients 10 and 17 were informative 
on this issue over significant timescales with the exception of PBMC-derived samples of patient 
10 with a shorter time frame of 2 months (Figure 3.15).  
 
Phylogenetic analysis was also conducted to examine and represent evolutionary relationships 
among different sequences. In the phylogenetic analysis of patients 10 and 17 the trees were 
rooted by including in the data set HCV genotype 5 (GenBank accession number L29612.1) as 
the 'out-group' to give the trees an order of branch events and provide direction to the 
evolutionary process (figure 3.15). 
 
In both patients, 10 and 17, IRESes derived from Plasma samples were closely related and the 
same occurred for IRESes derived from PBMC samples. Additionally, both trees indicated a 
very close genetic relationship between the A-A-A variants, which were detected mainly in 
PBMCs of patient 10 and only in plasma of patient 17 (figure 3.15). 
 
In patient 10, the frequency of the A-C-A variant decreased over time in plasma while it 
increased in PBMCs. On the other end, in patient 17 the A-C-A variant detected only in plasma 
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increased over time. The G-A-A variant frequency increased over time in plasma but was absent 
in PBMCs. The A-A-G and G-C-A variants had similar frequency over time while the A-A-A 
variant frequency detected at 14 months decreased by 25 months post infection. In PBMCs, the 
G-C-A and G-C-G variants were only detected at the beginning of infection. In both patients the 
A-A-A variant appeared in plasma after many months of infection; in patient 10 after 14 months 
in plasma but no appearance in PBMCs. 
 
In patient 17, the A-A-A variant was present at the beginning of infection in PBMCs and after 2 
months in plasma where it was no longer detectable at 22 months. In PBMCs, the A-A-A variant 
frequency reached 80% at two months post infection while that of A-A-G decreased from 73% to 
20% after 2 months. The A-A-G variant had low frequency in the plasma of patient 17.  The 
contrary occurred for variant G-A-A, which was present in plasma- but not in PBMC-derived 
samples of either patient (figure 3.15). 
 
Overall, the analysis of the distribution of variants over time indicated that between the two 
compartments, plasma and PBMCs, plasma-derived sequences were more variable than those 
from the PBMCs. In fact, plasma samples of both patients contained A-A-A, A-A-G, G-A-A, A-
C-A, A-C-G, and G-C-A variants. Dissimilarly, PBMCs contained mainly A-C-A, G-C-A and G-
C-G variants in patient 10 and only A-A-A, A-A-G and G-C-A in patient 17 (figure 3.15).  
 
In the analysis of the phylogenetic tree, high sequence divergence was found in A-A-A variants 
from both patients (figure 3.15). Both trees had similar diversification dynamics, however, the 
changes over time in evolutionary lineages represented by branches indicated a greater amount 
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of change as indicated by longer branches in patient 10 (figure 3.15). In both patients, the A-A-A 
variant diverged from the G-A-A variant. Additionally, both variants appeared closely related to 
each other (figure 3.15).  
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Figure 3.15 Distribution and evolutionary analysis of nucleotide combinations at positions 
107, 204 and 243 in PBMC- and plasma-derived IRES samples in patients 10 and 17 at 
different time points. 
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Phylogenetic tree analysis of PBMC- and plasma-derived HCV IRES sequences from patients 10 
and 17 overtime. The sequence names indicate month of infection and nucleotides at positions 
107, 204 and 243. The evolutionary history was inferred using the Neighbor-Joining method 
(362). The percentage of replicate trees in which the associated taxa clustered together in the 
bootstrap test (500 replicates), values ≥ 70% are shown on branches. The tree is drawn to scale, 
with branch lengths in the same units as those of the evolutionary distances used to infer the 
phylogenetic tree. The evolutionary distances were computed using the Jukes-Cantor method and 
are in the units of the number of base substitutions per site. The analysis involved 76 nucleotide 
sequences. For each patient, the analysis involved 75 nucleotide sequences. PBMC-derived HCV 
IRES nucleotide sequences (n=30; blue circles) and plasma-derived HCV IRES nucleotide 
sequences (n=45; red triangles). All positions containing gaps and missing data were eliminated. 
There were a total of 200 positions (nt 100 to 300) in the final dataset. The scale bar corresponds 
to 0.005 substitutions per site. The sequence of HCV genotype 5 indicated by accession number 
(black triangle) was used as out-group. Evolutionary analyses were conducted in MEGA6 (363). 
Data present in the tables represent the frequencies in percent of all different possible nucleotide 
combinations at positions 107, 204 and 243 detected in PBMC- and plasma-derived HCV IRES 
sequences of patients 10 and 17. Combination frequency was calculated from each data sample, 
which consisted of 15 clones. Patient 10 data of plasma samples: time 0, 07/06/2007; time 2 
months, 23/08/2007; time 22 months, 24/04/2009. Data of PBMC samples: time 0, 07/06/2007; 
time 2 months, 13/08/2007. Patient 17 data of plasma samples: time 0, 28/05/2009; time 14 
months, 27/07/2010; time 25 months, 21/07/2011. Data of PBMC samples: time 0, 30/05/2009; 
time 14 months, 19/08/2010.  
 
 
The sequence data obtained from all clones of PBMC- and plasma-derived samples were used to 
construct an unrooted phylogenetic tree (figure 3.16), which revealed lineages containing related 
PBMC- and plasma-derived HCV strains and one distinctive lineage with isolated plasma-
derived strains (figure 3.16, A). A-A-A variants detected in PBMC and plasma suggest possible 
evolutionary selection (figure 3.16, B).    
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Figure 3.16 Phylogenetic tree analysis of all PBMC- and plasma-derived HCV IRES 
sequences. 
 Luca Mercuri 
173 
Imperial College London 
The evolutionary history was inferred by using the Maximum Likelihood method based on the 
Kimura 2-parameter model (357). The tree with the highest log likelihood (-1129.7196) is 
shown. Initial tree(s) for the heuristic search were obtained by applying the Neighbor-Joining 
method to a matrix of pairwise distances estimated using the Maximum Composite Likelihood 
(MCL) approach. The tree is drawn to scale, with branch lengths measured in the number of 
substitutions per site. The analysis involved 450 nucleotide sequences. PBMC-derived HCV 
IRES nucleotide sequences (n=225; coloured in blue) and plasma-derived HCV IRES nucleotide 
sequences (n=225; coloured in red) (A). HCV IRESes with the triple adenine variant (AAA) in 
PBMC (n=36; blue triangles) and in plasma (n=26; red triangles) (B).  All positions containing 
gaps and missing data were eliminated. There were a total of 200 positions (nt 100 to 300) in the 
final dataset. The bootstrap values along the branches indicate percent confidence of branches. 
Bootstrap values greater than 70% are shown. The scale bar corresponds to 0.01 substitutions per 
site. Evolutionary analyses were conducted in MEGA6 (363). 
 
 
3.2.6 Predicted secondary structure of 5’ UTR 
Due to the limitation in the accuracy of thermodynamic structure predictions from individual 
sequences, the prediction of conserved consensus secondary structures from all 5’ UTR 
sequences was essential for subsequent analyses. The availability of many 5’ UTR sequences 
from PBMC- and plasma-derived samples helped to determine through multiple RNA sequence 
alignment the consensus 2D structure within aligned RNAs. All sequences were used to obtain 
the best possible prediction of the consensus structure common to many 5’ UTR sequences with 
regions of significant structural conservation. The computation was performed using the 
RNAalifold program (226), which took into account both thermodynamic stability and sequence 
covariation to predict a minimal energy structure that is conserved across all variants .  
 
The predicted consensus structures obtained from alignment of all sequences (263 from PBMCs 
and 241 from plasma) and different HCV genotype nucleotide sequence data had similar 
structure and common base-pairing elements within the sequence (figure not shown). 
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The predicted consensus structure obtained from alignment of all PBMC-derived sequences was 
compared to the predicted consensus structure obtained from alignment of all plasma-derived 
sequences (figure 3.17). All predicted consensus structures of nucleotide regions 140-252 and 
140-281 had similar conserved structural features with similar regions of predicted base-pairing.  
 
The ΔG values of PBMC-derived 5’ UTR nt 140-252 and nt140-281 regions (ΔG -78.7 kcal/mol; 
ΔG -92.0 kcal/mol) were higher than the equivalent ones of plasma-derived 5’ UTRs (ΔG -76.9 
kcal/mol; ΔG -90.0 kcal/mol) (figure 3.17 left column).  
 
In the analysis of the mountain plots where the x- and y-axes represent the nucleotide position in 
the RNA versus the number of base pairs, similar graphics were obtained between PBMC- and 
plasma-derived samples, with only a few compensatory mutations with respect to the structure 
indicated by different colours (figure 3.17 centre column). The predicted consensus structures 
obtained from RNA alignments using RNAalifold matched the RNA secondary structures 
predicted with mfold and IPknot software (222, 225) and visualised with VARNA software (358) 
(figure 3.17 right column). In these structures, to produce base-pairing probabilities, the 
McCaskill model was used as the scoring model, taking no account of pseudoknotted structures. 
Folding temperature was fixed at 37°C, the ionic conditions were fixed at [Na+] = 1 M and [Mg++] 
= 0 M. Additionally, in all these structures, A-U pairs were indicated by a single line with a 
bullet, a G-C pair with a double line and a G-U pair with a single line. Subdomains were labelled 
in grey (figure 3.17 to 3.21). 
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Figure 3.17 Consensus secondary structures and mountain plots of the 5’ UTRs. 
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Consensus secondary structures and mountain plots of the 5’ UTRs were obtained from aligned 5’ 
UTR sequences (nt: 140-252) derived from PBMCs (n=225) (a1) and from plasma (n=225) (a2), 
and (nt: 140-281) derived from PBMCs (n=225) (b1) and from plasma (b2). Colours indicate the 
number of different types of base pairs (red 1, ochre 2, green 3, turquoise 4, blue 5 and violet 6). 
Saturated colour indicates that all sequences can form the base pair, while two levels of pale 
colour mean that 1 or 2 input sequences have non-pairing bases. Annotated structures were 
obtained from the RNAalifold output and VARNA 3.9 software. 
 
As the mutant constructs were genotype 2a, similar predicted structural analysis was conducted 
for HCV genotype 2a sequences to examine whether the inserted mutations at position 107, 204 
and 243 caused structural changes in the predicted 5’ UTR structures. Thus, multiple sequence 
alignments of IRES sequences were also used with the RNAalifold program to compute 
conserved structures from sequence co-variation. The predicted consensus structures matched the 
RNA secondary structures of HCV IRES domains II and III predicted with mfold and IPknot 
software (222, 225) and visualised with VARNA software (358) (figure 3.18 to 3.21). Tertiary 
RNA structures were also predicted using the  3dRNA (http://biophy.hust.edu.cn/3dRNA/) and 
MC-Fold & Mc-Sym web servers (http://www.major.iric.ca/MC-Pipeline/) and visualised with 
the PyMOL molecular graphics system, version 1.3 software (Schrödinger, LLC) (359, 360). 
Additionally, the ΔG was computed at 37°C using the Turner model (364, 365) for the RNA 
parameters with the RNAeval web server (http://rna.tbi.univie.ac.at/cgi-bin/RNAeval.cgi). 
Sequences and dot-bracket notations can be found in appendix 8.4. 
 
The predicted secondary structures were used to observe if single nucleotide substitutions 
affected HCV IRES structure. The predicted IRES RNA secondary structures of domains II and 
III of consensus mutagenic IRES sequences were compared to the consensus sequence of 
genotype 2a, nt 44-116 and 140-252 to examine the effect of the mutations at positions 107, 204 
and 243 on the IRES domains II (figure 3.18) and III (figure 3.19). Additionally, the effect of 
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single point mutations detected in this study was also examined to observe any predicted 
structural changes on the IRESes (figure 3.20 and 3.21).  
 
Figure 3.18 2D and 3D diagram of the predicted secondary structure of IRES domain II. 
Secondary structure predictions, sequence and dot-bracket notation of IRES domain II predicted 
using Mfold and IPknot software and visualised with VARNA software (A and B). The 
conserved sequence of domain II [isolate JFH-1, genotype 2a, nt 44-116 (GenBank AB047639)] 
was used to predict its secondary RNA structure. In the dot-bracket notation each character 
represents a nucleotide, dots indicate unpaired nucleotides, open parentheses indicate that the 
nucleotide is paired to another nucleotide ahead of it and closed parentheses indicate that a 
nucleotide is paired to another nucleotide behind it. Nucleotide combinations in IRES domain II: 
G107 (A); A107 (B and B.1). Predicted tertiary structure of IRES domain II (B.1). The backbone 
is in a cartoon presentation and coloured in orange with the sugar and bases coloured in blue and 
green. All residues (R) are labelled with nucleotide site and position number. The structure was 
computed with Mc-Sym and/or 3dRNA and visualised with the PyMOL version 1.3 software. 
Residue adenine 64 (RA64) represents nt 107A. 
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Figure 3.19 2D and 3D diagram of the predicted secondary structures of IRES domain III. 
Secondary structure predictions, sequence and dot-bracket notation of IRES domain II predicted 
using Mfold and IPknot software and visualised with VARNA software (A and B). The 
conserved sequence of domain III [isolate JFH-1, genotype 2a, nt 140-252 (GenBank, 
AB047639)] was used to predict its secondary RNA structure. In the dot-bracket notation each 
character represents a nucleotide, dots indicate unpaired nucleotides, open parentheses indicate 
that the nucleotide is paired to another nucleotide ahead of it and closed parentheses indicate that 
a nucleotide is paired to another nucleotide behind it. Nucleotide combinations in IRES domain 
III: C204/ G243 (A); A204/ A243 (B and B.1). Predicted tertiary structure of IRES domain III 
(B.1). The backbone is in a cartoon presentation and coloured in orange with the sugar and bases 
coloured in blue and green. All residues (R) are labelled with nucleotide site and position number. 
The structure was computed with Mc-Sym and/or 3dRNA and visualised with the PyMOL 
version 1.3 software. The residues adenine 62 (RA62) and 101(RA101) represent nt 204A and 
243A. 
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Some mutations caused changes in the predicted secondary structures. In genotype 2a, nucleotide 
substitution G107A resulted in an increase in the size of the interior loop (nt 51-54 and 107-110) 
as the substitution from guanine (G) to adenine (A) removed the three intermolecular hydrogen 
bonds between G and the C at nucleotide positions 54 and 107 (figure 3.18). Nucleotide 
substitutions at positions 204 and 243 of the IRES (C204, A204, G243 and A243) did not cause 
any conformational changes on the IRES structure, as position 204 is located on the hairpin loop 
of subdomain IIIb, while nt 243 forms a one-nucleotide asymmetric interior loop (figure 3.19). 
 
Some of the single mutations detected in PBMC- and plasma-derived samples affected the 
predicted IRES secondary structure of genotype 1a (figure 3.20 and 3.21). These mutations were 
located at positions 107, 108, 152, 204, 207, 243 and 270. The mutation  G107A did not cause 
any structural changes on the predicted IRES domain  II genotype 1a, contrary to the increase in 
size of the interior loop seen in genotype 2a (figure 3.18). Nucleotide substitution C108A 
disrupted the structure of domain II. This mutation was only detected in PBMC-derived IRESes 
(table 3.2). The mutation increased the size of the first asymmetrical internal loop, caused the 
second internal loop to form a duplex structure and transformed the internal mismatch loop to an 
asymmetrical loop with the upper part of the domain orientated to the opposite side inducing a 
zigzag conformation (figure 3.20, B). The addition of both mutations, G107A to C108A, 
restructured the first asymmetrical loop into a symmetrical internal loop, formed a larger 
symmetrical second loop and caused the inclination of the upper part of the domain towards the 
opposite side formed by the reverse orientation of  the upper asymmetrical loop (figure 3.20, C).  
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Figure 3.20 Structural changes in the predicted secondary and tertiary structure of IRES 
domain II by nucleotide substitutions detected in PBMC and plasma-derived IRESes. 
Predicted secondary and tertiary structures of IRES domain II using the conserved sequence of 
the IRES domain II [genotype 1a, nt 44-118 (GenBank, NC004102)] where single point 
mutations were introduced. Nucleotide substitutions in IRES domain II WT genotype 1a (A): 
C108A (B); G107A & C108A (C). Predicted tertiary structures of IRES domain II were 
computed with Mc-Sym and/or 3dRNA and visualised with the PyMOL version 1.3 software. 
The backbone is in a cartoon presentation and coloured in orange with the sugar and bases 
coloured in blue and green. All residues (R) are labelled with nucleotide site and position number. 
The residues adenine 64 (RA64) and 65(RA65) represent nt 107A (B) and 108A (C). ΔG was 
computed at 37°C with the RNAeval web server using the Turner model for the RNA parameters. 
 
Single point mutations that lead to structural changes in the IRES domain III were located at 
nucleotide positions 152, 207 and 270. Mutations G152A and C207A were detected only in 
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plasma-derived samples (13% and 8.3%, table 3.2) while C270U was detected in both PBMC- 
and plasma-derived samples (table 3.2). 
 
The mutation G152A increased the size of the internal loop, which became asymmetrical, and 
reduced its ΔG value (figure 3.21, C). Mutation C207A increased the ΔG value and resulted in 
the formation of an asymmetric internal loop on the upper part of domain III. This loop was not 
present before and reduced the size of the hairpin loop of the predicted subdomain IIIb (figure 
3.21, B). Additionally, it led to the formation of a duplex structure from previously unbound 
nucleotides (nt 199 to 202) located in loop IIIb. On the other hand, mutation A207C reversed this 
conformation (figure 3.21, A). Mutation C207U disrupted the structure of subdomain IIId, 
decreased the ΔG value and led to the formation of a double branch loop junction and a duplex 
structure from the asymmetrical loop (figure 3.21, D).  
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Figure 3.21 Structural changes in the predicted secondary and tertiary structure of IRES 
domain III by nucleotide substitutions detected in PBMC- and plasma-derived IRESes. 
Predicted secondary and tertiary structures of IRES domain III using the conserved sequence of 
the IRES domain III [genotype 1a, nt. 140-281 (GenBank, NC004102)] where single point 
mutations were introduced. Nucleotide substitutions in IRES domain III WT genotype 1a (A): 
C207A (B); G152A (C) and C270U (D). Predicted tertiary structures of IRES domain II were 
computed with Mc-Sym and/or 3dRNA and visualised with the PyMOL version 1.3 software. 
The backbone is in a cartoon presentation and coloured in orange with the sugar and bases 
coloured in blue and green. All residues (R) are labelled with nucleotide site and position number. 
Residue adenine 71 (RA71) represents nt 207A (B). The ΔG was computed at 37°C with the 
RNAeval web server using the Turner model for the RNA parameters. 
 
The effect of single point mutations on the thermodynamic stability of the RNA was examined 
on the relevant IRES domains (table 3.5). A decrease in ΔG indicated an increase in stability of 
the relevant domain while an increase in ΔG indicated a decrease in stability. Mutations G200A, 
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A204C, A214U, U216C and G243A had no effect on the stability of the RNA secondary 
structure. However, mutations A107G, A108C in the IRES domain II and mutations A152G, 
C207A, U262C and U270C in the IRES domain III increased the stability of the IRES structure. 
On the other hand, reversion of these mutations decreased IRES stability.  
G200A and U216C were only detected in PBMCs while G152A and C207A only in plasma-
derived IRESes. Additionally, the highest change in ΔG was detected at position 113 (table 3.5). 
 
 
 
Table 3.5 The effect of single point mutations on the thermodynamic stability of the 
relevant IRES domains. 
The thermodynamic stability of the relevant domains was calculated using the RNAeval program 
with RNA free energy parameters and ΔG set at 37°C. Blue cells indicate mutations detected 
only in PBMC-derived IRESes while red cells indicate mutations detected only in plasma-
derived IRESes. 
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The IRES sequences of HCV genotypes 1b, 2a, 3a, 3b, 4a, 4d, 5a and 6a were compared with 
consensus sequence genotype 1a to identify nucleotide differences detected in this study at 
positions 107, 108, 152, 200, 204, 207, 214, 216, 243, 262 and 270 (table 3.6). No changes were 
detected in any of the HCV genotypes at positions 108, 152, 200, 207 and 216. Nucleotide 
changes among different HCV genotypes occurred at positions 107, 204 and 243. Substitutions 
U 214, C262 and C270 occurred only in genotype 2a (table 3.6). 
 
 
 
Table 3.6 Nucleotide differences at selected positions among different HCV genotypes. 
Nucleotide positions where mutations occurred in the IRES from PBMC- and plasma-derived 
RNA. The HCV subtype 1a consensus sequence was used as reference sequence. Nucleotide 
differences from the reference sequence are indicated in larger bold font size.  
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3.3 Discussion 
The primary goal of this investigation was to analyse the IRES region of the HCV genome.  
Although the IRES sequence is known to be highly conserved, the results in this study indicated 
nucleotide sequence variability within this region of the HCV genome in different patients.  
 
Sequence analysis of the amplicon products from PBMC- and plasma-derived samples 
confirmed the presence of SNPs in the IRES region, particularly at positions 107, 204 and 243 
(figure 3.3). In PBMC-derived samples the triple adenine variant (107A, 204A and 243A), was 
the dominant variant (36.8%) detected among the 38 investigated samples while it was not 
detected in any of the 16 plasma-derived samples (figure 3.4).  
 
Point mutations (G107A, C204A and G243A) in the HCV IRES have been previously detected 
in HCV RNA extracted from PBMCs, lymph nodes and brain tissue (321, 322). In these and 
other studies, the A-A-A HCV variant arose from nucleotide substitutions in the wild type HCV 
G-C-G variant (310, 311, 318) . However, in this study, the A-A-A variant appeared to be the 
natural wild-type variant for PBMCs, possibly the fittest variant that adapts to PBMCs with the 
possible ability to multiply and spread in these compartments given certain conditions. In other 
words, conditions in plasma might favour the G-A-A variant while in PBMCs the A-A-A variant 
prevails possibly due to adaptation to the different environment conditions and cellular tropism. 
Thus, the A-A-A variant might display a preferential tropism for PBMCs resulting in 
compartmentalisation of HCV in PBMC subsets, which has been shown to support productive 
HCV infection  (366). 
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The presence of the A-A-A variant only in PBMC-derived IRESes was supported by the high 
frequency of As present at position 107 in PBMC-derived samples while at this position plasma-
derived samples had the highest frequency of Gs (figure 3.4). In fact, the wild type G-A-A 
variant was the main variant (43.7%) presents in plasma-derived IRESes and absent in PBMC-
derived samples. Additionally, plasma-derived IRESes had a higher frequency of A-C-A and G-
C-G variants compared to PBMC-derived IRESes (figure 3.5). In previous experiments, the A-
A-A variant increased translation activity in lymphoid cell lines compared to wild-type G-C-G 
variants but not in cell lines derived from monocytes, granulocytes and hepatocytes (311). 
Additionally, the A-A-A variants have also been detected in the brain suggesting the CNS as a 
candidate site of extrahepatic replication (303, 314). 
 
IRES polymorphism and nucleotide variation at positions 107, 204 and 243 was examined in 
more depth with the sequence analysis of 15 clones from 7 patients (table 3.1). The analysis of 
all 5’ UTR sequences obtained from amplicon products and clones confirmed the presence of 
mixtures of viral strains within each patient (figure 3.12).  
 
The A-A-A variant  in PBMC samples (26%) versus plasma samples (10%) confirmed the A-A-
A as the dominant variant in extrahepatic reservoirs of HCV together with the A-C-A variant 
(figure 3.12). In fact, the majority of PBMC samples had the A-C-A variant with a frequency 
percentage of 31% while the majority of plasma-derived samples had the wild type G-A-A 
variant (34%). Additionally, PBMC-derived samples had the highest frequency of the A-G-G 
variant (21%) compared to plasma-derived samples, which had an A-G-G variant frequency of 
only 7% (figure 3.12). These results seem to suggest that the G-A-A variant, present only in 
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plasma, is the wild-variant and possibly not required in PBMCs where the IRESes diverged from 
the G-A-A variant to the A-C-A and A-A-A variants. These variants may be a determinant in the 
re-infection of the liver after antiviral treatment and therefore a contributing factor in the 
persistence of HCV infection, a viral strategy for latency and immune escape.  
 
The distribution of nucleotide combinations at positions 107, 204 and 243 was examined in each 
patient (figure 3.13). In this analysis, the plasma samples were more diverse in the population of 
variants than PBMC ones. These results may be caused by a reduced exposure of the virus in 
PBMCs to the immune system, passively evading thus its response. Thus, the A-A-A variant 
which appeared to be the natural wild-type for PBMCs might display a preferential tropism for 
these cells.  
 
It is possible that these extrahepatic strains with divergent IRESes between PBMCs and plasma 
may compete through the efficiency of their IRESes, which may have an effect on the HCV life 
cycle. Additionally, nucleotide substitutions at positions 107, 204 and 243, may also correlate 
with serum HCV RNA concentration, ALT and interferon levels in infected patients, as 
translational efficiency may dictate epitope display on infected cells. Additionally, the presence 
of PBMC variants not detected in plasma of the same patient, and therefore derived from his/her 
liver, may indicate provenance from replication in PBMCs or other extrahepatic sites or may 
represent archived HCV RNA from quasispecies no longer present in plasma or may be caused 
by selection of viral variants in PBMCs. 
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Samples derived from patients 10 and 17 were examined to detect the frequency of combination 
changes at positions 107, 204 and 243 at different time points (figure 3.15). This analysis also 
confirmed the presence of mixtures of viral strains within a patient and possible selection of 
extrahepatic strains that co-infect a single individual. The G-A-A variant was the dominant 
sequence among plasma-derived samples (figure 3.15). The PBMC compartment appeared less 
variable than the plasma possibly due to a reduced exposure to immune selection. Additionally, 
the variation in PBMC variants overtime may not exclude possible efficient viral propagation.   
 
The different combination frequencies detected at different time points in both patients may 
indicate a continuous variant evolution at these positions. Changes in the frequency of variants 
occurred at different times for PBMCs and plasma indicating separation between the two 
compartments, also confirmed by sequence analysis where no concomitant sequence changes 
were detected in both compartments and at the same time point (figure 3.15).  Undoubtedly, 
there are sequence changes overtime in both Plasma and PBMCs which in the latter case may 
enable the virus to adapt and/or escape the host’s immune response. The frequency of changes of 
the different variants over time may also be dependent on viral fitness. Additionally, the detected 
variants may influence subsequent mutations overtime in each compartment. Although the 5’ 
UTR does not encode any protein, it does control polyprotein translation. Therefore, down-
regulation of translation may allow escape from immune detection of PBMC variants. Further 
studies are required to determine whether the detected mutations occur randomly or are 
dependent on external factors. 
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The frequency of the A-A-A variant among the different patients indicated the dominance of this 
variant in PBMCs. The A-A-A variant, detected mainly in PBMCs of most patients suggested a 
viral adaptation specific to PBMCs. However, in patient 17 the A-A-A variant was detected only 
in plasma quasispecies (figure 3.15).  
 
In the phylogenetic analysis of samples derived from patient 10 (figure 3.15), the A-A-A 
lineages detected in PBMC branched off the A-A-A in plasma suggesting that the PBMC A-A-A 
variant originated or was derived from plasma. By looking at evolutionary lineages changing 
over time, the A-A-A had the larger amount of changes at 67 days in patient 10 and at 784 days 
in patient 17 (figure 3.15). In patient 17 the big evolutionary changes occurred in plasma A-A-A 
and G-A-A, both of which formed a sister group indicating that are both relatively distantly 
related. Additionally, the high bootstrap value of 91, which gave information about the stability 
of the tree topology, was strong evidence that both A-A-A and G-A-A sequences clustered 
together to the exclusion of any others (figure 3.15). 
 
Phylogenetic analysis of all PBMC- and plasma-derived IRES sequences suggested that on the 
whole, PBMC-derived IRESes were the most divergent variants with the longest branch lengths 
and appeared to have originated from plasma. Additionally, the tree suggested a non-random 
distribution of PBMC- and plasma-derived IRESes (figure 3.16). The Phylogenetic tree 
suggested that the A-A-A variant possibly evolved and/or derived from plasma. However, more 
data is required to understand the relationship of the different phylogenetic polytomies. 
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The Maximum Composite Likelihood Estimate of the pattern of nucleotide substitutions in HCV 
IRES sequences derived from PBMCs and plasma indicated that the transitions are dependent 
upon the percentage of T + C or C + T content within the IRES sequences as PBMC- and 
plasma-derived samples were T + C rich (table 3.4). This result suggested that T-C bonds are 
important in stabilising the IRES and could play a role in promoting the correct binding of 
cellular factors. 
 
To examine the differences between PBMC- and plasma-derived IRESes, the positional entropy 
plot data was analysed statistically. Entropy differences at nt positions between the two 
compartments were already detected in the positional entropy plot (figure 3.8), however, in the 
statistical analysis the sites were tested for significant differences using a randomisation test 
highlighting thus the significant differences between the two compartments (figure 3.9). The 
analysis indicated significant entropy differences according to the randomisation between 
PBMC- and Plasma-derived sequences (figure 3.9). By comparing the sites with high entropy in 
PBMCs (nt positions 104, 108, 119, 124, 200, 205, 216, 221, 243, 245 and 282) and high entropy 
in plasma (nt positions 107, 152, 163, 207, 210, 211, 214, 220, 223, 224, 262 and 270), 
significant differences with high entropy values were located in domain II in PBMCs and only 
on the right side of the predicted IRES domain III. On the other hand, the high entropy in plasma 
concerned only position 107 in IRES domain II and both sides of domain III, in particular 
domain IIIb and domain IIId, which are involved in the binding to eukaryotic initiation factor 3a 
and the 40S ribosomal subunit (274). This suggests some sort of selective pressure in these 
regions and the relation of entropy changes with IRES activity. Regarding nt positions 107, 204 
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and 243, the entropy was higher only in Plasma at positions 107 and 243 while no significant 
differences occurred at position 204.  
 
Some of the nucleotide substitutions detected in PBMC- and plasma-derived IRESes (figure 3.6) 
may have a strong inhibitory effect on cellular proteins and/or cause possible structural changes 
within IRES elements as RNA is a flexible molecule that can form alternative structures based 
on the mutations, virus life cycle, biological functions, and cellular environment (367, 368). 
IRES structural/thermodynamic stability is an important factor for efficient binding to host 
ribosomes for viral polyprotein translation. Thus, IRES structure was predicted to examine the 
effect of the mutations detected in this study on IRES structural/thermodynamic stability. 
 
The effect of the detected mutations on IRES function can be analysed as follows. The ribosomal 
subunits recognised the structure of the IRES and not necessarily the nucleotide sequence. This 
can be deduced through comparison of the HCV and GBV-B IRESs whereby domains II and III 
assume almost identical structure, even though there is very little nucleotide homology. 
Therefore, nucleotide changes that do affect adversely the structure would have a negative 
impact on translational efficiency. Where this does occur, then co-variant substitutions are 
encountered, but this was not the case in the substitutions encountered in this study. Having said 
the above, there are nucleotides which are critical in host factor binding and their mutation may 
have a deleterious effect, or may up-or down-regulate translational efficiency.  
 
As structure predictions for a set of aligned RNA sequences produce more accurate results than 
energy directed folding of single sequences (369), the availability of many 5’ UTR sequences 
 Luca Mercuri 
192 
Imperial College London 
permitted the analyses of the conserved structures on the basis of sequence co-variation with the 
use of RNAalifold software (369). 
  
In the analysis of RNA secondary structures, mutation of a single base, which is involved in a 
pairing, should compensate by a change in its pairing partner in order to retain isosteric base 
pairs. This phenomenon termed co-variation or compensatory mutation was identified from 
multiple sequence alignments; only very few mutations affected the pairing centrical where a 
single mutation on one side of the RNA helix compensated with a second mutation on the other 
side. These mutations were detected at positions 187-210 and 179-220 in both PBMC- and 
plasma-derived samples (figure 3.6 and 3.17). At positions 187-210 a C-G pair changed into a U-
A pair while at position 179-220 an A-U pair changed into a G-C pair (figure 3.6). 
Compensatory mutations had no impact on the predicted IRES domain III structure. 
 
On the other hand, consistent mutations, single point mutations that resulted in no changes in 
their pairing partners, were detected at positions 223, 224, 247, 248, 262 and 270 in both PBMC- 
and plasma-derived samples.  Consistent mutations at positions 152, 185 and 207 were detected 
only in plasma-derived samples and only mutations at positions 152 and 207 caused structural 
changes in the predicted IRES domain III due to mismatch 152A*C240 and 190G*A207 (figure 
3.21). Mutations detected in the IRES domain II at positions 107, 113 and 115, some of which 
caused structural changes in the predicted 2D RNA structures (figure 3.6 and 3.19) could not be 
considered either compensatory or consistent mutations as the other side of the RNA helix of 
IRES domain II was not examined. Additionally, mutations detected in IRES domain III loops 
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did not result in any predicted structural changes as additional pairing and mispairing were not 
detected. 
 
The predicted consensus secondary RNA structures obtained from aligned RNA sequences were 
compared to confirm the accuracy of structure predictions. Similar predicted RNA consensus 
secondary structures were obtained from PBMC and plasma sequence alignments. The predicted 
structure analysis identified RNA motifs with the same pairing partners in both PBMC- and 
plasma-derived consensus structures (figure 3.17). Structure comparisons indicated similar 
folding with structural regions in similar locations. Additionally, these secondary structures were 
similar to the predicted RNA consensus secondary structure obtained from aligned RNA 
sequences of different HCV genotypes (figure not shown). These results indicated the strong 
conservation and identical pairing partners occurring in the examined IRES regions (domains 
IIIa-d), which are highly conserved among different genotypes of HCV. Additionally, the 
predicted structures obtained in this study proved to be accurate when compared to the predicted 
secondary IRES structure proposed by Brown et al. (235) and Honda et al. (278), indicating 
again a similar structural conservation for the HCV 5’ UTR, which is essential to maintain the 
correct functioning of the IRES. 
 
Due to time limitations and the fact that structure analysis and validation was beyond the scope 
of this thesis, structure probing analysis was not performed in this study, although in hindsight it 
would have been quite informative. Chemical and enzymatic probing combined with 
mutagenesis would have been critical for validating and interpreting RNA structure or modelling. 
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Additionally, structure probing data could have been compared to consensus RNA structures. 
Thus, probing analysis will be useful for future analysis of IRES mutants. 
 
In the analysis of point mutations present in domains II and III of the IRES, PBMC-derived 
samples had a much higher number of mutations in domain II compared to plasma-derived 
samples (7 versus 2 mutations), particularly between nts 107 and 130 (figure 3.6). Although 
domain II is not directly involved in the binding to the ribosome and eIF3, recent studies have 
shown that domain II induces a conformational change in the 40S ribosomal subunit  and 
possibly holds the coding RNA into the decoding centre of the ribosome during the assembly of 
the translation machinery (267, 367). Thus, the predicted structural changes caused by the 
detected mutations C108A alone or in combination with G107A in domain II could possibly 
influence the initial steps that lead to translation initiation in PBMCs. Mutation C108A, detected 
only in PBMC-derived IRESes, may help HCV to possibly reduce HCV translation and avoid 
immune detection. However, sequence analysis took into account only the IRES region between 
nt 100 to 300 and for this reason is not possible to establish in detail all nucleotide variations that 
occurred in domain II.   
 
In this study, sequence variability was more pronounced in domain III, particularly in the upper 
part, above a 4-way junction (IIIa, b and c), and between subdomains IIIc and IIId.  
Domain III, which represents a stable, large structure with multiple stem-loops, is the major 
target of cellular factors (261) and the  only  domain  that  interacts efficiently with all other 
domains (306). Thus, mutations in the IRES may result in the loss of interaction between the 
IRES and cellular factors. Substitution regions were located between nts 175 to 187, 204 to 224 
 Luca Mercuri 
195 
Imperial College London 
and 243 to 270 (figure 3.6 and table 3.2). The apical part of domain III is believed to interact 
with eIF3, the 40S ribosomal subunit and some trans-acting factors (370) and might facilitate the 
recruitment of the ribosome to the IRES. Sequence polymorphisms between nts 175 to 187 and 
nts 210 to 224 have also been detected in previous studies (371). Additionally, the proximity of 
the 40S subunit to the helical junction IIIabc of domain III  might be the cause of the 
concentration of substitutions in this IRES region, a region that has an important role during the 
formation of the 48S preinitiation complex and during the recruitment of the 43S subunit and 
eIF3(259). 
 
In this study, both stem-loops IIIa and IIIc were all conserved among PBMCs and plasma-
derived IRESes, except for a single mutation in stem-loop IIIc at position 234 detected only in 
PBMC-derived samples (figure 3.6 A). The analysis of this mutation revealed no changes in the 
predicted structure and thermodynamic stability of the IRES (data not included).  
 
Overall, the results suggested that the IRES is subject to more modifications in PBMCs than in 
plasma as a larger number of mutations were identified only in PBMC-derived IRESes at 
positions 108, 113, 115, 124, 130, 198, 200, 216, 234, 255 and 259 (figure 3.6 A). It is possible 
that some of the different mutations detected in PBMCs and plasma might also be caused by the 
origin of the released virus particles, which could have been released from the liver or from 
lymphocytes, and based on the mutations acquired may allow viral replication or inhibition in 
extrahepatic sites. This hypothesis could also explain the minor variants detected in each 
population from the cloning study. B cells and/or monocytes have been shown to frequently 
harbour specific HCV variants during chronic infection (346).  
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Despite the overall sequence divergences in the IRESes derived from plasma and PBMC samples, 
conserved IRES regions were located at positions 120 to 178 and 271 to 300 in PBMC-derived 
IRESes, while in plasma-derived IRESes there were two more regions, at positions 188 to 203 
and 225 to 242 (figure 3.11). Some of these regions are located in ribosomal binding sites as 
previously reported (294). The conserved region between nt 271 to 300 was common in both 
PBMC- and plasma-derived IRESes as this region is essential for binding to the 40S subunit 
(372). This region contains subdomain IIId, an essential component of the HCV IRES, as 
previous studies have shown that mutations within domain  IIId  disrupted  IRES-mediated 
initiation  caused by the structural reorganisation of the HCV IRES leading to reduced IRES 
activity (273, 274). PBMC-derived samples had more mutations in domain IIId than in plasma-
derived IRESes suggesting a possible reduction in IRES activity by the acquired mutations in 
domain IIId in PBMCs. 
 
In the analysis of the effect of mutations at positions 107, 204 and 243 on the predicted IRES 
structures, nucleotide substitution G107A resulted in an increase in the size of the interior loop 
(nt 51-54 and 107-110) as the substitution from G to A removed the three intermolecular 
hydrogen bonds between G and C at nucleotide positions 54 and 107 (figure 3.18). IRES 
thermodynamic stability increased with mutation A107G and decreased with G107A. All these 
changes caused by nucleotide substitution G107A did not occur in the IRES of genotype 1a as in 
this position a wobble base pair, a non-Watson-Crick base, between U and G in the WT sequence 
(figure 3.20, A) becomes a U-A base pair (figure not shown).  This once again indicates that as 
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long as secondary structure is maintained irrespective of nucleotide change, then translational 
efficiency is not affected. 
 
Nucleotide substitutions detected in the samples at position 204, located on hairpin loop 
subdomain IIIb, and at position 243, located in the IIIc/IIId junction, did not cause any 
conformational changes in the predicted IRES structure and had no effect on the thermodynamic 
stability of the IRES (figure 3.19 and table 3.5). However, previous studies reported that nt 243 
has the role of maintaining IRES function in genotype 1b where A243 binds to U149 resulting in 
altered pairing in this position (373).  
 
The occurrence of nucleotide substitutions at positions 107, 204 and 243 was also clear in 
different HCV genotypes (table 3.6). These changes might influence the differential binding of 
cellular factors that may be involved in the formation of the translational complex. It is possible 
that the identified mutations may occur during the life cycle of the virus under certain cellular 
environmental conditions and that the location of the point mutations on the IRES may disrupt 
IRES function or reduce translation efficiency as seen in previous studies (303, 311, 367).  
 
The predicted IRES structure and thermodynamic stability were also affected by single point 
mutations located at positions 152, 207 and 270 (figure 3.21 and table 3.5). Interesting results 
were obtained from the two mutations, G152A and C207A, detected only in plasma-derived 
IRESes. The mutation G152A disrupted the Watson-Crick base pair between nt 152 and 240 
resulting in an increase in size of the internal loop, which became asymmetrical (figure 3.21, C). 
This event destabilised the predicted secondary structure as it introduced a non-Watson-Crick 
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base pairing at this site. Mutation C207A resulted in the formation of a predicted asymmetric 
internal loop, not present before, and reduced the size of the predicted hairpin loop of subdomain 
IIIb. This event disrupted the Watson-Crick base pair between nt 190 and 207 and altered the 
predicted secondary structure in this region. Additionally, it created a duplex structure from 
previously unpaired nucleotides (nt199 to 202) (figure 3.20, B). On the other hand, nucleotide 
substitution C270U disrupted the predicted subdomain IIIb structure. This substitution is located 
in a region (nt 277 to 295) known to be essential for binding to 40S subunits (372). 
 
The analysis of the effect of the examined mutations on the thermodynamic stability of the IRES 
indicated that mutations G200A, A204C, A214U, U216C and G243A had no predicted effect on 
the stability of the RNA secondary structure. However, IRES stability decreased with mutations 
A107G, A108C, A152G and U262C, and increased with mutations G107A, C108A, G152A, 
A207C, C262U and C270U as these mutations led to a ΔG value decrease (table 3.5). It is 
possible that the effect of one mutation on IRES stability might be counteracted by the 
occurrence of another mutation. For example the effect of A107G and/or A108C might be 
counteracted by the effect of G107A and/or C108A together or in combination (figure 3.20). 
The IRES may acquire a single point mutation, as C207A was detected only in plasma-derived 
IRESes to decrease the thermodynamic stability of the IRES and thus possibly reduce viral 
translation in plasma or acquire mutations such as G107A, G152A and C207A to increase IRES 
stability and possibly increase viral translation. 
 
Previous studies indicated that specific mutations located in IRES domains II and III result in 
substantial reductions and abolish IRES activity (242, 274, 367). The detected mutations were 
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functionally important as mutations on the apical region of domain II led to conformational 
changes that had a severe effect on IRES function while mutations on stem loop IIId had an 
effect on RNA folding that resulted in the loss of affinity for the 40S-ribosomal subunits with the 
loss of IRES function. Further experiments are thus required to draw conclusions on the 
biological implications of the mutations detected in this study as they may or may not have 
implications on the function of the IRES. Additionally, the full genome sequence should also be 
examined for viral diversity and any specific polymorphisms across the viral genome. As in the 
case of the 3’ UTR which is involved in intramolecular base pairing with the NS5B encoding 
region, there remains possible that similar interactions may occur between the 5’ UTR and 
down-stream encoding regions. 
 
Regarding the thermodynamic stability, the results obtained in this study may not predict the 
affinity of RNA binding to ribosomal subunits but it is possible that the IRES stability might 
affect HCV replication. Thus, thermodynamic stability is significant but not a sufficient 
parameter for prediction of viral replication or binding to ribosomal subunit complexes. Further 
studies are required to unravel the exact role of the IRES in HCV persistence. 
 
HCV might acquire mutations to decrease the thermodynamic stability of the IRES and to 
control its replication while present in immunopriviledged sites. This might explain the different 
infection outcomes among HCV patients. Additionally, populations with acquired mutations may 
increase over time resulting in long-term clinical consequences. The hypothesis of extrahepatic 
replication in PBMCs is supported but not confirmed by the finding of PBMC-derived variants in 
plasma samples. However, the finding of similar variants between the different compartments 
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does not prove viral replication in PBMCs but suggests viral adaptation and selection pressures. 
Thus, the host immune pressures on the virus could possibly have had an effect with sequence 
diversity detected in PBMC- and plasma derived IRESes. Sequence diversity could possibly lead 
to divergent phenotypic properties that can have an effect on HCV fitness, cell tropism and 
immunologic escape. 
 
3.4 Conclusions 
The results reported here clearly indicated sequence variability of the IRES sequences derived 
from PBMC samples versus these from plasma samples. These sequences may also differ from 
liver samples, as a previous study indicated that circulating quasispecies do not reflect the viral 
population replicating in the liver (374). The mutations and regions of similarities identified in 
this study may be a consequence of functional, structural, or evolutionary relationships between 
IRES sequences.  
 
The results of this study indicated that strains co-infecting an individual may have divergent 
IRESes. This result raises the possibility that these strains may compete through the efficiency of 
their IRES based on the acquired point mutations. In fact, previous results suggested that plasma 
IRESes were more competent than B cell IRESes in hepatocyte cultures indicating  a selective 
pressure on extra-hepatic strains and, therefore, extra-hepatic replication (375). 
 
HCV variants might give a selective advantage in immunoprivileged sites and allow the 
persistence of the virus in these sites without immune detection as previously suggested (316). In 
other words, viral adaptation to a state of latency in extrahepatic sites. This could explain why 
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nucleotide substitutions occurred more often in PBMCs than in plasma-derived samples. In 
future experiments it will be necessary to understand the balance between the functional effects 
of the IRES mutations on translation versus replication. 
 
The sequence variability detected in this study may have implications for the replication of the 
virus as some of these sequence mutations changed overtime and altered the predicted structure 
of the HCV IRES. These changes may possibly influence the binding of cellular factors and may 
reduce translation efficiency.  
 
The primary conclusion of this work is the presence of lymphotropic HCV, the coexistence of 
subpopulations of IRESes in patients, the prevalence of the combination of the three mutations 
and nucleotide differences in the IRESes derived from PBMCs versus plasma-derived IRESes. 
The results suggest quasispecies dynamics and the ability of HCV to adapt to its host 
environment through IRES diversity. Thus, although the IRES region is the most conserved part 
of the HCV genome, the sequence diversity identified in PBMCs and plasma-derived samples 
might be a survival mechanism of the virus to regulate translational activity and tropism in 
different cells. However, more experiments are required to understand whether mutations in 
IRES domains II and III confer a survival advantage or disadvantage.  
 
Nucleotide substitutions detected in domain III had a predicted effect on the IRES structure and 
as the IRES requires a stable and specific secondary structure to perform its function, the 
mutations might affect IRES functional activity. Structural changes predicted in this study could 
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result in different binding abilities of cellular factors to the IRES region having an effect on 
translation efficiency and may have an effect on replication capacity of the virus as well.  
 
It is possible that HCV replication in vivo is associated with mutations and selection, and the 
sequence with the most advantageous characteristics may persist, replicate and avoid the host 
immune response. Thus, it is important to understand the possible clinical role of these detected 
mutations, which are located in a highly conserved region of the HCV genome, as they may have 
functional roles in ribosome binding/translation initiation and regulatory effect on viral 
replication and propagation.  
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CHAPTER 4 
CONSTRUCTION OF HCV MUTANT AND CHIMAERIC VIRUSES 
 
4.1 Introduction 
The treble adenine substitutions, alone and in combination, were first introduced along the 5’ 
UTR by site direct mutagenesis and the sequences of the mutated IRESes confirmed by direct 
sequencing. The amplified products based on genotype 2a were then cloned and sub-cloned in 
different plasmids to enable their introduction in the JFH-1 infectious clone, thus creating JFH-1 
constructs with the desired mutations in the IRES region. Additionally, in order to study the 
effect of mutated genotype 1b IRESes in the JFH-1 infectious culture system, chimaeric JFH-1 
plasmids bearing mutant genotype 1b 5’ UTRs were also constructed. 
 
4.2 Results 
4.2.1 Site-directed mutagenesis 
The plasmid containing the HCV JFH-1 genotype 2a full sequence (appendix 8.2.1) was used to 
amplify the IRES region. The amplified fragment of circa 470bp in length was separated from 
possible primer dimers and other small non-specific by-products by electrophoresis in a 2% 
agarose gel (figure 4.3) and gel extraction was used to purify the PCR product. 
The amplified 5’ UTR was used in site-directed mutagenesis in order to introduce mutations at 
positions 107, 204 and 243(figure 4.1). The three point mutations were introduced either alone or 
in combination. After mutagenic PCR, which introduced the desired base substitutions in 
amplified DNA products, different amplicons were generated based on the combination of 
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primers used and on the genotype of the 5’ UTR (figure 4.1). These amplicons were separated by 
electrophoresis in a 2% agarose gel (figure 4.4). DNA fragments were purified, overlapped and 
extended using outer primers (figure 4.2) resulting in a final product of 470bp in length (figure 
4.4, lane 6). All introduced mutations were confirmed by sequence analysis (figure 4.5). The 
sequences of the mutagenic primers and outer primers can be found in appendices 8.1.2 and 8.1.3. 
 
 
Figure 4.1 Schematic diagrams depicting mutagenic primer combinations used for the 
generation of mutated constructs by splice extension PCR. 
The red arrows indicate and mark the approximate position of the mutagenic primers.  Blue 
arrows indicate outer primers containing restriction sites. The diagram indicates the stepwise 
splice extension PCRs that were undertaken in order to derive constructs containing the desired 
combinations of SNPs.  
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For the construction of 1b/2a inter-genotypic chimaeric viruses, site directed mutagenesis was 
performed after the amplification of the 5’ UTR from pHCVrep 1b BB7 with specific primers 
(appendix 8.1.3). The forward primer (HCV1bEcoRI) contained an EcoRI restriction site and 18 
nucleotides from the beginning of the genotype 2a IRES, while the reverse primer (HCV1b SnaI, 
Isoschizomer BstZ17I) contained a SnaI restriction site and 63 nucleotides of the core coding 
region of genotype 2a (figure 4.2). 
 
 
 
 
Figure 4.2 Schematic diagrams of primers used in the amplification of the 5’ UTR from 
genotypes 2a and 1b. 
Each diagram illustrates the oligonucleotide primers used (underlined nt) in constructing mutated 
HCV genotype 2a and 1b 5’ UTRs. Forward primers contained an EcoRI restriction site (nt 
highlighted in pink) while reverse primers contained SnaI restriction sites (nt highlighted in 
turquoise). The primers used to construct the genotype 2a 5’ UTR contained the first 14bp of the 
genome and downstream genotype 2a-specific nucleotides (nt highlighted in green, 2a) as shown. 
The primers used to construct the genotype 1b 5’ UTR contained 18bp from the beginning and 
63bp downstream of the genotype 2a genome (nt highlighted in green, 1b/2a), followed by 14bp 
upsteam and 16bp downstream of genotype 1b-specific nucleotides highlighted in blue (1b/2a). 
The start codon AUG (ATG) is highlighted in red. The nucleotide sequences shown are those of 
the HCV genotype 2a (nt 1-469 including restriction sites, JFH-1, GenBank AB047639) and 
genotype 1b (nt 1-471 including restriction sites, GenBank AJ238799) 5’ UTRs. Nucleotide 
positions 107, 204 and 243 are highlighted in yellow. 
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Figure 4.3 2% agarose gel electrophoresis of amplified 5’ UTR fragments obtained by 
splice extension mutagenesis. 
Amplicons were run on a 2% agarose gel and stained with 5µl SYBR safe. 
The size of the amplified products was assessed using the 100bp mol. wt. DNA marker (Lane 1). 
PCR amplicon of genotype 2a 5’ UTR of 463 bp in size (Lane 2). PCR amplicon of genotype 1b 
5’ UTR of 465bp in size (Lane 3). 
 
 
 
Figure 4.4 2% agarose gel electrophoresis of mutagenic PCR products. 
Amplicons were run on a 2% agarose gel and stained with 5µl SYBR safe. The size of the 
amplified products is variable depending on the position of the mutagenic primers (refer to figure 
4.1) and was assessed using the 100bp mol. wt. DNA marker (Lane 1). Lane2, amplicon of 
142bp in size containing 107C; Lane 3, amplicon of 328bp in size containing 107A; Lane 4, 
amplicon of 278bp in size containing 243G; Lane 5, amplicon of 239bp in size containing 204C; 
Lane 6, final mutagenic 5’ UTR genotype 2a of circa 470 bp in size containing the 107A, 204A 
and 243A substitutions. 
 Luca Mercuri 
207 
Imperial College London 
4.2.2 Sequence analysis of mutant constructs 
All mutant constructs were confirmed by sequence analysis (figure 4.6). DNA sequencing 
indicated that the plasmid constructs were identical to the 5’ UTR of the HCV-2a and -1b 
genotypes except for the nucleotide changes at positions 107, 204 and 243 (figure 4.5).  
 
 
Figure 4.5 Nucleotide alignment of mutagenised 5’ UTRs. 
The nucleotide sequence numbers are given from the alignment. Nucleotide changes present only 
at the specific positions (107, 204 and 243) in the 5’ UTRs of genotype 2a and genotype 1b/2a 
recombinants are shown. The nucleotide differences among the sequences are highlighted. 
Nucleotides that were invariant among all sequences are indicated by a dot in the alignment. 
Numbers in the figure indicate IRES nucleotide positions relative to strain HCV 2a isolate JFH-1 
(C-A-A wt, GenBank AB047639) and relative to HCV isolate con1 genotype 1b (G-C-G wt, 
GenBank AJ238799). 
 
4.2.3 Cloning assembly strategy 
The transformation efficiency of DH5α (Invitrogen) and DH10B cells (NEB, 10-beta competent 
E.coli) was assessed using 5µl (50 pg) of the pUC19 control DNA (10 pg/µl) (appendix 8.2.1). 
The transformation efficiency, estimated in colony forming units (CFU) per μg DNA, was 
obtained from the total number of transformed cells (transformants) growing on the LB agar 
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plate divided by the concentration of pUC19 DNA, which was diluted 1:10 with LB broth. A 
total volume of 100 µl was spread on LB agar + amp (100 µg/ml) + X-gal (50 µg/ml) plates. 
Bacterial growth confirmed successful transformation. 50 pg of pUC19 DNA yielded 54 DH5α 
bacterial colonies (figure 4.6, A) and 365 DH10B bacterial colonies (figure 4.6, B). The 
transformation efficiency of DH5α was thus estimated to be 1.08 x 108 CFU/µg while that of 
DH10B was 7.3 x 108 CFU/µg. Before starting the different cloning steps with the relevant 
restriction sites, the pJFH-1 sequence was verified by direct sequencing using different primers 
(appendix 8.1.4).  
 
 
 
Figure 4.6 Transformation efficiency of DH5α and DH10B cells. 
A total of 100 µl of transformed cells were plated and grown on LB agar + amp (100 µg/ml) + 
X-gal (50 µg/ml) plates. 50 pg of pUC19 DNA produced 54 DH5α (A) and 365 DH10B bacterial 
colonies (B). The colonies were counted manually and by using ImageJ software. 
 
 
The relative DNA sites generated during cloning and restriction digestion (refer to 2.3.4) were 
confirmed at each step of the process by agarose gel electrophoresis (figure 4.8 to 4.11). 
Additionally, all the JFH-1 mutant constructs thus generated were subjected to sequence analysis 
to exclude any wild-type plasmids.  
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The mutant PCR constructs, which contained at their 5’ end an EcoRI restriction site and at the 
3’end the BstZ17I restriction site, were first ligated into the pGEM-T easy vector, and then 
released by AatII / BstZ17I restriction digestion giving a fragment of 502bp in length (figure 
4.8)(Step1). A second construct was generated by releasing a JFH-1 fragment (2979bp) 
containing the WT HCV 5’ UTR, the core and part of the envelope coding region, by EcoRI/NotI 
digestion of pJFH-1 (figure 4.9, lane 6), and ligating it into pGEM-T easy vector (Step2). The 
mutated 5’ UTRs from Step 1 was released by AatII/ BstZ17I restriction digestion and 
introduced into the plasmid from step 2 which was similarly treated to remove the AatII/BstZ17I 
wt fragment forming  a vector of 5499 bp (3015bp+2516bp-32bp) in size (figure 4.9, lane 
2)(Step3). This third construct was then EcoRI/NotI digested to release an insert of 2979 bp in 
length containing the mutagenic IRES (figure 4.9, lane 4). This insert was ligated into the pJFH-
1 vector of 9382 bp in length after removing the wt region of 2979 bp in size by EcoRI / NotI 
digestion (figure 4.9, lane 6) (Step 4), giving a full infectious construct containing the desired 
mutated IRES (Step5).  
 
Subsequently, another restriction enzyme termed BsiWI was used instead of NotI (figure 4.10). 
This enzyme shortened the length of the pJFH-1 fragment (blue line, figure 4.10) and resulted in 
better separation between the vector and insert (figure 4.10) compared to EcoRI/NotI digestion 
(figure 4.9, lane 4). The concentration of vector and insert DNA was determined either by 
agarose gel electrophoresis against a known amount of DNA or by spectrophotometric 
measurements. Different vector:insert ratios were examined to establish the optimum ratio for 
ligation (figure 4.11).  The best molar ratio of vector:insert was 1:3 (figure 4.11, B). XbaI 
digestion identified the final positive full length clones of 12.3kb in size (figure 4.11, D and E). 
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Figure 4.7 0.5% agarose gel electrophoresis of EcoRI digested and undigested pJFH-1. 
80 µg/µl of pJFH-1 was run on a 0.5% agarose gel and stained with 3µl SYBR safe. 
The size of the linearised plasmid was assessed using the 1kb mol. wt. DNA marker (Lane 1). 
Lane 2, undigested  pJFH-1; Lane 3, EcoRI digested pJFH-1 of 12361bp in length; Lane 4, 
undigested pHCVrep1bBB7; Lane 5, EcoRI digested pHCVrep1bBB7 of 11313bp in length. 
 
 
Figure 4.8 1% agarose gel electrophoresis of plasmids containing 5’ UTR fragments 
digested with AatII and BstZ17I. 
100 µg/µl of digested plasmid was run on a 1% agarose gel and stained with 5µl SYBR safe. The 
size of the inserts was assessed using the1kb (Lane 1) and 100bp mol. wt. DNA markers (Lane 
2). Lanes 3 to 6, AatII and BstZ17I digested pGEM-T easy clones with inserts of 502bp in size. 
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Figure 4.9 1% agarose gel electrophoresis of pGEM-T+5’ UTR and pJFH-1 digested by 
restriction endonucleases. 
100 µg/µl of digested plasmid were run on a 1% agarose gel and stained with 5µl SYBR safe. 
The size of the vectors and inserts was assessed using the 1kb mol. wt. DNA marker (Lane 1, 3 
and 5). Lane 2, BstZ17I/AatII digested pGEM-T of 5499bp in size, containing the JFH-1 
BstZ17I/NotI fragment ; Lane 4, EcoRI/NotI digested subclone vector of 3015bp (pGEM-T) 
with an insert of 2979bp in size; Lane 6, EcoRI/NotI digested pJFH-1; vector (EcoRI-NotI) of 
9382bp and pJFH-1 insert (fragment EcoRI-NotI) of 2979bp in size. 
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Figure 4.10 1% agarose gel electrophoresis and schematic diagrams of unique restriction 
enzymes used in the cloning of the mutagenic 5’ UTRs. 
Schematic diagrams and 1% agarose gel electrophoresis of EcoRI/NotI digested pGEM-T clones 
(A) and EcoRI/BsiWI digested pJFH-1(B). 100 µg/µl of digested and undigested plasmids were 
run on a 1% agarose gel and stained with 5µl SYBR safe. The size of the vectors and inserts was 
assessed using the 100bp (Lane 1, A) and 1kb mol. wt. DNA markers (Lane 1, B); Lane 2 to 4 
(A), pGEM-T clones containing EcoRI-NotI inserts digested with EcoRI and BsiWI. Lane 2 (B), 
undigested pJFH-1; Lane 3 (B), EcoRI/BsiWI digested pJFH-1 of 10994bp in length (vector) and 
1367bp in length (insert). 
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Figure 4.11 1% agarose gel analyses by restriction digestion of constructed clones. 
100 µg/µl of digested and undigested plasmid were run on a 1% agarose gel and stained with 5µl 
SYBR safe. The size of the vectors and inserts was assessed using the 1kb mol. wt. DNA marker 
(first lane of each gel). For each mutant, three bacterial colonies were selected and the extracted 
plasmid was run on the gel (A, B and C). Vector:insert ratios were 1:1(A), 1:3 (B), 3:1 (C). XbaI 
digested clones (D and E), positive clones lane 2 and 3 (D), and 9 to 11 (E).  
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Nucleotide position 
107 204 243 
C A A (wt) ― V ― V 
2a 
C C G V V V V V 
A C G V V V V ― 
C A G V V V V V 
C C A V V V V V 
A C A V V V V V 
A A G V V V V V 
A A A V V V V V 
G C G (wt) V V V V 
1b/2a 
A C G V V V V V 
G A G V V V V V 
G C A V V V V V 
A C A V V V V ― 
G A A V ― ― ― ― 
A A G V V V V ― 
A A A V ― ― ― ― 
 
Table 4.1 Completed mutant clones. 
All possible combinations of mutations were considered in the construction of 16 mutagenic 
JFH-1 constructs of which 8 were genotype 2a and 8 genotype 1b/2a. 
 
4.3 Discussion 
Site-directed mutagenesis by overlap extension was an important task in the insertion of 
mutations at desired positions. This technique involved the design of specific primers with the 
desired mutation located in the middle of the primer with ~10-15 bases of the correct sequence 
on either side. Additionally, the reduction of PCR cycles (less than 35) and the presence of a 
proofreading thermostable polymerase in the PCR prohibited the chance of random mutations. 
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Cloning was very laborious as it consisted of many double restriction digestions and ligation 
reactions to construct four different clones. Additionally, in the first cloning steps, sequence 
analysis often indicated the presence of inserts in reverse orientation (3’-5’), while in the third 
and fourth cloning steps some unintended DNA constructs occurred during insert-insert ligation 
events. In fact, control digests with the same enzymes and/or linearisation with XbaI further 
confirmed the presence of defective clones and possible problems with EcoRI/NotI restriction 
digestion (data not shown) as some of the fragments, which were inserted into the EcoRI/NotI 
restricted JFH-1vector, resulted in an estimated 70 percent of incorrect constructs (data not 
shown). 
 
The use of compatible buffers for double digestion was checked from NEB, Stratagene, Promega, 
and Roche catalogues. Inefficient cutting by NotI seemed to be the cause of the mis-digestion of 
the inserts. To avoid this problem, phenol extraction prior to restriction digestion was performed 
to reduce the accumulation of possible inhibitors from plasmid extraction. Additionally, 
constructs were also examined by fragment size analysis after single restriction digestion with 
EcoRI, NotI and BstZ17I. The results suggested faulty digestion by NotI during double 
restriction digestion involving EcoRI. Due to the difficulties encountered with EcoRI/NotI 
digestion the use of the restriction enzyme BsiWI improved separation between vector and insert 
and the double digestion with EcoRI due to the use of a different buffer. 
 
The design of primers could have been one of the reasons related to restriction digestion 
problems as no extra sequences were included at the 5’end recognition site of the initial outer 
primers. This was done on purpose to exclude the introduction of any additional sequence.  
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Cloning efficiency was not a problem using a 3:1 molar ratio of insert:vector and the high-
efficiency competent cells DH5α (Invitrogen) during ligation and transformation. However, 
cloning efficiency was a problem in the final cloning step. DH10B cells had a higher efficiency 
of transformation (7.3 x 108 CFU/µg) than DH5α (1.08 x 108 CFU/µg) and more efficiently 
transformed with the largest mutated plasmids (pJFH-1). Additionally, use of SOC medium gave 
better results than LB broth. In fact, transformation efficiency increased almost 2 fold by using 
SOC medium (data not included). Thus, the choice of appropriate competent cells was important 
especially for the larger size of the mutant pJFH-1. 
 
After construction of the final clones, positive constructs were identified by restriction digestion 
with BstZ17I, which cuts 500bp downstream from the 5’end of the insert, the region containing 
the IRES element (Appendix 5.3). Sequence analysis of the final clones confirmed the presence 
of the desired mutations and the absence of wild-type clones. 
 
The construction of hybrids of pJFH-1 genotype 2a with the 5’ UTR derived from HCV 
genotype 1b (Appendix 5.2 fig.1), posed similar problems, as the inserts which were of the same 
length as the JFH-1 5’ UTR, and were flanked with the same restriction sites as used for the JFH-
1 vector. Additionally, initial PCR with the long reverse primer 1b increased chances of 
mispriming. 
 
4.4 Conclusions 
Cloning was laborious and time consuming, with many sub-cloning and restriction digestions 
that often led to unwanted products, low colony number and negative mini preps. The multi-step 
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processes involved often led to many difficulties. Common initial problems were related to the 
strategy or the inaccuracies of the plasmid map, especially the presence of additional restriction 
sites. In this case diagnostic digests helped address possible problems. 
 
The most important lesson learnt in the cloning was to avoid any poor quality plasmid stock with 
low DNA concentration, protein, salt, contaminating RNA, phenol and ethanol. Additionally, the 
preparation of the vectors was also a crucial step in the cloning strategy. High concentrated stock 
of undamaged vector free from contaminants often obtained from maxi-preps rather than midi-
preps increased the efficiency of the ligation. Overall, splice extension mutagenesis and 
molecular cloning were shown to be versatile tools for the cloning of any DNA sequence with 
multiple mutations and for the construction of chimaeric virus mutants.  
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CHAPTER 5  
REPLICATION CAPACITY OF HCV MUTANTS IN Huh7.5, JURKAT, 
EBV+ B-LCLs AND PBMCs 
 
5.1 Introduction 
To examine the effects of viral infection and replication, production of infectious viral particles was 
essential. The replication capacity of transcribed mutated JFH-1 RNAs in Huh7.5 cells was 
examined by monitoring virion release and by the ability of mutated viruses to propagate in naïve 
cultures. Additionally, the examination of HCVcc was indispensable in determining whether 
reversion to the wild-type sequence occurred with repeated virus passage. The replication capacity 
of the same RNAs was also studied in cell-lines of lymphocyte origin such as Jurkat, EBV+ B-LCL 
and PBMCs where siRNAs were used against components of the innate immune cascade. 
Furthermore, the expression of IRF3, IRF7, IFNα and IFNγ was also investigated in these cell lines.  
 
5.2 Results 
5.2.1 Viral propagation strategy 
5.2.1.1 Titration of JFH-1 WT virus stock 
To infect cell lines with JFH-1, it was first necessary to produce JFH-1 RNA transcripts from the 
JFH-1 wild-type and mutant plasmids. Sixteen micrograms of purified plasmid DNA were 
digested with XbaI and 250ng of each digested sample was run on an agarose gel to ensure 
complete linearisation (figure 5.1, A). HCV RNAs were then produced by transcription of the 
linearised plasmid by XbaI followed by Mung bean digestion and ethanol purification. 
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Transcription was carried out using the MEGAscript kit and the quality of the synthesised RNA 
was examined via agarose gel electrophoresis (figure 5.1, B) to ensure the correct size of each 
RNA transcript. Agarose gel separation revealed the correct size of linearised plasmid (12kb) and 
of transcribed full length JFH-1 RNA (9.6kb) (figure 5.1). 
 
Figure 5.1 Agarose gel electrophoresis of XbaI digested, undigested pJFH-1 and 
transcribed JFH-1 RNA. 
A: 250ng of digested and undigested pJFH-1 was run on a 1% agarose gel and stained with 3µl 
SYBR safe. The size of the linearised plasmid was assessed using the 1kb mol. wt. marker (Lane 
1). Lane 2, undigested pJFH-1; lane 3 digested pJFH-1 of circa 12.3 kb in size. 
B: 250ng of RNA transcription reaction was run with 3x RNA loading buffer with 60% 
formamide on a 1.5% agarose gel stained with SYBR safe. A ssRNA molecular weight ladder 
(1µg) (lane 4) was included for RNA size estimation. Lane 5, transcribed full length JFH-1 RNA 
(1µg) of circa 9.6 kp in size. 
 
 
The transcribed JFH-1 RNA was in-vitro transfected in Huh7.5 cells by lipid-mediated DNA-
transfection using lipofectamine (Invitrogen). To examine the transfection efficiency of 
lipofectamine in Huh7.5, the cells were transfected with pGFP and analysed by flow cytometry 
at different time points to determine transfection efficiency with lipofectamine. 
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The results indicated that at 16 hours post-transfection, 65.6% of cells were transfected with 
pGFP while after 24 hours the positive cells transfected with pGFP were 67.4% (figure 5.2). 
 
 
Figure 5.2 Detection of GFP expression in Huh7.5 cells by flow cytometry. 
The sorting gate parameters (i.e. size and granularity) were adjusted to analyse the majority of 
the cellular population (A). Number of cells with GFP expression were normalised against the 
negative control (non-transfected cells) (black line). GFP-expressing cells 16 hours (red line) and 
24 hours post-transfection (blue line) (B). The data was analysed with Cflow plus analysis 
software (Accuri). 
 
To produce high titre infectious JFH-1 stock to be used in further propagation of the virus, 
JFH-1 RNA was transfected into Huh7.5 cells. These cells were cultured and passaged every 
three days up to three passages. The infectious culture supernatant containing JFH-1 was 
clarified and serially passaged onto naïve Huh7.5 cells every three days up to 5 times. Naïve 
cells were cultured in a 25-cm flask at a concentration of 1 x 106 cells one day before virus 
inoculation. At each passage, the medium was clarified by centrifugation and filtered. The final 
concentrated virus stock was serially 10-fold diluted in complete DMEM growth medium and 
200 µl were used as inoculum to infect naïve monolayers of Huh7.5 cells, which were seeded 
into 24-well plates at a density of 7 × 104 cells per well one day before virus inoculation.  
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 Each dilution was plated in duplicate in wells containing plastic coverslips. Each infection of 
naïve cells was carried out for 4 hours at 37°C and 5% CO2 after which the inoculum was 
removed and the monolayer was supplemented with fresh complete DMEM.  
 
The level of HCV infection was determined 3 days p.i. by immunofluorescence staining for HCV 
core protein. HCV JFH-1 infectivity was calculated as the number of focus forming units per ml 
(ffu/ml) of virus stock (culture supernatant). This was done by counting the average number of 
HCV core-positive foci for each dilution in each well, which appeared as clusters of antigen-
positive cells produced per ml of the starting inoculum. Immunofluorescence staining for HCV 
core revealed HCV core-positive cells in the Huh7.5 cells infected with JFH-1(figure 5.3).  HCV 
core-positive cells increased as less diluted virus stock was used (figure 5.3). The ideal ffu 
counts were derived from two replicate wells showing between 20 and 60 foci of infection. The 
dilutions of the inoculums that produced too many or too few infectious foci were not counted. 
 
5.2.1.2 Quantification of HCV RNA 
Absolute quantification was attempted through the generation of an RNA standard curve by 
qRT-PCR using HCV 5’ UTR specific primers (primer 26 and 27), for both intracellular and 
extracellular HCV RNA. A calibration curve was derived using pJFH-1, which was in vitro 
transcribed and purified. 
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Figure 5.3 Immunofluorescence microscopy of HCV core protein in JFH-1 infected Huh7.5 
cells. 
To establish the viral titre by counting focus-forming units (ffu) per ml of supernatant, Huh7.5 
cells were inoculated with serially diluted virus stock. Three days p.i. Huh7.5 cells were fixed 
and stained with antibody to core protein using a mouse anti-core antibody (green staining), 
while cell nuclei were stained with DAPI (blue staining). Uninfected Huh7.5 cells (mock 
infected) were included in this study and served as negative control. Images were captured using 
a Nikon Eclipse TE2000S fluorescence microscope at a magnification of 10x. 
 
The RNA transcript was quantified using a Nanodrop 1000 spectrophotometer and diluted (101 
to 106). JFH-1 RNA standards were quantified by qRT-PCR to generate a standard curve ranging 
from 5 ng/µl to 50 fg/µl. Each dilution was tested in triplicate. 
RNA genome copy numbers were calculated based on the 5’ UTR RNA transcript product and 
its molecular weight. JFH-1 concentration in ng/µl was divided by the template molecular weight 
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in Daltons, which was obtained by multiplying the number of nucleotides with the molecular 
weight (MW) of the corresponding ribonucleotide monophosphate [(An x 328.2) + (Un x 305.2) + 
(Cn x 304.2) + (Gn x 344.2)]). The result was multiplied by the Avogadro’s constant, 6.022 x 1023. 
This allowed the conversion of the concentration of the RNA from ng per µl to genome copy 
number per µl. 
 
The amplification rate was calculated from the linear regression slope that was graphically 
represented as a semi-log of the Ct value vs. the log of input nucleic acid (figure 5.4). Mock 
infections were performed as contamination controls and all experiments were considered 
positive if melting curve analysis indicated the absence of non-specific amplicons such as primer 
dimers and or genomic DNA contamination, and if the correlation coefficient of the regression 
analysis was above 0.96. 
 
 
Figure 5.4 Standard curve of HCV RNA copy number (log) in serial dilutions against cycle 
number (Ct). 
The standard curve was generated by plotting the log of the DNA concentration used vs. the CT 
value for the sample obtained from the qRT-PCR amplification of serially diluted JFH-1 RNA. 
Each dot represents the results of triplicate RT-PCR amplifications for each dilution. The Ct 
values are the mean of three different experiments within triplicates. In the equation (y = ax + b), 
a represents the slope (-3.4948) and b the intersection at the y axis (46.225); R2 indicates the 
correlation coefficient between the variables.  
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The standard curve obtained from JFH-1 RNA standards showed linearity at all concentrations. 
Additionally, the regression coefficient was above 0.98 (figure 5.4). RNA extractions were 
performed to detect and quantify intracellular or extracellular HCV RNA by qRT-PCR. RNA 
samples were first treated with Deoxyribonuclease I (DNase I) using the turbo DNA-free Kit 
(Ambion) to remove any contaminating DNA and the quality of the extracted RNA was assessed 
by agarose gel electrophoresis. The results obtained showed clearly the 18S and 28S ribosomal 
sub-unit bands (figure 5.5). 
 
 
Figure 5.5 RNA extracted from Huh7.5 and EBV+ B-LCLs cells. 
250ng of RNA transcription reaction was run with 3x RNA loading buffer with 60% formamide 
on a 1.5% agarose gel stained with 2µl SYBR safe. 1µg ssRNA molecular weight ladder (lane 
1,5 and 9) was included for RNA size estimation. Extracted intracellular Huh7.5 RNA (lane 2 to 
4), and extracted intracellular EBV+ B-LCL RNA (lane 6 to 8). The two distinct bands indicate 
the small ribosomal subunit 18S and the large ribosomal subunit 28S present in each RNA 
sample. 
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5.2.1.3 Replication and propagation strategy of HCV mutant virus  
In the infection strategy, the production of high titre virus particles was obtained by transfecting 
naïve cells with 5-10 µg HCV RNA. After 72 or 96 hours HCV replication efficiency was 
examined by monitoring cellular levels of HCV RNA while HCV infection and replication was 
validated by western blot analysis. Additionally, virus release was quantified by examining 
extracellular levels of HCV RNA by qRT-PCR using oligonucleotide primers 26 and 27 sited in 
the 5’ UTR region of the HCV genome.     
 
In most cases, transfected cells were passaged every 3 days up to 3 times to obtain cell culture 
supernatants with high amounts of HCVcc. Additionally, transfected cells were passaged for up 
to 10 times (30 days) and before each passage, supernatants were collected and extracellular 
levels of HCV RNA were examined and compared to the levels of wt JFH-1 to determine the 
replication capacity of each HCV mutant versus the wt. Mock infections (no viral RNA) and 
extractions were also performed in parallel as contamination controls.  
 
To investigate whether HCVcc were infectious, the viral stocks obtained by harvesting cell 
culture supernatants were used as inoculum to infect naïve cells. The inoculum was applied for 4 
hours followed by its removal, washing the monolayer with PBS and applying fresh complete 
culture medium. Three or four days p.i. HCV infection and replication was confirmed by 
immunostaining for HCV core protein expression.  
 
To test if mutated viruses reverted to wt, virus was passaged from mutant cultures at 3-4 day 
intervals. Supernatants collected prior to each passage were subjected to RNA extraction, 
 Luca Mercuri 
226 
Imperial College London 
purification and RT-PCR analysis using oligonucleotide primers sited in the 5’ UTR region of 
the HCV genome. The amplicons generated were cloned into pGEM-T easy vector and 
sequenced to investigate the possibility of reversion of the mutants to the wt sequence after serial 
passage of the virus.  
 
The propagation and replication strategy was applied to Huh7.5, Jurkat, EBV+ B-LCL and 
PBMCs. The levels of host gene mRNA expression in infected and non-infected cells were also 
measured by using quantification methods such as qRT-PCR, using relative quantification by 
fold change calculation, while absolute quantification was used to calculate the intracellular JFH-
1 RNA titres. Contamination controls included a water sample instead of extracted RNA and a 
mock extraction.  
5.2.2 Replication capacity of HCV mutants 
5.2.2.1 Evidence of mutant HCVcc replication in Huh7.5 cells 
The wild type or mutant pJFH-1 were  in vitro transcribed and 5µg of the transcribed viral RNA 
were transfected into the highly permissive Huh7.5 cell line with high levels of expression of 
CD81 and a defective interferon response caused by the inactive RIG-I gene. Liposome-
mediated transfection was performed at an RNA/lipofectamine ratio of 1:2 by using 5 µg of JFH-
1 RNA. Cell confluence at the time of infection was circa 70%.  
 
Three days post-transfection, the cells were immunostained for HCV core to detect viral 
replication (figure 5.6, A). Immunostaining indicated HCV replication in Huh7.5 cells 
transfected with JFH-1 wt (CAA) and mutant AAG constructs (figure 5.6). Low HCV RNA 
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levels were detected in Huh7.5 cells transfected with the AAA mutant (figure 5.6, B) and at each 
passage of AAA transfected cells HCV RNA levels decreased. The experiment was repeated and 
the same negative results occurred. Later analysis of the 5’ UTR sequence revealed nucleotide 
mutations at the beginning of the core coding region (data not included). Thus, the AAA mutant 
was excluded from any further study. 
 
Intracellular RNA was analysed by qRT-PCR to detect viral HCV RNA (figure 5.6, B). The use 
of a standard curve resulted in errors in RNA titre (see 5.3), thus, only cycle threshold (Ct) 
values are shown as indication of HCV RNA quantification. HCV RNA levels were detected in 
Huh7.5 cells transfected with the CAA wt and the AAG mutant. No HCV RNA was detected in 
Huh7.5 cells transfected with the AAA mutant (figure 5.6, B). Levels of HCV RNA appeared 
high with low Ct values in the presence of wt compared to RNA levels detected in cells 
transfected with mutant AAG, which was the first mutant that appeared to replicate in Huh7.5 
cells. Additionally, the AAG mutant showed lower HCV RNA levels compared to wt (figure 5.6, 
B). 
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Figure 5.6 WT C-A-A and A-A-G mutant HCV RNA and core protein expression in 
transfected cells.  
A: Huh7.5 cells producing infectious mutant particles were stained for HCV core protein at day 3 
post-transfection using a mouse monoclonal antibody (C7-50) to HCV core antigen (red staining) 
while nuclei were stained with  DAPI (blue staining). Images were captured at a magnification of 
20x with a fluorescence microscope. 
B: Results of quantitative RT-PCR analysis are depicted as Ct values measured at day 3 post-
transfection. Data are mean of three biological replicates. P values were calculated using one-
way analysis of variance (ANOVA) followed by a Dunnett's post test, ***P<0.001. 
 
 
Immunofluorescence was used to confirm virus replication in AAG mutant transfected cells. 
While performing these initial studies on HCV replication, more final positive mutant clones 
were obtained after changing the cloning strategy (see 4.2.2). Thus, liposome-mediated 
transfection of HCV RNA was applied in Huh7.5 cells using the mutated HCV genotype 2a 
(CCG, CAG, CCA, ACA and AAG) and chimeric HCV genotype 1b/2a (GCG, ACG, GAG and 
GCA) constructs.  
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Intracellular and extracellular HCV RNA was not detected by qRT-PCR in cells transfected with 
chimeric mutants, which were unable to replicate when transfected into Huh7.5 cells (data not 
included). On the other hand, intracellular and extracellular HCV RNA levels were detected in 
Huh7.5 cells transfected with HCV mutants AAG, CCG, CCA and CAG (figure 5.7, A).  
 
At 4 days post-transfection, 100 ng of the total RNA extracted from supernatant was used for 
qRT-PCR.  Extracellular HCV-RNA levels appeared similar, with similar Ct values, between 
mutant AAG and wt CAA, while lower HCV-RNA levels (higher Ct) were obtained with 
mutants CCG, CCA and CAG (figure 5.7, B). To validate HCV replication, cell extracts from 4 
days post-transfected cells were prepared and total proteins were separated by SDS-PAGE. 
These were separated by Western blotting and stained with anti-core HCV antibody. Western 
blot revealed the presence of HCV core proteins in all mutant and wt CAA HCV transfected 
Huh7.5 cells (figure 5.7, C).  
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Figure 5.7 HCV RNA levels and core protein expression in Huh7.5 cells. 
A and B: Intracellular and extracellular RNA was harvested by the Trizol method from Huh7.5 
cells 4 days post-transfection with wt or HCV mutants. Results of quantitative RT-PCR analysis 
are depicted as Ct values. Data presented are the means from two separate experiments 
performed with duplicate transfections. P values were calculated using one-way analysis of 
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variance (ANOVA) followed by a Dunnett's post test, ***P<0.001, **P<0.01, NS, not 
significant (P>0.05). 
C: Western blot analysis of HCV core proteins during JFH-1 mutant infection, HCV core 
proteins detected in transfected cells. Transfected Huh7.5 cells were washed with PBS, lysed and 
50 µg of protein extract electrophoresed on 10% SDS-PAGE gels. The proteins were transferred 
to nitrocellulose membranes and then blocked and immunoreacted with a primary antibody. The 
membrane was washed and incubated with peroxidase labelled secondary antibody and 
developed by the ECL-chemiluminescence method. The membrane was stripped and 
immunoreacted with β-actin primary antibody as a control to make sure that equal amount of 
protein was present in the extracts. Negative controls consisted of cells transfected with no HCV 
RNA (mock infected). 
 
 
Figure 5.8 Immunofluorescence assay of HCV core protein in Huh7.5 cells infected with 
JFH-1 WT and JFH-1 mutants. 
Naïve Huh7.5 cells were seeded into 6-well plates and 100 µl of the supernatant collected at 9 
days post-transfection was used to infect naïve cells in triplicate. Three days p.i. cells were 
stained for HCV core protein using a mouse monoclonal antibody (C7-50) to HCV core antigen 
(green staining), while cell nuclei were stained with DAPI (blue staining).  Images  were 
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captured  at  a  magnification  of  20x and 40x with  a  fluorescence  microscope. Mock-infected 
Huh7.5 cells served as negative control.  
 
 
The potential of released mutant virions to infect new cultures was examined by exposing naïve 
cells to HCVcc extracted from supernatants of transfected cells. To obtain enough HCVcc, 
transfected cells were passaged twice and at each time the culture supernatant was collected and 
purified. Naïve Huh7.5 cells were exposed to 100 µl supernatant collected from transfected cells 
for 4 hours at 37°C and 5% CO2 followed by removal of the inoculum and replacement with 
complete culture medium. After 3 days p.i, Huh7.5 cells were subjected to immunostaining for 
HCV core to detect replication of mutant viruses in naïve Huh7.5 cells. Immunostaining revealed 
HCV core protein production indicating viral replication in all Huh7.5 cells inoculated with all 
HCV mutants, confirming infectivity of HCVcc mutants (figure 5.8). 
 
5.2.2.2 Transfection of HCV mutants into EBV+ B-LCLs and Jurkat cells 
The transcribed mutant JFH-1 RNAs were in-vitro transfected by electroporation in Jurkat and 
EBV+ B-LCLs. At 4 days post-transfection, intracellular RNA was extracted, purified and 
examined by qRT-PCR to determine HCV RNA levels (figure 5.9). qRT-PCR analysis of 
intracellular RNA in Jurkat cells 4 days post-transfection resulted in low Ct values indicating 
high HCV RNA levels in cells infected with mutant CCG, CCA and CAG RNAs. On the other 
hand, high Ct values suggested very low HCV RNA levels in cells transfected with mutant AAG 
and wt CAA RNAs (figure 5.9, A).  
 
In EBV+ B-LCLs, HCV RNA was detectable in all cells transfected with mutant and wt RNAs, 
with the highest HCV RNA levels detected in cells transfected with the CCG mutant (figure 5.9, 
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B). Unfortunately, extracellular RNA was not detected in the supernatant of 4 day post-
transfected Jurkat and EBV+ B-LCLs. However, HCV RNA was detected in the supernatant of 
EBV+ B-LCLs only after serial viral passage and used to examine nucleotide substitutions (see 
5.2.5).  
 
To validate HCV replication, cell extracts from 4 days post-transfection were prepared and total 
proteins were separated by SDS-PAGE and revealed by Western blotting following staining with 
anti-core HCV antibody. Immunoblot analysis revealed no production of HCV core proteins in 
Jurkat cells (figure not included). However, HCV core proteins were detected in all EBV+ B-
LCL cultures transfected with mutant RNAs (figure 5.9, C). Immunostaining revealed no 
production of HCV core proteins in transfected Jurkat cells (figure not included) also. Production 
of HCV core proteins occurred in all EBV+ B-LCL transfected cells, as documented by positive 
immunostaining against HCV core protein (figure 5.10).  
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Figure 5.9 Intracellular HCV RNA levels and core protein expression in transfected Jurkat 
and EBV+ B-LCLs. 
Jurkat and EBV+ B-LCLs were electroporated with 10 µg mutant HCV RNA. Four days post-
transfection intracellular RNA was harvested by the Trizol method and HCV RNA was 
quantified by qRT-PCR. Results of quantitative RT-PCR analysis are depicted as Ct values 
measured from intracellular RNA at day 4 post-transfection in Jurkat cells (A) and in EBV+B-
LCLs (B). Data represents mean ± s.e.m. of duplicate samples extracted in one experiment.  
C: Detection of HCV core protein in EBV+ B-LCLs transfected with wt and HCV mutants. EBV+ 
B-LCLs electroporated with 10 µg wt or HCV mutant RNA.  96 hours post-transfection, cells 
were washed with PBS, lysed and 50 g of protein extracts were electrophoresed on 10% SDS-
PAGE gels. The proteins were transferred to nitrocellulose membranes and then blocked and 
immunoreacted with a primary antibody. The membrane was washed and incubated with 
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peroxidase labelled secondary antibody and developed by the ECL-chemiluminescence method. 
The membrane was stripped and immunoreacted with β-actin primary antibody.  Detection of β-
actin protein served as a loading control while mock infected cells served as negative controls. 
 
 
Figure 5.10 HCV core protein immunostaining of EBV+ B-LCL cells transfected with JFH-
1 wt and mutant viruses. 
EBV+ B-LCLs were electroporated with ten micrograms of in vitro-transcribed HCV RNA and 
stained for HCV core protein using a mouse monoclonal antibody (C7-50) to HCV core antigen 
(red staining). Nuclei were stained with DAPI (blue staining) 4 days post-transfection. Core 
protein staining in the infected cells was compared to uninfected EBV+ B-LCLs; mock infected 
cells served as a negative control. Images were captured using a Nikon Eclipse TE2000S 
fluorescence microscope at a magnification of 20x. 
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5.2.2.3 Unsuccessful HCV replication in PBMCs 
To examine whether HCV mutants were able to replicate in PBMCs, mutant HCV RNAs were 
transfected into PBMCs, which were isolated from healthy donors by Ficoll-Paque centrifugation. 
To maintain the viability and proliferation of PBMCs, 5µg/ml of PHA were added to cell 
cultures. Additionally, to determine whether mutant progeny viruses were able to infect naïve 
PBMCs, the cells were exposed to supernatant previously removed from infected Huh7.5 cells. 
Transfected cells were cultured up to 4 days, at which point intracellular and extracellular RNA 
was subjected to qRT-PCR analysis targeting the 5’ UTR. qRT-PCR analysis did not detect any 
intracellular and extracellular HCV RNA (data not included). Additionally, cell lysates from 
uninfected and infected PBMCs were run on SDS-PAGE gels and probed with anti-core and 
anti-β-actin antibody. No HCV core protein expression was observed by western blot analysis 
(figure 5.11, A) and immunofluorescence staining (figure 5.11, B). 
 
Figure 5.11 Detection of HCV core protein in PBMCs 4 days post-transfection with mutant 
HCV.  
A: Identification of HCV core protein in PBMCs electroporated with 10 µg wt or mutant HCV 
RNA. After 96 hours, cells were washed with PBS, lysed and 50 g of protein extracts were 
electrophoresed on a 10% SDS-PAGE gel. The proteins were transferred to nitrocellulose 
membranes and then blocked and immunoreacted with a primary antibody. The membrane was 
washed and incubated with peroxidase labelled secondary antibody and developed by the ECL-
chemiluminescence method. Intracellular proteins extracted from Huh7.5 cells infected with 
JFH-1 wt at a MOI of 1 served as positive control. Negative control siRNA and no HCV RNA 
were used in the mock infected cells. Immunoreaction with β-actin primary antibody failed 
(image not included). B: PBMCs transfected with wt HCV RNA were stained for HCV core 
protein at day 4 post-transfection using a mouse monoclonal antibody (C7-50, red staining) while 
nuclei were stained with  DAPI (blue staining). Images were captured at a magnification of 20x 
with a fluorescence microscope.  
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Following the negative results obtained in the replication of mutants in PBMCs, the small 
amount of RNA extracted from supernatant 4 days post-transfection was subjected to RT-PCR to 
investigate the presence of HCV RNA. After RT-PCR using the primers for 5’ UTR 
amplification, the samples were run on a 2% agarose gel (figure 5.12).  Amplicons were detected 
in the supernatant of PBMCs transfected with mutant CCA (figure 5.12, lane 5). 
 
 
Figure 5.12 2% agarose gel of RT-PCR 5’ UTR amplicons from extracellular RNA at 4 
days post-transfection of PBMCs. 
RT-PCR amplicons separated on a 2% agarose gel and stained with ethidium bromide.  
RT-PCR amplicons of 243 bp in length obtained with primers 26 and 27: Lane 2, 5’ UTR CAA 
(wt); Lane 3, 5’ UTR AAG; Lane 4, 5’ UTR CCG; Lane 5, 5’ UTR CCA; Lane 6, 5’ UTR CAG; 
Lane 7, mock infected. The size of the DNA fragments was assessed using the 100bp DNA 
ladder plus mol. wt. marker (lane 1 and 8). 
 
5.2.2.3.1 Inhibition of the antiviral cascade 
Following the negative results in the attempt to infect PBMCs with mutant HCV, PBMCs were 
electroporated with siRNAs that targeted IRF3 and NF-B in order to inhibit the host antiviral 
response and support HCV replication. In the experiment, two specific siRNA-targeted 
sequences were used together with mutant HCV RNAs; four predesigned siRNAs directed 
against human IRF3 (GenBank accession numbers: NM_001197122, NM_001197123, 
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NM_001197124, NM_001197125, NM_001197126, NM_001197127, NM_001197128, 
NM_001571, NR_045568) (product SI00026418, Qiagen) and two predesigned siRNAs directed 
against human NF-B1 (GenBank accession numbers: NM_001165412, NM_003998) (product 
SI02662618, Qiagen) (appendix 8.1.7). For the negative control, AllStars negative control 
siRNA that does not bind to any human mRNA sequences was used (product 1027280, Qiagen). 
The optimum confluency at the time of transfection was around 60-70%. 
 
Primers specific to NF-kB1 and IRF3 were tested on intracellular primary PBMC RNA and 
subjected to RT-PCR. Amplicons were run on agarose gels to make sure that specific 
amplification of the NF-kB1 and IRF3 genes had occurred. RT-PCR with NF-kB1 specific 
primers resulted in DNA amplicons of 192 bp in size while RT-PCR with IRF3 specific primers 
resulted in DNA amplicons of 293 bp in length (figure not included). The primer sequences can 
be found in appendix 8.1.5.  
 
 
Figure 5.13 The effect of IRF3 and NF-kB siRNAs in PBMCs. 
PBMCs were electroporated either with –ve control siRNA, a pool of IRF3 specific- (A) or NF-
kB specific-siRNAs (B). At 72 h post-transfection, total cellular RNA was extracted from 
PBMCs, purified and analysed by qRT-PCR for IRF3 or NF-kB mRNA levels. Cells treated with 
IRF3 or NF-kB siRNAs were compared to cells treated with non-targeting siRNAs (-ve control). 
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Fold change in GAPDH expression was calculated using relative quantification and data for 
IRF3 and NF-kB were normalised using GAPDH. Data were analysed using Prism 4 software 
(GraphPad).  
Data are mean ± s.e.m. of three biological replicates. The knockdown of IRF3 and NF-kB was 
statistically significant, **P<0.01, ***P<0.001. P values were calculated using two-tailed 
unpaired Student’s t-test. 
 
 
qRT-PCR was used to analyse gene expression levels 72 hours post-transfection. Fold change in 
host gene expression was calculated using the ΔΔCT equation with GAPDH as the normalising 
control reference gene. Gene expression results indicated a 50-55% reduction in IRF3 gene 
expression and a 42-48% reduction in NF–kB gene expression (figure 5.13).  
 
In order to determine whether IRF3 and NF-kB knockdown had an effect on HCV mutant 
replication, PBMCs were electroporated with IRF3 and NF-kB siRNAs together with 10 µg 
mutant HCV RNA. The results from intracellular RNA extracted 4 days post-transfection 
indicated no HCV RNA replication in PBMCs. Additionally, no efficient IRF3 and NF-kB 
silencing was observed in all PBMCs when transfected with HCV mutants (figure 5.14). 
Contrary, over-expression of the IRF3 gene was detected in most cells, particularly in PBMCs 
transfected with wt CAA and mutant CAG RNAs (figure 5.14, A).  
 
In NF-kB gene expression analysis, NF-kB was over-expressed up to 7.75 fold in wt RNA 
transfected PBMCs while similar gene expression, circa 2.5 fold, occurred in cells transfected 
with the CCG and CAG mutants (figure 5.14, B). No increase or decrease in NF-kB gene 
expression occurred in PBMCs transfected with the AAG mutant. A 2 fold increase in expression 
of NF-kB gene occurred in cells transfected with mutant CCA RNA (figure 5.14, B). 
 
 Luca Mercuri 
240 
Imperial College London 
 
 
Figure 5.14 The effect of IRF3 and NF-kB siRNA in PBMCs transfected with HCV 
mutants. 
PBMCs were electroporated with control and a pool of IRF3 specific- (A) and a pool of NF-kB 
specific-siRNAs together with 10 µg HCV RNA. At 72 h post-transfection, total cellular RNA 
was extracted from PBMCs, purified and analysed by qRT-PCR for IRF3 or NF-kB mRNA 
levels. Cells treated with IRF3 and NF-kB siRNAs were compared to cells treated with non-
targeting siRNAs (-ve control). Fold change in IRF3 and NF-kB expression was calculated using 
relative quantification and data were normalised using GAPDH. Data represents mean ± s.e.m. 
of duplicate samples extracted in one experiment. Data were analysed using Prism 4 software 
(GraphPad).  
 
 
5.2.3 Levels of IFNα, IFNγ, IRF3 and IRF7 expression  
The level of expression of IFNα, IFNγ, IRF3 and IRF7 was investigated with qRT-PCR using the 
∆∆CT equation; the qRT-PCR CT values of the target and reference genes. The expression data 
was normalised using the housekeeping gene GAPDH and mRNA levels of host genes were 
analysed during transfection with HCV mutants.  
Fold change in host gene expression was calculated using the ΔΔCT equation with GAPDH as 
the normalising control reference gene. Additionally, host gene expression was investigated in 
negative control cells that had been mock infected for 72 hours to identify gene expression 
changes occurring as a result of HCV mutant transfection.   
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In all cells infected with mutant or wt HCV, IFNα gene expression was slightly under-expressed 
with values ranging between 0.84 to 0.65 (figure 5.15, A). In comparison, the overall IFNγ fold 
change expression values were significantly lower than those of IFNα ranging between 0.57 to 
0.31 (figure 5.15, B). IRF3 and IRF7 gene expression was not examined in Jurkat cells. 
 
 
 
Figure 5.15 Fold change in host gene expression of IFNα and IFNγ in HCV mutant infected 
Jurkat cells. 
Jurkat cells were transfected with HCV mutants for 72 hours.  Total cellular RNA was extracted, 
purified and analysed by qRT-PCR for quantification of IFNα and IFNγ gene expression levels. 
Cells were compared to mock infected cells. Fold change in IFNα and IFNγ expression was 
calculated using relative quantification and expression levels were normalised against that of 
GAPDH. Data represents mean ± s.e.m. of duplicate samples extracted in one experiment. Data 
were analysed using Prism 4 software (GraphPad). 
 
EBV+ B-LCLs transfected with mutant or wt HCV RNA resulted in under-expression of IFNα 
(figure 5.16, A) while IFNγ under-expression was recorded only in cells infected with mutants 
CCG and CAG (figure 5.16, B). On the other hand, IFNγ was over-expressed only in wt CAA 
transfected cells (figure 5.16, B).  IRF3 was over-expressed in cells transfected with wt CAA and 
mutant AAG, and under-expressed in cells transfected with the mutant CCG (figure 5.16, C). All 
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transfected cells showed an increase of IRF7 expression, which was significatly high in wt CAA 
and mutant AAG transfected cells (figure 5.16, D).   
 
Figure 5.16 Fold change in IFNα, IFNγ, IRF3, IRF7 gene expression in HCV mutant 
infected EBV+ B-LCL cells. 
Gene expression levels were quantified by qRT-PCR using 100 ng intracellular RNA per 
reaction. Fold change in gene expression was calculated using relative quantification and the 
expression levels were normalised against that of GAPDH. Data represents mean ± s.e.m. of 
duplicate samples extracted in one experiment. Data were analysed using Prism 4 software 
(GraphPad). 
 
 
 
5.2.4 Patient-derived HCV was able to infect different cell lines 
HCV positive serum samples, obtained from Dr Emma Thomson’s patients, were used to test 
whether Huh7.5, Jurkats and EBV+ B-LCLs were susceptible to infection with patient-derived 
HCV, and to establish if native virus was capable of infecting these cells. Thus, five plasma 
samples (sample 55 to 59) from four different patients (patient number 21 to 24) collected at 
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different times (see table 2.1) served as HCV infectious inocula; two samples (55 and 56) were 
derived from the same patient (patient 21). 
 
Huh7.5, Jurkats, EBV+ B-LCLs and PBMCs were seeded at 1 x 105 cells/well in 6 well plates 
using 2ml culture medium. PBMCs were pre-treated with 5µg/ml of PHA 24h before plasma 
inoculation. Cells were exposed for 4 hours at 37°C and 5% CO2 to each HCV infected plasma 
(number 55 to 59) carrying HCV genotype 1a at levels of circa 5x105 to 7x106 vge/ml. After 5 
hours exposure to an inoculum, the plasma was removed, and the cells were washed with PBS 
and cultured in fresh complete medium for 4 days. Infections were carried out in duplicate and 
all types of cells were exposed to normal human plasma (NHP) that served as negative control 
(mock infected). Additionally, JFH-1 at a MOI of 1 was used as “positive” control.  
 
Four days post-infection one hundred ng of the total intracellular RNA sample extracted from 
cells was used for qRT-PCR to examine the amount of HCV RNA (figure 5.17, A1, B1 and C1). 
To further ascertain that productive HCV infection was established in these cells, the presence of 
HCV core protein was examined by immunoblotting (figure 5.17, A2, B2 and C2).  
HCV RNA was detected intracellularly in all plasma exposed Huh7.5 cells (figure 5.17, A1). 
Additionally, immunoblot analysis detected HCV core proteins in all cells except mock infected 
ones (figure 5.17, A2).  
 
In plasma exposed Jurkat cells, intracellular HCV RNA was not detected in cells exposed to 
plasma samples 56, 57 and 58; only very low levels of HCV RNA were detected in Jurkat cells 
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exposed to plasma samples 55 and 59 (figure 5.17, B1). HCV core proteins were not detected in 
any Jurkat cells (figure 5.17, B2).  
 
Similar results were obtained with HCV RNA detected intracellularly in most plasma exposed 
EBV+ B-LCLs (figure 5.17, C1). However, immunoblot analysis detected HCV core proteins in 
all cells except mock infected (figure 5.17, C2).  
 
 
Figure 5.17 Intracellular levels of HCV RNA and core protein expression in cells exposed 
to HCV infected plasma. 
Huh7.5 (A1) Jurkat (B1) and EBV+ B-LCLs (C1) were exposed for 5 hours to HCV infected 
plasma from different patients. Subsequently the infected plasma was removed and the cells were 
washed with 5ml PBS and cultured with 5ml DMEM. After 72 hours, intracellular RNA was 
harvested by the Trizol method and purified. Intracellular HCV RNA was analysed via qRT- 
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PCR using primers 26 and 27. Results of quantitative RT-PCR analysis are depicted as Ct values.  
Data presented are the means from one experiment performed with duplicate infections. Western 
blot analysis of HCV core proteins in Huh7.5 (A2) Jurkat (B2) and EBV+ B-LCLs (C2). After 72 
hours, cells were washed with PBS, lysed and 50 µg of protein extracts were electrophoresed on 
10% SDS-PAGE gels. The proteins were transferred to nitrocellulose membranes and then 
blocked and immunoreacted with primary antibody. The membrane was washed and incubated 
with peroxidase labelled secondary antibody and developed by the ECL-chemiluminescence 
method. Membrane was stripped and immunoreacted with -actin primary antibody.  Detection 
of β-actin served as a loading control while mock infected cells served as negative controls.  
 
5.2.5 Nucleotide substitutions present in mutated virions 
Infectious culture medium containing mutant HCV, which was obtained from the supernatant 
collected before each passage of transfected cells, was passaged onto naïve cells every three days 
and at each passage extracellular RNA was analysed to detect and amplify the HCV IRES region 
by RT-PCR. Amplicons were purified, cloned and sequenced to investigate the possibility of 
reversion of the mutants to the wild-type sequence after serial viral passage. Due to time 
limitations, only a couple of clones from each mutant were sequenced. Ideally more clones 
should have been sequenced, but if revertans had arisen and became the dominant quasispecies, 
then this may have been apparent by sequencing just two clones. 
 
A 30 day passage history was initially attempted with wt CAA and the first positive mutant AAG. 
The 5’ UTR was amplified by RT-PCR from the supernatant of transfected cells. Sequence 
analysis of the 5’ UTR clones revealed that the variant sequence AAG did not revert to the wt 
sequence (CAA) during the 30 days of the experiment. This was investigated in Huh7.5 and 
EBV+ B-LCLs. Additionally, the variant sequence AAG was still present after 30 days of culture. 
However, the wild type CAA acquired a C107A mutation at day 15, passage 5, only in EBV+ B-
LCLs, becoming the AAA variant. This variant was also present at day 21.  
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Sequence analysis of the 5’ UTR RNAs derived from supernatant of infected Huh7.5 cells was 
also conducted in cells transfected with mutant CCA, CCG, CAG and again CAA (wt) and AAG 
RNAs. Initially, 5’ UTR amplicons obtained by RT-PCR of RNA extracted from supernatants 
using primers 26 and 27 (figure 5.18, A) were cloned in pGEM-T easy vector.  Additionally, to 
confirm the specific amplification of the HCV IRES region, nested PCR was applied using a 
second set of primers, namely primers 28 and 29 (figure 5.18, B) 
 
 
 
Figure 5.18 2% agarose gel of 5’ UTR amplicons by RT-PCR from extracellular viral RNA 
after the third viral passage into naïve Huh7.5 cells.  
RT-PCR amplicons separated on a 2% agarose gel and stained with ethidium bromide.  
A: RT-PCR amplicons of 243 bp in length obtained with primers 26 and 27: Lane 2, 5’ UTR 
CAA (wt); Lane 3, 5’ UTR AAG; Lane 4, 5’ UTR CCG; Lane 5, 5’ UTR CCA; Lane 6, 5’ UTR 
CAG; Lane 7, mock infected. The size of the vectors and inserts was assessed using the 100bp 
DNA ladder (hyperladder IV) mol. wt. marker (lane 1 and 8). 
B: Amplicons of 204 bp in length obtained from nested-PCR with primers 28 and 29: Lane 2, 5’ 
UTR CAA (wt); Lane 3, 5’ UTR AAG; Lane 4, 5’ UTR CCG; Lane 5, 5’ UTR CCA; Lane 6, 5’ 
UTR CAG; Lane 7, positive control 5’ UTR CAA; Lane 8, mock infected. The size of the 
vectors and inserts was assessed using the 100bp DNA ladder plus (lane 1) and1kb DNA ladder 
plus (lane 9) mol. wt. markers.  
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Due to the absence of HCV replication in Jurkats and PBMCs, all cell lines were again 
transfected with wt or viral mutants and passaged up to 9 days (3 passages). 9 days post-
transfection, intracellular and extracellular RNA was used to detect and amplify the HCV 5’ 
UTR using primers 26 and 27. PCR amplicons were run on an agarose gel (figure 5.19), purified, 
and cloned. 5’ UTR amplicons were detected both intracellularly and extracellularly in all cell 
lines except Jurkats (figure 5.19).  
 
Sequence analysis at positions 107, 204 and 243 of intracellularly-derived 5’ UTRs, revealed the 
presence of the introduced mutations after 3 passages and new mutations at positions 204 and 
243. No mutations occurred at position 107 while other mutations were detected along the IRES 
region (table 5.1). The viral mutant that acquired more mutations was CCA in Huh7.5, CCG in 
Jurkats and EBV+ B-LCL, and AAG in PBMCs (table 5.1).  
 
The C231G mutation was present in all cell lines except Huh7.5 and no mutations were detected 
on the IRES derived from all cells infected with the wt CAA. Additionally, reversion to the wild 
type sequence at nt position 204 and 243 was detected only in HCV mutants CCG and CCA. No 
mutations were detected in HCV mutant CAG extracted from Huh7.5, Jurkats or EBV+ B-LCLs 
(table 5.1). 
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Figure 5.19 2% agarose gel of 5’ UTR amplicons by RT-PCR from intracellular and 
extracellular viral RNA from infected Huh7.5, Jurkat, EBV+ B-LCL and PBMCs.  
Cells were transfected with wt or mutant HCV and passaged three times. 9 days post-transfection 
intracellular and extracellular RNA was collected and amplicons of 5’ UTRs were generated by 
RT-PCR. RT-PCR amplicons were separated on a 2% agarose gel and stained with ethidium 
bromide. The size of the vectors and inserts was assessed using the 100bp DNA ladder (Promega) 
mol. wt. marker (lane 1, 17 and 24). RT-PCR amplicons of 243 bp in length obtained from 
intracellular RNA (A) and extracellular RNA (B) in different cell lines were aligned in the 
following order: 5’ UTR CAA (wt), 5’ UTR AAG, 5’ UTR CCA, 5’ UTR CCG, 5’ UTR CAG 
and mock infected.  
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Table 5.1 5’ UTR mutations detected from intracellular RNA derived on the 9th day post-
transfection. 
Huh7.5, Jurkats, EBV+B-LCL and PBMCs were transfected with HCV mutant viruses. PBMCs 
were also transfected with siRNAs against IRF3 and NF-kB. 9 days post-transfection, 
intracellular RNA was extracted, purified and used to generate amplicons of 5’ UTRs by RT-
PCR. PCR amplicons were purified, cloned in PGEM-T easy vector and sequenced. In bold are 
variant sequence changes at positions 204 and 243 (*). Underlined is the common nucleotide 
mutation (C231G). Undetected intracellular 5’ UTRs (n/a). Squares left blank indicate no 
detectable mutations. Alignments were performed using BioEdit 7.1.3 software and IRES 
nucleotide positions are relative to strain HCV 2a (GenBank, AB047639).  
 
To observe if the detected mutations affected HCV IRES secondary RNA structure, the 
nucleotide sequences obtained from clones were analysed to predict IRES RNA structures and 
structural changes caused by the detected mutations. In the analysis of the IRES mutations 
derived from mutant infected Huh7.5 cells (table 5.1), mutations C147U, C196U and C212U 
detected in cells infected with mutant CCA caused conformational changes of the IRES structure 
(figure 5.20). These mutations led to the formation of a large asymmetrical internal loop between 
IRES stem loop IIIb and IIIc. This event changed the inclination of stem loop IIIa, b and c, 
increasing the size of the internal loop located between stem loop IIIa and IIIc. Additionally, a 
new single base bulge occurred at position 242 (figure 5.20, A).  
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Figure 5.20 2D diagram of the predicted secondary structures of IRES domain I and III. 
IRES sequence of domain III (A, B and C) and domain I (E) obtained from sequence analysis of 
IRES clones. A, mutations C147U, C196U and C212U detected in mutant CCA in transfected 
Huh7.5; B, C204A detected in mutant CCG in transfected Huh7.5; C, mutations C147A, U174A, 
C204A, C206A, C231G and G243A detected in mutant CCG in transfected Jurkats; D, C196U, 
C212U and C231G detected in mutant AAG in transfected EBV+ B-LCLs; E, U105G detected in 
mutant CAG in transfected PBMCs. Secondary structure of IRES domains were predicted using 
Mfold and IPknot software and visualised with VARNA software. To produce base-pairing 
probabilities, the McCaskill model was used as the scoring model and taking no account of 
pseudoknotted structures. Folding temperature was fixed at 37°C, the ionic conditions were fixed 
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at [Na+] = 1 M and [Mg++] = 0 M. A-U pairs are indicated by a single line with a bullet, a G-C 
pair with a double line and a G-U pair with a single line. Sequences and dot-bracket notations 
used to construct 2D structures are available in the appendix 8.4.1. 
 
Mutation C204A detected in mutant CCG, a reversion to wild type sequence at position 204, 
increased the size of hairpin loop IIIb (figure 5.20, B). Reverse mutation C204A and mutation 
A243G in mutant CCA detected in Jurkat cells caused an increase in size of the hairpin loop IIIb 
with no other structural changes along the IRES. On the other hand, all the mutations detected in 
mutant CCG (table 5.1) led to a complete predicted structural change of IRES domain III (figure 
5.20, C).  
 
In EBV+ B-LCLs mutation C231G detected in mutant AAG caused no structural changes on the 
IRES (data not included). However, mutations C196U, C212U and C231G led to the formation 
of a predicted large asymmetrical loop between stem loop IIIa and IIIc (figure 5.20, D) as seen 
with mutations detected in mutant CCA Huh7.5 cells (figure 5.20, A). In both cases C196U and 
C212U were the common mutations detected in different mutants (CCA and CCG) and in 
different cells, Huh7.5 and EBV+ B-LCLs.  Single point mutation U105G detected in mutant 
CAG from PBMCs caused an increase in size of the predicted asymmetric internal loop of IRES 
subdomain IIa (figure 5.20, E). 
 
The effect of the examined mutations on the thermodynamic stability of the RNA was examined 
(table 5.2). A decrease in ΔG indicated an increase in stability of the relevant domain while an 
increase in ΔG indicated a decrease in stability. All detected mutations had an effect on the 
stability of the RNA structure. Most mutations detected in HCV mutants in different cell lines 
increased the stability of the IRES structure. Only single point mutation, C231G, present in the 
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AAG mutant in EBV+ B-LCLs and mutations detected in mutant AAG in PBMCs decreased 
IRES structure stability (table 5.2). 
 
 
 
Table 5.2 The effect of detected mutations on the thermodynamic stability of the IRES. 
The thermodynamic stability of the relevant domain was calculated using the RNAeval web 
server with RNA free energy parameters and ΔG set at 37°C.  
 
In infectivity studies using patient derived material (see 5.2.4), intracellular RNA was extracted 
from the different cell types exposed to HCV infected plasma and examined for HCV 5’ UTR 
amplicons by RT-PCR. Amplicons were run on agarose gels (figure 5.21), purified, and 
directly sequenced.  Agarose gels revealed a small concentration of 5’ UTR amplicons in 
PBMCs, Jurkats, EBV+ B-LCL and Huh7.5 cells after exposure to HCV genotype 1a infected 
plasma (figure 5.21).  
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Figure 5.21 2% agarose gel of 5’ UTR amplicons by RT-PCR from intracellular RNA 
extracted from Huh7.5, Jurkat, EBV+ B-LCL and PBMCs after exposure to HCV infected 
plasma.  
Two microliters of twenty in total of RT-PCR amplicons were separated on a 2% agarose gel and 
stained with ethidium bromide. The size of the vectors and inserts was assessed using the DNA 
hyperladder IV mol. wt. marker (lane 1, 13, 14 and 27). RT-PCR amplicons of 243 bp in length 
obtained from intracellular RNA of cells exposed to plasma samples were loaded in this order: 
sample 55, 57, 58, 59, 56, and mock infected. Lane 2 to 6, 5’ UTR amplicons from intracellular 
PBMC RNA; Lane 7 to 12, amplicons from intracellular Jurkat RNA; Lane 15 to 20, amplicons 
from intracellular EBV+B-LCL RNA; Lane 21 to 26, amplicons from intracellular Huh7.5 RNA.  
 
 
Direct sequencing of RT-PCR amplicons showed few point mutations (table 5.3), but overall the 
IRES region was conserved. Major nucleotide changes occurred at positions 107 and 243. No 
changes were detected at position 204 and no mutations occurred in the only PBMC-derived 
sample. Additionally, the majority of the IRES sequences were AAG variant followed by AAA 
and CAG (table 5.3). 
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Table 5.3 5’ UTR mutations detected in intracellular RNA derived from cells exposed to 
HCV infected plasma. 
Huh7.5, Jurkats, EBV+ B-LCL and PBMCs were exposed to HCV infected plasma for 5 hours 
and cultured for 4 days followed by intracellular RNA extraction, purification and amplification 
of 5’ UTR by RT-PCR. PCR amplicons were purified and sequenced. In bold are variant 
sequence changes at positions 107 and 243. Undetected intracellular 5’ UTRs (n/a). Squares left 
blank indicate no detectable mutations. Alignments were performed using BioEdit 7.1.3 software 
and IRES nucleotide positions were relative to HCV1a consensus sequence. 
 
 
In all analyses of transfected and infected cells, beside mutations at positions 107, 204 and 243, 
new common mutations appeared frequently on the IRES at nucleotide positions 147, 196, 212 
and 231 (table 5.1, 5.2 and 5.3). Additionally, sequence analysis indicated a tendency to 
include all uracil bases between nt positions 191 to 200 on hairpin loop IIIb.  
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5.3 Discussion 
The initial transfection of wt JFH-1 RNA into Huh7.5 cells allowed the recovery and replication 
of viable JFH-1 virus, which was serially passaged and used for infectious studies. Serial 
dilutions of JFH-1 led to viral replication, which was confirmed by the formation of infected cell 
foci that allowed the quantitation of HCVcc produced. The increase in viral titre resulted in an 
increase in the number of infected cell foci.  
 
To assess the role of the mutations and to study the replication capacity of transcribed mutated 
JFH-1 RNA, the mutant constructs were first transfected into Huh7.5 cells. HCV RNA 
replication was monitored by qRT-PCR. Additionally, to support the results in this study and to 
further ascertain that productive HCV infection was established in transfected cells, Western blot 
analysis of intracellular core expression was performed. Core protein expression was also 
examined in naïve cells exposed to culture medium from transfected cells to prove viral 
infectivity.  
 
Absolute quantification was performed using the standard curve method to quantify unknowns 
based on a known quantity. HCV RNA pre-quantitated by a spectrophotometer was serially 
diluted and used to generate standard curves. Analysis of the Ct values obtained for the dilution 
series of HCV RNA showed linearity over a large range of copy numbers and a regression 
coefficient of 0.99 was obtained (figure 5.4). HCV real-time RT-PCR was thus based on linearity 
using known copy numbers of HCV RNA but unfortunately the dilution method used was not 
correct for determining viral titre. An international WHO standard for HCV RNA (376) available 
for calibration curves should have been used to report results in international units (IU)/ml and 
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also to verify the calibration of the standard curves used in this thesis. However, even in clinical 
practice, viral loads were reported in copies/ml for some years in spite of the existence of the 
standard, which was adopted only in recent years. Therefore, provided the standard curve gave 
more or less the same Ct values for each dilution, then experiment variability in determining 
HCV RNA levels was minimised.  
 
The concentration range of the external standards resulted in the wrong dynamic range. In fact, 
the Ct values for the –ve control gave a high CT range within the standard curve as a 
consequence of which was the generation of  false negative results. External standards lack 
internal control for RT and PCR inhibitors while the unknown samples may contain substances 
that might reduce the efficiency of the RT-PCR. Thus, the reliability of an absolute real-time RT-
PCR assay, which is depended on conditions of ‘identical’ amplification efficiencies for both the 
native target and the calibration curve, and the dynamic range of the performed calibration curve, 
had resulted in incorrect quantification. 
 
Limitations within the given application should have been considered as quantification with 
external standards required validation, careful optimisation and reproducibility to ensure 
confidence in the results and reliability of the method used. As a result, the assay used to 
quantify HCV RNA produced wrong quantification results and was considered not sufficiently 
robust. Thus, in order not to exclude some of the results, only Ct values have been reported as an 
indication of viral RNA quantity.  
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Better quantification results could have been achieved by using the WHO international standard 
and for example the TaqMan technology, which offers better sensitivity, greater dynamic range, 
and higher throughput than heterogeneous format tests (377). Additional factors such as the low 
efficiency of the preparation process of nucleic acids, in other words the partial loss of nucleic 
acid during sample processing from virus particles might have resulted in very low viral RNA 
detection. This may explain the high Ct values obtained in quantification assays. Additionally, 
RNA purified from cells and viruses may have different secondary and tertiary structures from in 
vitro RNA transcripts and this may have an impact on the efficiency of reverse transcription and 
the subsequent PCR, thus affecting RNA quantification.  
 
5.3.1 Replication of HCV mutant constructs in Huh7.5 cells 
Detection of extracellular HCV-RNA positive strand by qRT-PCR confirmed replication of viral 
mutants AAG, CCG, CCA and CAG in Huh7.5 cells (figure 5.7). Agarose gels of extracted RNA 
showed a 2:1 ratio of 28S:18S, a good indication that the extracted RNA was completely intact 
(figure 5.5). Western blot confirmed that transfected cells were producing HCV core protein 
(figure 5.7) while immunofluorescence staining indicated replication in those cells, and 
infectiousness of released virions was documented by passage into new cultures (figure 5.8). 
 
The difference between the mutant AAG and WT CAA was substitutions C107A and A243G, 
while A204 was present in both viruses. Mutation C107A might have caused IRES structural 
changes as seen in chapter 3 (figure 3.17) that was predicted to lead to IRES conformational 
changes. This event might have had a negative effect on the replication of the virus by disturbing 
cap-independent translation of the viral polyprotein or a positive effect causing replication 
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advantages, enhancing the production of infectious HCV. Thus, it is possible that the AAG virus 
required successive amplification in cells to possibly counteract mutations C107A and A243G, 
which could have reduced viral translation. 
 
In HCV RNA quantification analysis, Ct values suggested that mutant CCA and AAG appeared 
to have similar intracellular and extracellular HCV RNA levels 4 days post-transfection in 
Huh7.5 cells. Lower HCV RNA levels, with respect to wt and AAG, were detected in 
extracellular CCG, CCA and CAG RNAs (figure 5.7). CCG RNA levels were the lowest among 
all other intracellular HCV RNAs. Mutations A204C and A243G, both of which have previously 
been shown to have no effect on the stability of the IRES (table 3.6), might have had an effect on 
viral translation, which appeared to be down-regulated by the low levels of intracellular and 
extracellular CCG RNA detected (figure 5.7).  
 
Mutants CCA and CAG had similar intracellular RNA levels. However, extracellular CCA RNA 
levels were slightly higher than CAG RNA levels. As changes at position 204 and 243 had no 
effect on the thermodynamic stability of the IRES, it is possible that the small differences in 
extracellular RNA levels might have been caused by a possible translation advantage by the 
CCA mutant versus the CAG.  Overall, the different mutant viruses showed small differences in 
their ability to replicate  suggesting that the single point mutations at position 107, 243 and less 
so 204 on the 5’ UTR, also detected in previous studies (303, 310, 326), had an effect on the 
production of infectious HCV particles based on the differences in extracellular RNA detected in 
the different mutants. Unfortunately, due to errors in the quantification method as previously 
discussed, further analysis is required to establish the significance of these quantification results.   
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The mutated JFH-1 RNA hybrids between genotype 2a (JFH-1) and 1b with the mutated IRES 
region of HCV genotype 1b were not able to replicate in Huh7.5 cells. The attempt to replicate 
chimeric viruses in different cell lines failed. The insertion of the 5’ UTR from genotype 1b into 
the JFH-1 clone might have caused structural changes to the secondary RNA structure 
downstream from the polyprotein initiation codon as the reverse primer used was situated at 
positions 411-479, well into the core encoding region. This is a region that forms stem-loops V 
and VI. 
 
The preservation of domains V and VI  has been previously shown to play an important role in 
IRES activity and replication (378), thus the possible disruption of these structures by the 
insertion of the 5’ UTR from genotype 1b might have impaired viral translation, as previous 
studies reported that mutations in this region result in defective translation initiation, inhibiting 
HCV IRES activity (379, 380).  
 
The analysis of HCV core protein production confirmed HCV mutant replication in Huh7.5 cells. 
Additionally, the results were in agreement with the detected intracellular HCV RNA levels 
except for mutant CCG (figure 5.7). This result may suggest that in comparison to mutant CCA 
and CAG, from CCG to CCA, G243A, seems to reduce viral translation and the addition of 
mutation C204A might additionally reduce HCV core protein production. These results were 
consistent with the results obtained by immunofluorescence (figure 5.8).   
 
In this study Western blots were scanned and chemiluminescent signals were captured by 
exposure to x-ray film. Pixel intensity was then measured using Image J software to quantify 
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HCV core. The results of this approach were not included in this study as the method used had 
no validation and was not accurate due to limitations and variabilities from day-to-day. 
 
The inherent non-linear response of film to faint and strong signals, known as reciprocity failure, 
affected data interpretation and quantification as the optical density (OD) of the developed film 
is an indirect function that depends on the non-linear response of film to light (381). Thus, as the 
film response is proportional to light intensity and duration of exposure, the quantification of 
bands was variable and led to poor quantitative results. This was obvious where both strong and 
faint signals were detected on the same blot (figure 5.7 C and 5.17). 
 
The use of a digital blot scanner would have been a more appropriate method to quantify HCV 
core levels as strong bands do not blur and faint bands are clearly resolved. Additionally, it is 
possible to adjust brightness, contrast, control the saturation range by varying exposure time and 
select a background. Additionally, HCV core could have been quantified by Elisa kits specific 
for this marker. However, it is well known that although the HCV core Elisa does mirror HCV 
RNA levels to a certain extent, it is not as sensitive as the detection of HCV RNA. Hence, it is 
not used at all in clinical practice.   
5.3.2 No replication of HCV mutant constructs in Jurkat cells 
HCV replication of mutant constructs was also examined in Jurkat cells. Intracellular HCV RNA 
levels were detected only in Jurkat cells electroporated with CCG, CCA and CAG (figure 5.9). A 
surprising result, as these viral mutants yielded very low HCV RNA levels in Huh7.5 cells. The 
experiment was repeated and a small amount of viral RNA was detected 4 days post-transfection 
but after serial passage no viral RNA was detected intracellularly (see 5.2.5).  
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The detection of intracellular RNA might have been caused by input RNA. In Huh7.5 cells 5 µg 
of HCV RNA was introduced by liposome-mediated transfection while in other cells including 
Jurkats the amount of viral RNA was doubled (10 µg) and introduced by electroporation. 
 
It is also important to consider that total cellular RNA, which may vary in different cell cultures, 
may reduce RT and PCR reaction efficiencies and generate unreliable and "wrong" 
quantification results. Cellular RNA contains subfractions such as ribosomal RNA (rRNA) and 
transfer RNA (tRNA) (10-15%). The detection of intracellular viral RNA was not proof of viral 
replication. Intracellular HCV RNA levels in transfected Jurkat cells were possibly due to slow 
degradation of the input HCV RNA (10 µg) rather than representing active replication of the 
mutant and wt virus.  So, in spite of the fact that detection of HCV core is less sensitive, its 
detection is a more reliable marker of active viral replication, as it signifies production of the 
polyprotein and its processing into the various structural and non-structural proteins of the virus.  
 
Therefore, transfected Jurkat cells were also examined for HCV core protein production. The 
absence of HCV core in all cells suggested that HCV viruses were unable to replicate in Jurkats.  
Jurkat cells failed to support viral replication as no extracellular RNA was detected in any of the 
experiments. Additionally, to confirm the results, the supernatant extracted from such transfected 
cells was used to infect naïve cells, which were then examined for HCV core protein by 
immunostaining 4 days post-infection. The absence of HCV core indicated no viral protein 
production, also confirmed by the absence of extracellular virus in supernatants. Thus, HCV 
replication was not possible in Jurkat cells.  
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5.3.3 Replication of HCV mutant constructs in EBV+ B-LCLs 
Intracellular HCV-RNA levels were detected in all EBV+ B-LCLs electroporated with HCV 
mutant constructs with the higher HCV RNA levels detected in EBV+ B-LCLs transfected with 
mutant CCG (figure 5.9).  
 
Mutant and WT CAA transfected Huh7.5, Jurkat and EBV+ B-LCLs were serially passaged for 
30 days with HCV wt (CAA) or mutant AAG, which was the first positive mutant that was 
constructed. Due to errors in the viral quatification analysis as already explained, although the 
intracellular HCV RNA levels examined at each passage appeared to be slightly different based 
on the cell type with no HCV replication in Jurkat cells, the data was not included as it was not 
sufficiently robust. The different results between Huh7.5 and EBV+ B-LCLs could be related to 
the different levels of cell type-dependent host factors required for viral replication or translation.  
 
Immunoblot analysis revealed production of HCV core proteins in all transfected EBV+ B-LCLs 
(figure 5.9, C). Additionally, the presence of EBV in B-LCLs might have had an effect on CCG 
replication as previous studies reported that EBV-encoded nuclear antigen 1 (EBNA1) expressed 
in EBV-infected cells enhanced and supported HCV replication (382). The results of HCV core 
protein production obtained with AAG were opposite to the results obtained in transfected 
Huh7.5 cells. It is also possible that intracellular host factors in EBV+ B-LCLs and single point 
mutations might have resulted in a more efficient IRES translation, not seen in Huh7.5 cells.  
 
The detection of HCV core proteins by immunofluorescence confirmed in vitro replication of 
mutant constructs in EBV+ B-LCLs, which have been shown to support JFH-1 wt and mutant 
 Luca Mercuri 
263 
Imperial College London 
replication (figure 5.10). HCV mutants appeared to replicate less well in EBV+ B-LCLs than in 
Huh7.5 cells producing low yields of progeny viruses, not surprising due to the specificity of 
HCV to Huh7.5. Previous experiments indicated that B cells can harbour occult variants, which 
have a poor translational efficiency in hepatocytes (375). This suggests that these variants could 
derive from an extra-hepatic origin and there might be competition between HCV variants with 
different IRESes driven at the translational level in hepatic, as well as in extra-hepatic sites. 
Additionally, it is also possible that HCV infection in EBV+ B-LCLs might have induced a 
double-stranded RNA antiviral defence pathway that possibly delayed viral replication in these 
cells and not in Huh7.5 cells, which are more susceptible to HCV replication due to the mutation 
in RIG-I. This could explain the different HCV titres between infected Huh7.5 cells and B-LCLs.  
5.3.4 No replication of HCV mutant constructs in PBMCs 
The replication capacity of mutant constructs was also examined in PBMCs, which were 
stimulated with PHA (5µg/ml), a nonspecific inducer of T-cell proliferation stimulating CD8+ 
and CD4+ cells via lectin binding to glycosylated T-cell receptor complex proteins (326). 
As the expression of cytokines such as IFN-α and -γ, as well as IRF-3 and IRF7, could 
potentially influence the susceptibility of PBMCs to HCV infection, siRNAs against IRF3 and 
NF-kB were used to prevent induction of interferon by the input HCV RNA. The concentration 
of siRNA used was 50nM maximum as previous studies indicated off-target effects with higher 
concentrations of siRNA, and that it was possible to avoid such effects and achieve maximal 
target knockdown with the use between 25 and 75nM of siRNA (383, 384). 
 
The use of siRNAs against IRF3 and NF-kB efficiently reduced IRF3 gene expression by 50-55% 
and NF-kB gene expression by 42-48% (figure 5.13). Although the results confirmed the 
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efficiency of electroporation and the specificity of down-regulation caused by IRF3 and NF-kB 
siRNAs, gene knockdown by RNA interference was not efficient as it should have provided 
around 90% reduction of the IRF3 and NF-kB mRNA levels. It is possible that due to the 
different cell types present in PBMCs not all cells were easily transfected. Additionally, the 
electrical pulses required to transfect siRNAs and HCV RNA through the cellular and nuclear 
membranes might have induced significant cell death. Overall, electroporation was an 
advantageous method to use as electropermeabilisation is independent of cell-cycle stage. 
However, a previous study indicated that it requires a 10-fold higher amount of siRNA for 
successful gene silencing, compared to the chemical transfection methods (385). 
 
Inhibition of IRF3 and NF-kB had no apparent effect on HCV replication as HCV RNA was 
neither detected intracellularly or extracellularly. Additionally, transfection with siRNAs and 
HCV RNA resulted in inefficient IRF3 and NF-kB silencing suggested by overexpression, over 
two fold, of these genes in some of the mutant transfected cells (figure 5.14).  
 
The experimental design was not ideal in order to obtain strong supportive data, as the negative 
control siRNA was used with uninfected cells instead of been used with each viral mutant to 
distinguish sequence-specific silencing from non-specific effects. Additionally, siRNA that 
targets a housekeeping gene expressed in all cell types should have been used to optimise and 
monitor the efficiency of siRNA delivery into the different cell types.  
 
It should also be considered that electroporation of 10 µg of HCV RNA, possible undetectable 
HCV RNA replication and the long incubation period of 72 hours after transfection might have 
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allowed the cells to recover from the effects of RNA silencing, especially in the presence of 
HCV RNA, which might have induced overexpression of the IRF3 and NF-kB genes as seen in 
this study (figure 5.14). Additionally, the inefficient NF-kB silencing during HCV infection 
might have contributed to NF-kB activation via TNF induction by HCV core protein, which 
might have induced an anti-apoptotic state in PBMCs that could lead to oncogenic 
transformation.  
 
NF-kB is considered the central mediator of the immune system that can promote the expression 
of many target genes that participate in the host immune response and it  participates at multiple 
steps during oncogenesis with its involvement in the regulation of programmed cell death (55). 
Moreover, induction of cell-death related genes and the activation of caspase-3 in HCV-infected 
cells coincided with peak viral replication, suggesting a link between viral load and apoptosis 
(386). The overexpression of IRF3 and NF-kB in HCV transfected PBMCs might have prevented 
HCV infection by inducing an innate antiviral response compromising HCV replication in 
PBMCs.  
 
As the results indicated that the tropism of mutant viruses was limited in PBMCs as the cells 
failed to become infected, HCV core protein production was also examined to exclude possible 
HCV replication even if viral RNA was not detected intracellularly and in the supernatant.  
The absence of HCV core protein in PBMCs confirmed the absence of HCV replication (figure 
5.11) and siRNAs directed against IRF3 and NF-kB did not enhance HCV mutant replication and 
did not inhibit IRF3 and NF-kB gene expression (figure 5.14). One may ask why the difference 
in results between PBMCs and EBV+ B-LCLs. It seems possible that the EBV transformed cells 
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may also have down-regulated innate immune responses as a result of some EBV protein 
expression, thus creating an environment that favours HCV replication. 
 
Similar fold changes in gene expression occurred between IRF3 and NF-kB based on the 
transfected mutant. The largest over-expression of IRF3 and NF-kB occurred in PBMCs 
transfected with HCV wt CAA. On the other hand, the lowest over-expression of IRF 3 and NF-
kB occurred in PBMCs transfected with mutant AAG (figure 5.14). These differences between 
mutant constructs suggest that single mutations on the IRES might have had an effect on host 
factors that resulted in different IRF3 and NF-kB gene expression. Additionally, the activation of 
pro-inflammatory cytokine production through the exposure of PBMCs to HCV-RNA might 
have had a negative effect on virus production and a cytopathic effect in cells, such as arrest of  
the cell cycle and induction of apoptosis. 
5.3.5 Different outcome in gene expression analysis of transfected cells 
In gene expression analysis, where normalisation was performed by comparing the expression 
levels of the gene of interest with a housekeeping gene, downregulation and upregulation of IFN-
α, IFN-γ, IRF3 and IRF7 expression detected in this study was not significant as most of the fold 
change in gene expression was less than two-fold. Thus, further analysis is required to examine 
fold change with a more efficient knock-down of IRF3 and NF-kB and to explain why IFN and 
IRF gene expression were down-regulated in most viral mutant transfected cells, as these 
changes may have important biological effects, and why differences occurred between the 
different viral mutants in the same cell type. 
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IFN-α and -γ levels were slightly down regulated in transfected Jurkat and EBV+ B-LCLs. 
Usually IFN-α and -γ should be upregulated to prevent JFH-1 virus infection as IFN-α and IFN-γ 
are induced directly in response to viral infection and are capable of controlling most viral 
infections in the absence of adaptive immunity (387). All cells transfected with mutant and wt 
virus had a down-regulation in IFN-α by 16-35% and in IFN-γ by 69-45% (figure 5.15).  
 
It is possible that the down-regulation of IFN-α and -γ could have been caused by different 
transcriptional inhibitors involved in down-regulation of the IFN response such as IRF2, ICSAT, 
IRF8 (ICSBP), and STAT1B previously detected in hepatocytes and PBMCs (388). Additionally, 
electroporation of viral RNA might have bypassed activation of extracellular receptors such as 
the Toll-like receptor 3 (TLR3), which is activated by viral RNA. Its activation recruits the 
adaptor TRIF, which recruits signalling components and leads either to the IRF-3 or NF-kB 
pathways (387). 
 
A small down-regulation in IFN-γ was also detected in most transfected EBV+ B-LCLs. Only 
cells transfected with mutant AAG showed IFN-α and -γ to be slightly up-regulated. 
Additionally, cells transfected with wt CAA resulted in overexpression of IFN-γ to nearly two 
fold (figure 5.16, A and B). Overexpression of IFN-γ detected only in wt CAA transfected EBV+ 
B-LCLs may suggest that the  IFN-α and -γ signalling pathway was not impaired as HCV-core 
protein can degrade STAT-1 protein and suppress the Jak-STAT pathway, which can lead to the 
inhibition of IFN-α responses (217, 389). Additionally, a previous study also reported that HCV 
core protein may limit IFN signalling by interfering with IRF-1, which is involved in the 
induction of several IFN-stimulated antiviral and immunomodulatory genes (390). 
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It should also be considered that the mutations that affect IRES structure as reported in this study 
might prevent dimerization of protein kinase PKR, an interferon-inducible enzyme, and hence its 
activation. In fact, different studies conducted on the inhibition of PKR by RNA viruses reported 
that the HCV IRES can inhibit the activation of PKR as the IRES is able to bind to PKR and 
prevent autophosphorylation and activation of the kinase (391, 392). HCV NS3/4A protease-
mediated cleavage of the mitochondria-adapter MAVS results in low IFN induction (393). EBV 
has also been shown to act as inhibitor to PKR (394). This might explain the down-regulation of 
IFN-α detected in EBV+ B-LCLs (figure 5.16, A). 
 
IRF-3 genes were slightly over expressed in all transfected EBV+ B-LCLs except in cells 
transfected with mutant CCG where was under-expressed (figure 5.16 C). The most significant 
over-expression was detected in levels of IRF7 in most of the transfected cells (figure 5.16 D). 
Over-expression of IRF-3 and -7 was possibly caused by the replication of mutant viruses in 
EBV+ B-LCLs. HCV mutants were still able to replicate possibly by using a strategy of 
circumventing at least partially the IFN response. It should also be considered whether IFN-α 
and -γ including IRF-3 and -7 genes are expressed differentially in the distinct cell types used.  It 
is possible that the sensitivity of HCV versus host protein synthesis to inhibition by interferon 
treatment may vary between cell types as seen in previous studies (392, 395). 
 
HCV replication might have down-regulated IFN-α, IFN-γ, IRF3 and IRF7 expression by 
inhibiting the IKK enzyme complex and/or by degrading an adaptor protein in the RIG-I antiviral 
pathway termed Cardif, as seen in previous studies (387, 396). This event might have limited the 
production of IFNs and inhibited the activation of the transcription factors IRF3 and NF-kB.  
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Further analysis is required to establish the significance and reproducibility of gene expression 
levels detected after HCV transfection. 
5.3.6 Different cell lines were susceptible to infection with HCV infected plasma 
All cells, Huh7.5, Jurkat and EBV+ B-LCLs were found to be susceptible to infection with HCV 
infected plasma (figure 5.17). HCV replication/entry was assessed by RT-PCR. Naïve cells 
exposed to uninfected plasma (mock infected) showed no viral entry. 
 
HCV titres appeared higher in Huh7.5 cells than in EBV+ B-LCLs, probably due to the ability of 
Huh7.5 cells to support more efficient viral replication and production, as obtained from 
transfection studies. It is possible that the high levels of CD81 receptor expression could have 
increased virus uptake in Huh7.5 cells compared to EBV+ B-LCLs, explaining the higher 
intracellular HCV RNA levels in Huh7.5 cells. 
 
B cells might have preferentially bound free virus, while Jurkats might have preferentially bound 
virus-antibody complexes as the surprising result of HCV entry in Jurkat cells, which do not 
express receptors for HCV binding, might indicate. Thus, HCV entry could have occurred 
through binding by Jurkats of virus-antibody complexes present in the plasma as no 
electroporation was used during exposure of naïve cells to infected plasma, or via passive 
adsorption of virus particles to the cell surface. Thus, the hypothesis of a possible contamination 
due to infected serum particles attached to the external cell membrane cannot be excluded. 
 
It is possible that the binding of HCV to antibody complexes might have allowed cell entry 
through Fc receptors present in small quantities on Jurkats and monocytes, including B cells. 
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Monoclonal antibodies to FcRII, a low affinity immunoglobulin G receptor, abolished binding by 
immune complexes, suggesting that HCV could enter cells that express Fc receptors as seen in 
previous experiments (397, 398). The detection of 5’ UTR amplicons in intracellular RNA from 
cells exposed to HCV infected plasma confirmed viral attachment and possible entry in Huh7.5, 
Jurkats and EBV+ B-LCLs.  
 
Western blot analysis was conducted to examine whether HCV core protein production could 
possibly have occurred in plasma exposed cells. HCV core protein production was detected in 
Huh7.5 and EBV+ B-LCLs while not in Jurkats (figure 5.17). These results, similar to the ones 
obtained with HCV mutants, confirmed viral entry, the infectivity of HCV in hepatocytes, the 
reduced infection in EBV+ B-LCLs and failure to do so in Jurkats based on HCV RNA and core 
protein detection results. 
5.3.7 Mutations detected in the 5’ UTR of transfected and infected cells 
5’ UTR amplicons obtained by RT-PCR from intracellular and extracellular RNA from HCV 
mutant infected cells indicated replication and propagation of mutant viruses in Huh7.5 cells, 
EBV+ B-LCLs and possibly in PBMCs. On the other hand, the absence of 5’ UTR amplicons 
from extracellular RNA of mutant transfected Jurkats excluded viral replication in these cells 
(figure 5.18 and 5.19).  
 
The cloning and sequence analysis of extracted HCV-RNA allowed examination of whether 
these single point mutations in the IRES revert to the wild-type sequence. Repeated WT and 
mutant AGG passage in Huh7.5, Jurkat and EBV+ B-LCLs showed that only the C107A 
mutation converted the wt CAA to the AAA variant from day 15 onwards (passage 5). No 
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mutations at position 107, 204 and 243 occurred in the mutant AAG. These results suggest a 
trend by the virus to acquire the 107A mutation, a mutation that was present in AAG and did not 
revert to CAG during 30 days of passage in all cell lines. These results suggest that once the 
substitutions at positions 107, 204 and 243 are acquired, they are quite stable at least as shown 
for the short duration of these passage experiments. The 107A mutation may favour IRES 
activity as it increases the size of the IRES interior loop and the stability of domain II (see 3.2.7).  
 
In the analysis of nucleotide substitutions identified in replicating mutant viruses, mutations were 
common at position 204 and 243, and were detected only in mutant CCA and CAG in Huh7.5 
and also in the intracellular RNA detected in transfected Jurkat cells. Additionally, although 
HCV replication did not occur in Jurkat cells exposed to plasma, IRES sequence changes 
detected from intracellular viral RNA in mutant transfected Jurkat cells suggested a tendency of 
the IRES to acquire mutations in order to possibly adjust to the host protein environment which 
was different from that of Huh7.5 and EBV+ B-LCLs. 
 
Substitutions at positions 204 and 243 have been previously observed in dendritic cells (DCs) 
and in PBMCs of infected patients and are regarded as lymphoid specific (310, 316). Previous 
experiments were unable to infect PBMCs with JFH-1, suggesting that the ability to infect 
PBMCs could be a characteristic of native, patient-derived HCV and does not depend on HCV 
genotypes (399).  
 
Amplification of the 5’ UTR from RNA extracted from the medium of mutant transfected cells 
indicated the presence of a small number of particles, 9 days post-transfection but not at 4 (figure 
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5.19). These results suggested poor viral replication in PBMCs. Proliferation of PBMCs 
following mitogenic stimulation with phytohemagglutinin (PHA) should have enhanced viral 
replication and consequently the number of virus particles in PBMCs. It is also possible that 
these results  may have been due to a very low transfection efficiency of the viral mutants which 
at 4 days post-transfection did not allow detection of HCV-RNA in PBMCs, as HCV might 
infect one cell subset among PBMC subpopulations of CD4+, CD8+ and CD19+ cells (400).  
 
The lack of detection of HCV RNA in most PBMCs exposed to infected plasma and the high Ct 
values obtained in the experiments may be the result of the low sensitivity of the RT-PCR 
particularly in lymphocytes, where virus levels may be below the lower detection limit. This 
could explain the detection of HCV RNA only after 9 days. As the quantification method applied 
in this study appeared to be limited, a better detection method should have been used to increase 
sensitivity of HCV RNA detection in infected PBMCs, as the detection of small amounts of 
HCV RNA by RT-PCR is also hampered by a partial loss of virus nucleic acid due to the 
extraction process limiting further the successful detection of HCV RNA.  
 
It is possible that minute quantities of extracellular HCV RNA may be lost by degradation during 
the isolation steps, compounding further viral quantification. Thus, the qRT-PCR applied in this 
study might not have been in a position to detect viral loads which were too low or close to the 
detection limit. In fact, other studies using a novel real-time quantitative PCR detected very low 
levels of  positive RNA strands in lymphocytes and macrophages undetectable with standard 
PCR (401, 402). 
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In this study, the detection of HCV RNA may suggest that the virus might utilise PBMC 
compartments as an immune privileged site to reinitiate viral replication, particularly after 
termination of HCV treatment as seen in previous studies (403). 
 
The absence of core protein production in PBMCs and the difficulties in detecting extracellular 
HCV RNA suggest poor or no viral replication in PBMCs. The difficulties encountered by HCV 
in order to replicate in PBMCs may relate to the absence of the machinery needed for HCV 
replication. Additionally, cellular physiological stresses may have down-regulated HCV IRES-
driven protein synthesis inhibiting HCV RNA replication.  
 
It follows that in HCV mutant replication studies the undetectable intracellular and extracellular 
mutant RNA in PBMCs after 4 days post-transfection was not sufficient to determine HCV 
replication, quite unusual after electroporation with 10 µg of HCV RNA. However, the presence 
of viral RNA in the culture supernatant (figure 5.19) after 9 days post-transfection strongly 
suggests that HCV mutant construct replication might require longer incubation as not all PBMC 
subpopulations of cells might become infected with HCV. Thus, a robust cell-culture system is 
needed to compare HCV replication in different cell populations as HCV replication may vary in 
extrahepatic reservoirs depending on the cell type. 
 
Sequence analysis indicated that the mutant virus that had the least mutations was CAG, which 
acquired only mutation U105G in PBMCs. This mutation increased the size of the predicted 
asymmetric internal loop of IRES subdomain IIa (figure 5.20, E). Additionally, the mutation 
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increased the stability of IRES domain II, a similar effect seen with mutation C107A in Huh7.5 
cells. 
 
Mutations C147U, C196U and C212U detected in cells infected with mutant CCA caused 
conformational changes of the predicted IRES structure (figure 5.20, A). The mutations detected 
in mutant CCG (see table 5.1) led to a complete structural change of the predicted IRES domain 
III (figure 5.20), that could have led to the diminished IRES activity as seen in previous studies 
(309).  
 
C196U and C212U were the most common mutations detected in different mutants (CCA and 
CCG) and in different cells, Huh7.5 and EBV+ B-LCLs. These mutations located on domain IIIb 
may have had an effect in the binding of eIF3. Additionally, the predicted IRES structural 
changes caused by the detected mutations may have interfered with long-range RNA-RNA 
interactions between the 5' and the 3'ends of the viral genome, in other words, between the apical 
loop of domain IIId and the internal loop of 5BSL3.2 within the cis-acting replication element 
(CRE) located at the 3’end of the viral genome (404). 
 
Overall, most mutations detected in HCV mutants in different cell lines increased the stability of 
the IRES structure except point mutation C231G in the AAG mutant in EBV+ B-LCLs and the 
mutations detected in mutant AAG in PBMCs that decreased IRES structure stability (table 5.2).  
Other point mutations, which were not detected in PBMCs and plasma-derived IRESes (see 
3.2.3), included those at positions 147, 196, 212 and 231 (table 5.1 and 5.2). Additionally, 
sequence analysis indicated a tendency to include all uracil bases between nt position 191 to 
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200 on hairpin loop IIIb, which is known to be involved in the binding of eIF3a and the 40S 
ribosomal subunit (274). Mutations on hairpin loop IIIb have less probability to disrupt IRES 
geometry as seen with base-pairing sequences along the IRES, in particular mutations in the 
internal loops that cause disruption of the three-dimensional structure of the predicted IRES. In 
fact, previous results indicated that mutations in the internal loop on subdomain III reduced 
IRES activity (256).  
 
 
                     (-) negative; (+) positive; Y=yes, N=no 
 
Table 5.4 Summary table showing level of replication according to transfected mutant 
constructs in different cell lines and predicted effect on IRES structure  
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5.4 Conclusions 
In this chapter, an attempt was made to document HCV replication following transfection of 
different cell lines with the mutant and wt constructs generated, and at the same time attmpts 
were made to infect the same cell lines following exposure to HCV containing plasma. Different 
assays were employed in order to prove successful replication in these cells, primarily RT-
PCRfor the detection of HCV RNA, particularly in supernatants that would indicate release of 
virions, and detection of HCV core protein intracellularly. A number of difficulties were 
however encountered as discussed below.  
 
The accuracy of absolute quantification in real-time RT-PCR as employed here is questionable, 
as it depended entirely on the accuracy of the standard curve, which for the reasons explained 
earlier may have been a contributor in the generation of false positive results.  
Due to the errors in the quantification analysis, detection of intracellular HCV RNA suggested 
possible HCV genome replication. Intracellular HCV RNA was not a reliable indication of 
genome replication. Additionally, the technical conditions used do not allow one to draw strong 
conclusions and therefore the results remain questionable, and the likely subject of additional 
work. On the other hand, the detection of viral RNA in supernatants remains the strongest 
indication of viral replication while the detection of HCV core protein supported further the 
evidence of some degree of viral replication.  
 
Based on these observations and the results obtained in the different cell lines, HCV replication 
appeared to be cell type specific. The short duration of these experiments did not allow the study 
of the evolution of 5”UTR mutations over time as in the in vivo situation, particularly with the 
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wild type virus in lymphoid cells. The short scale passage of wt and mutant viruses over 30 days 
indicated relatively stable viruses over this period, in the absence of course of all other factors 
that come in play in the host. 
 
The results in this study confirmed the ability of mutant viruses to infect Huh7.5, EBV+ B-LCLs, 
possibly PBMCs, and their inability to infect Jurkats. These cells, particularly Huh7.5, proved to 
have the ability to support some steps of the mutant viral lifecycle.  
Although previous studies indicated the inability of HCV JFH-1 clones to infect human primary 
T cells, PBMCs and Jurkat cells (405), the results in this study indicated that HCV mutants were 
able to target cells of the immune system such as B-LCLs and possibly PBMCs suggesting a 
different tropism with a lower level of replication than that seen in hepatocytes.  
 
The different results obtained between the viral mutants and wt in Huh7.5 cells indicates that 
single nucleotide changes seem to be involved in the mechanism of the increased or decreased 
infectious HCV titre observed with the mutant JFH-1 versus wt strains.  Additionally, infection 
of naïve cells indicated different infection kinetics of mutant constructs versus JFH-1 wt, 
suggesting that the single point mutations in the IRES had an effect on HCV replication, which 
varied between different cell types as reported in previous experiments. Nucleotide substitutions 
at positions 107, 204 and 243, increased translational activity in the lymphoblastoid cells (311) 
and several nucleotide mutations within the IRES structure have been associated with 
lymphoid replication (46, 310, 311, 317, 318).  
 
 Luca Mercuri 
278 
Imperial College London 
The detected mutations in different cell lines might be adaptive mutations to possibly enhance or 
decrease virus infectivity and could confer a putative replication advantage or disadvantage in 
cells of lymphoid origin. Thermodynamic stability of the IRES structure was a significant 
indication of the effect of specific mutations but not a sufficient parameter for prediction of IRES 
stabilisation due to the presence of many host proteins and ribosomal subunit complexes that 
bind to the IRES. 
 
The detected mutations might also be an adaptability of HCV to respond to host factors and/or a 
way to evade the immune system and possibly antiviral treatments. Thus, the differences in the 
mutant HCV RNA levels detected between the different cell lines may be due to differences in 
levels of host factors that are required for viral replication or translation. In fact, cell type-
specific differences in IRES activity have been shown in picornaviruses such as Hepatitis A and 
poliovirus (406, 407). Unfortunately, it remains difficult to understand whether host factors of 
each cell type exert their function directly or through the action of other cell components, which 
can be altered by changes such as localisation, post-translational modification or proteolysis in 
infected cells. 
 
HCV mutants replicated less well in EBV+ B-LCLs than in Huh7.5 cells producing a low yield 
of progeny viruses, however, progressive passage in cell culture might have led to progressive 
adaptation with higher yields of infectious viruses. Previous experiments  identified among B-
cell subsets, memory B cells, as the main reservoir of HCV infection possibly due to their long 
lifespan (323), and that memory B cells CD19+ and CD27+ are recruited to the liver of patients 
with CHC through the interaction between CXCR3 expressed on these cells and IP-10 (IFN-γ-
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inducing protein 10 kD) produced in the liver (323, 337, 408). This is a beneficial strategy for 
HCV in securing sites for long-lasting infection. As HCV replicates in B cells, the elimination of 
peripheral B cells in CHC patients with for example anti-B cell antibodies such as rituximab 
(409) could be therapeutically beneficial during antiviral treatments, as it may eliminate 
circulating HCV in the blood. 
 
The detection of intracellular HCV RNA in PBMCs exposed to infected plasma enforced the 
possibility that HCV may infect PBMCs possibly through Fc receptors or monocyte lineage cells 
that express CD81(334). Previous in vitro studies have reported HCV infection not only through 
free virus but also by cell-to-cell contact of hepatocytes (410). This cell-to-cell transmission 
mechanism, also seen in animal viruses and documented in HIV (411), could allow HCV to 
move across the narrow spaces between cells by tight and adherent junctions escaping thus 
neutralising antibodies and other immune system components. The evidence of HCV infection of 
several peripheral blood cell types, including B lymphocytes, granulocytes, 
monocytes/macrophages, and dendritic cells (344, 412) and the long-term persistence of HCV in 
PBMC could allow the outgrowth of  HCV RNA+ B-LCLs capable of infecting primary PBMC 
cultures as seen in previous studies (329). 
 
The comparison of HCV mutant infections in the different cell lines provides a unique 
opportunity for the future to analyse possible critical virus-host interactions in immune 
privileged sites and whether the elimination of the virus within these cells may lead to the 
success of antiviral therapies.  
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5.5. General Discussion     
The results of this study indicated the presence of mixtures of viral strains that co-infect a single 
individual with divergent IRESes. Combinations of mutations were detected at positions 107, 
204 and 243. Nucleotide differences at these positions varied in the IRESes derived from 
PBMCs versus plasma-derived IRESes. The quasispecies dynamics detected in this study and the 
AAA HCV variant detected predominantly in PBMCs suggested functional, structural, or 
evolutionary relationships between HCV IRES sequences and the host cell. 
 
The nucleotide changes detected among HCV quasispecies that differed between plasma- and 
PBMC-derived IRESes possibly indicates HCV adaptation to immuno-privileged sites. For 
example, PBMC-derived samples had a high frequency of As present at position 107, while 
plasma-derived samples had the highest frequency of Gs at this position. This nt change at 
position 107 resulted in IRES structural changes. Additionally, in plasma-derived IRESes the 
reversion from C204 to A204 explained why the majority of plasma-derived IRESes had the 
GAA variant.  
 
Overall, the HCV IRES appeared to be subjected to more modifications in PBMCs than in 
plasma as a larger number of mutations were identified only in PBMC-derived IRESes. The 
acquired point mutations that differed between plasma and PBMC-derived IRESes might have 
imparted a selective replication advantage or disadvantage based on the host environment. 
 
The results suggested competition of extrahepatic strains, between PBMC- and plasma-derived 
HCV quasispecies with divergent IRESes, through the efficiency of their IRESes. This 
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hypothesis was enforced by the predicted structural changes and variation in the thermodynamic 
stability of the IRES caused by the detected mutations and by HCV mutant replication studies.  
 
The introduction of mutations detected in lymphotropic quasispecies at nt positions 107, 204 and 
243 in the JFH-1 infectious clone was essential for the study of the replication capacity of mutant 
HCV in Huh7.5 and in cell-lines of lymphocyte origin such as Jurkat, EBV+ B-LCL and PBMCs. 
HCV replication occurred in Huh7.5 and EBV+ B-LCL with some variations between the 
different mutants, while HCV replication appeared abortive in Jurkat and was not established in 
PBMCs. Mutations in the IRES may have had a strong inhibitory effect on cellular proteins 
and/or cause possible structural changes within IRES elements influencing thus the binding of 
cellular factors to the IRES region.  
 
The results obtained in this study confirmed the ability of HCV to target cells of the immune 
system with a lower level of replication than that seen in hepatocytes and that single point 
mutations in the 5’ UTR may affect HCV replication as suggested by the differences in the 
ability of the different mutant viruses to replicate in a particular cell line. Future studies are 
needed to provide additional evidence of HCV replication and quasispecies diversification in 
PBMCs distinct from those in serum.  
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CHAPTER 6 
FUTURE WORK & FINAL CONCLUSIONS 
 
6.1 Future work 
Following on from this work, further experimental investigation could be planned and some of 
the assumptions made in this study will have to be validated by further studies.  
Further research based on the results of this study includes: 
 To finish the rest of the mutant constructs.   
 The analysis of more quasispecies may help to unravel HCV adaptation in extrahepatic 
sites.  
 As PBMCs include many cell types, cell sorting could be done prior to RNA extraction in 
order to identify which cell components within the PBMC population harbour HCV, and 
the conduct sequence variance analysis. 
 Analyse the translational efficiencies of compartmentalized mutant IRESes in 
hepatocytes and B-LCLs in order to examine the IRES-driven cellular tropism of HCV in 
these cells.  
 Examine other viral regions of the viral mutant genomes that could be involved in the 
cellular tropism of HCV, as mutant constructs might accumulate cell culture adaptive 
mutations along the viral genome that could have an effect on viral replication, 
production and infectivity. 
 It will be useful, if not essential, to detect low levels of HCV RNA, possibly the HCV 
RNA replicative (negative) strand, in extra-hepatic sites with the use of highly sensitive 
HCV RNA detection assays such as RT-PCR-nucleic acid hybridization (RT-PCR-NAH) 
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as HCV RNA can persist at very low levels in the serum and peripheral lymphoid cells 
(348). 
 Different culture conditions should be experimented with to increase HCV genome 
expression in PBMCs. For example, T cell lines could be stimulated to increase CD5 
expression in order to facilitate HCV infection. Additionally, an increase in the number 
of cell passages of transfected cells could allow the detection of HCV core protein-
positive cells and core secretion in the supernatant. 
 Supernatants from HCV RNA-transfected cells could be tested by ELISA for IFNα to see 
if the level of IFNα (between 100-800pg/ml) is sufficient to inhibit HCV replication in 
cells. 
 Northern blot hybridisation of RNA extracted from different cells could be used to test 
lymphocytic and microglial cell lines for miR-122, which promotes HCV-RNA 
replication and  exerts its function by direct binding to the 5’ UTR of HCV RNA (nts 21-
43) (299).   
 Synthetic miR-122 could be transfected into extrahepatic cells to establish whether it can 
modulate HCV-RNA replication.  
 The host cell factor termed cyclophilin (Cyp), which is known to promote HCV-RNA 
replication (413), could also be investigated in lymphoid cells as this has not been done 
yet.  
 It would also be interesting to see whether HCV RNA+ B-LCLs could infect primary 
PBMC cultures. 
 The predicted RNA secondary structure could be confirmed using structural probing 
assays 
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6.2 Final conclusions 
This study has given an account of the presence of specific HCV 5’ UTR mutations in 
extrahepatic sites and the impact of these mutations on the replication efficiency of the virus in 
different cell lines.  
 
The most obvious finding to emerge from this study was the sequence variability that occurred in 
the 5’ UTR of HCV derived from PBMCs and plasma of infected patients. 5’ UTR quasispecies 
detected in PBMCs differed from those found circulating in the serum, supporting the concept of 
HCV replication in PBMCs. This sequence variability occurred mainly in stem loop III, the 
binding region of eIF3 and the 40S ribosomal subunit.   
 
The detected specific point mutations of the HCV 5’ UTR, derived from extrahepatic sites, 
occurred mainly at positions 107, 204 and 243. In particular, the AAA variant, which was the 
dominant variant in PBMCs, appeared to derive from plasma as indicated by phylogenetic 
analysis. Additionally, the detected mutations caused conformational changes of the IRES and 
had an effect on its stability.   
 
To determine the effect of 5’ UTR mutations on HCV replication mutant viruses were created to 
study HCV replication in Huh7.5 cells and in immune privileged sites such as Jurkat, EBV+ B-
LCLs and PBMCs. HCV mutants were able to replicate in Huh7.5 and EBV+ B-LCLs.  
The acquired mutations detected in transfected mutant constructs differed between cell lines 
suggesting a possible adaptation of HCV to respond to viral and host factors and a way to evade 
the immune system and antiviral treatments. 
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The detection of HCV RNA in extrahepatic reservoirs such as PBMCs has important 
implications for transmission, disease progression, and effective treatment. HCV replication in 
PBMCs appeared to be impaired suggesting that limited or no viral replication in these cells. 
 
HCV 5’UTR quasispecies diversification detected in plasma and PBMC and phylogenetic 
analysis may provide additional evidence that HCV replication and evolution are distinct in these 
compartments and that PBMCs are an important extrahepatic reservoir for HCV. The virus may 
later reinitiate viral replication after termination of HCV treatment, when conditions become 
more favourable, contributing thus to the persistence or recurrence of HCV infection.  
 
It is possible that HCV acquire mutations in the 5’ UTR alter replication in extrahepatic sites and 
allow persistence at a low level within the cell population. Thus, the absence of HCV viraemia 
does not exclude the possibility of reappearance of the virus. Therefore these mutations might be 
sufficient for a more or less efficient or specific production of HCVcc in the different cell types. 
Additionally, successful inoculation of different cells with serum of HCV-infected patients 
proved that HCV can easily propagate in extrahepatic sites. 
 
A limitation of this study was the large quantity of patient samples, the extensive sequence 
analyses, subcloning, PCRs, transcriptions and in vitro RNA transfections in four different cell 
lines. Termination of the construction of 15 mutant constructs towards the end of my studies left 
a short time frame to conduct the large amount of transfection experiments and gene expression 
analysis. This lead to errors in the quantification and experimental procedures only detected at 
the end of this study. Moreover, the inability of funding at the end of the final year due to the 
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costs associated with carrying out many real-time RT-PCR reactions and sequence analysis lead 
to the restriction of quantification analysis to duplicate samples.  
 
The adopted method of constructing and cloning in vitro HCV mutant constructs with specific 
mutations and the examination of their replication capacity in Huh7.5 cells and in other cells 
such as Jurkat, EBV+ B-LCLs and PBMCs offered valuable insights into the role of single 
mutations in the HCV life cycle in different cell lines. Additionally, it established the 5’ UTR as 
a significant area for investigation that could be used for development of novel antiviral 
strategies against viral protein synthesis and possible eradication of HCV that propagates in the 
lymphatic system. 
 
The results obtained in this study provided additional arguments in favour of extrahepatic 
replication of HCV, considering HCV as a lymphotropic virus, and provided evidence with 
respect to the possible role of these mutations, only detected in extrahepatic sites, in HCV 
replication as an important determinant in the persistence of HCV infection. Extrahepatic HCV 
occurrence remains the largest reservoir of HCV and a potential risk for infection reactivation.  
 
The work described in this thesis has achieved the following goals in relation to the aims set at 
the beginning of the work: 
1. It has generated a large number of sequences from the 5’ UTR of the genome from 
patients with acute HCV infection (co-infected with HIV), which have allowed the study 
of the evolution of the AAA variant over time in PBMCs compared to the sequences 
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present in serum. Phylogenetic tree analyses have established quite clearly that 
quasispecies from PBMCs group together on branches distinct from those in serum. 
2. Site directed mutagenesis was used to successfully introduce carefully selected 
combinations of substitutions at the three nucleotide positions (107, 204, 243) that give 
rise to the AAA mutant, based on the quasispecies sequences obtained from the acutely 
infected patients. Mutated 5’ UTR fragments were successfully ligated into the infectious 
JFH-1 clone giving rise to fifteen different constructs, including chimaeric ones with the 
1b 5’ UTR. 
3. The above constructs were tested for their replication capacity in the Huh7.5 cell line 
following tranfection of transcribed full-length HCV RNA. Successful replication was 
documented using RT-PCR but also western blotting to detect the core protein of the 
virus. Detection of both markers was taken to indicate the best possible evidence of 
replication. The AAA mutant and the chimaeric construct failed to replicate. 
4. Successful replication was further supported by passage of the virus from culture 
supernatants to naïve cultures. This indicated that constructs allowed viral replication and 
that virus released into the culture supernatants was infectious. Repeated passage of these 
viruses for a limited number of mutants and wt indicated that all the substitutions but one 
were quite stable at least for the 30 days of the duration of the experiment. 
5. Transfection of the constructs, which replicated successfully in Huh7.5 cells, into Jurkat 
cells and PBMCs did not provide the evidence required to conclusively deduce that there 
was replication in these cells lines. HCV RNA testing gave erroneous results as a result 
of inaccurate standard curves whilst failure to detect the core protein may have been due 
to western blots being unable to detect small amounts of the protein. Therefore these 
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experiments need to be repeated with the use of more sensitive PCR platforms such as 
Taqman. 
6. In contrast, there was successful replication of transfected constructs in B-LCLs as 
indicated by the detection of HCV RNA as well core protein expression. 
7. In view of the limitations described above, the siRNA knockdown experiments 
undertaken are made more difficult to interpret. It is therefore necessary to repeat this 
work, once the extrahepatic culture systems become more robust. 
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8. APPENDIX  
 
8.1 Oligonucleotide sequences 
8.1.1 Oligonucleotides used to amplify HCV IRES  
Name Orientation Sequence (5'-3') Position (nt) Amplicon (bp) 
P26 Sense GCTTAGCCATGGCGTTAG 77-95 
243 
P27 Antisense GCACGGTCTACGAGACCT 322-339 
P28 Sense GTGTCGTGCAGCCTCCAG 101-118 
204 
P29 Antisense GGTGCTTGCGAGTGCCCC 301-318 
 
8.1.2 Oligonucleotides used for in vitro mutagenesis 
Mutation  Forward Primer sequence (5'-3') Reverse Primer sequence (5'-3') 
JFH-1107A GTATGAGTGTCGTAAAGCCTCCAGGCCCC GGGGCCTGGAGGCTTTACGACACTCATAC 
JFH-1204C GTCCTTTCTTGGATACACCCACTCTATGCCC GGCATAGAGTGGGTGTATCCAAGAAAGGAC 
JFH-1243G GTGCCCCCGCAGGACTGCTAGCC GGCTAGCAGTCCTGCGGGGGCAC 
HCV1b107A GTATGAGTGTCGTACAGCCTCCAGGAC GTCCTGGAGGCTGTACGACACTCATAC 
HCV1b 204A GGTCCTTTCTTGGATAAACCCGCTCAATGCC GGCATTGAGCGGGTTTATCCAAGAAAGGACC 
HCV1b 243A CGTGCCCCCGCAAGACTGCTAGC GCTAGCAGTCTTGCGGGGGCACG 
 
Mutations introduced in the HCV IRES are underlined in bold. 
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8.1.3 Oligonucleotides used in the construction of mutant clones  
 
 
 
 
 
 
 
 
 
Restriction sites are underlined in bold. 
8.1.4 Oligonucleotides used for sequence analysis 
Name Orientation Sequence (5'-3') 
EcoRI JFH-1 Sense GAATTCTAATACGACTCACT 
BstZ17I JFH-1 Antisense GTATACTCCGCCAACGATCT 
EcoRI HCV1b Sense 
GAATTCTAATACGACTCACTATAGGCCAGCCCCCGA
TT 
BstZ17I HCV1b Antisense 
GTATACTCCGCCAACGATCTGGCCGCCGCCCGGGAA
CTTAACGTCTTCTGGGCGACGGTTGGTGTTTCTTTTG
GTTTTTCTTTGA 
Name Orientation Sequence (5'-3') HCV nt position 
JFH 1 Sense CTGTGAGGAACTACTGTCTT 64-84 
JFH 2 Sense TGGGCAGGATGGCTCCTGTC 637-657 
JFH 3 Sense GATGTCCGCCACCTTCTGCT 1158-1178 
JFH 4 Sense AACTTCACTCGTGGGGATCG 2305-2325 
JFH 5 Sense CCTGGGCGCCATAGTGGTGA 3489-3509 
JFH 6 Sense AAAGTGTGACGAGCTCGCGG 4566-4586 
JFH 7 Sense CTGGGTAAGGTGCTGGTGGA 5902-5922 
JFH 8 Sense GCGAGCTCCTCAGTGAGCCA 6967-6987 
JFH 9 Sense TCTGCAAGATCCAAGTATGG 7972-7992 
JFH 10 Sense CTTCACGGAGGCCATGACCA 8700-8720 
P26 Sense GCTTAGCCATGGCGTTAG 77-95 
P27 Antisense GCACGGTCTACGAGACCT 322-339 
T7 Sense ATTAACCCTCACTAAAGGGA n/a 
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8.1.5 Oligonucleotides used in qRT-PCR analysis of host genes 
Target gene Forward primer sequence (5'-3') Reverse primer sequence (3'-5') 
GAPDH CCCAATACGACCAAATCCG TCTCTGCTCCTCCTGTTCGAC 
ARP CGACCTGGAAGTCCAACTAC ATCTGCTGCATCTGCTTG 
IFN-α CAGCCTGAGTAACAGGAGGA GCAGATGAGTCCTTTGTGGT 
IFN-γ TCAGCTCTGGATCGTTTTGG TGTTTTAGCTGCTGGGGACA 
IRF3 TACGTGAGGCATGTGCTGA AGTGGGTGGCTGTTGGAAAT 
IRF3 GGGCCCCCAGATCTGATTAC TGGAAATCCATGCCCTCCAC 
IRF7 GCCCTTGCCTCCCCTGTTAT CCACTGCAGCCCCTCATAG 
NF-kB CGCTTAGGAGGGAGAGCCC TATGGGCCATCTGTTGGCAGTG 
 
8.1.6 Oligonucleotides used for SYBR green SNP PCR 
Name Primer sequence (5'-3') 
HCV1 107A TGGCGTTAGTATGAGTGTCGTA 
HCV2 Rev GGCAATTCCGGTGTACTCAC 
HCV3 107G GGCGTTAGTATGAGTGTCGTG 
 
8.1.7 siRNA sequences 
siRNA 
name 
Sense strand (5'-3') Antisense strand (5'-3') Target sequence (5'-3') 
 
IRF3 
GCUCUGCCCUCAACC
GCAATT 
UUGCGGUUGAGGGC
AGAGCGG 
CCGCTCTGCCCTCAA
CCGCAA 
 
NF-kB 
CGCCAUCUAUGACAG
UAAATT 
UUUACUGUCAUAGA
UGGCGTC 
GACGCCATCTATGAC
AGTAAA 
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8.2 DNA plasmids  
 
8.2.1 DNA plasmid maps 
 
pUC19  
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pGEM-T easy vector 
 
pHCVrep1bBB7 
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pJFH-1 
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8.2.2 Cloning strategy 
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Clone A containing mutant 5’ UTRs and clone B containing a 2.5kb JFH-1 region upstream of 
the 5’ UTR were both restriction enzyme digested with the same enzymes (AatI and BstZ17I) 
and ligated to form a new clone (Subclone C). Subclone C and wild type pJFH-1 (D) were both 
restriction enzyme digested with the same enzymes (EcoRI and NotI) and ligated to construct the 
final mutant JFH-1 clone (E). 
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8.3 Molecular weight ladders  
8.3.1 DNA ladders 
 
              Promega 1kb        Promega 100bp              HyperLadder I 
 
            HyperLadder II                 HyperLadder IV               HyperLadder V 
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8.3.2 RNA ladders 
 
                    NEB ssRNA ladder                        Ambion Millennium RNA ladder             
8.3.3 Protein ladder 
 
                                            Invitrogen SeeBlue Pre-Stained Standard 
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8.4 IRES sequences and dot-bracket notations used to construct 2D structures 
In the dot-bracket notation each character represents a nucleotide, dots indicate unpaired 
nucleotides, open parentheses indicate that the nucleotide is paired to another nucleotide ahead of 
it and closed parentheses indicate that a nucleotide is paired to another nucleotide behind it. 
8.4.1 Nt sequences and dot-bracket notations of IRESes derived from transfected 
cells 
 140-281 CCA RNA: 
UAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUCUUGGAUAGACCCACUCUAUGCCCGGCCAUUUGGGCGUGCCCCCGCAAGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....))))))(((.((((((.(((.((((((............)))))).)))...)))))).))).(((....))))))).)))))))))((......))...((
((........)))). 
 
After C147U, C196U and C212U: 
UAGUGGUUUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUUUUGGAUAGACCCACUUUAUGCCCGGCCAUUUGGGCGUGCCCCC 
GCAAGACUGCUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....)))))).((.((((((.....((((((............)))))).......)))))).))..(((....))))))))).)))))))((......))...((((
........)))). 
 
 140-281 CCG RNA: 
UAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUCUUGGAUAGACCCACUCUAUGCCCGGCCAUUUGGGCGUGCCCCCGCACGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....))))))(((.((((((.(((.((((((............)))))).)))...)))))).))).(((....)))))))).))))))))((......))...((
((........)))). 
 
After CAG: 
UAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUCUUGGAUAAACCCACUCUAUGCCCGGCCAUUUGGGCGUGCCCCCGCACGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....))))))(((.((((((.(((.(((((..............))))).)))...)))))).))).(((....)))))))).))))))))((......))...((
((........)))). 
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 140-281 CCA RNA: 
UAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUCUUGGAUAGACCCACUCUAUGCCCGGCCAUUUGGGCGUGCCCCCGCAAGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....))))))(((.((((((.(((.((((((............)))))).)))...)))))).))).(((....))))))).)))))))))((......))...((
((........)))). 
 
After C204A and A243G: 
UAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUCUUGGAUAAACCCACUCUAUGCCCGGCCAUUUGGGCGUGCCCCCGCAGGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....))))))(((.((((((.(((.(((((..............))))).)))...)))))).))).(((....))))))))).)))))))((......))...((
((........)))). 
 
 140-281 CCG RNA: 
UAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUCUUGGAUAGACCCACUCUAUGCCCGGCCAUUUGGGCGUGCCCCCGCACGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....))))))(((.((((((.(((.((((((............)))))).)))...)))))).))).(((....)))))))).))))))))((......))...((
((........)))). 
 
After mutations C147A, U174A, C204A, C206A, C231G and G243A: 
UAGUGGUAUGCGGAACCGGUGAGUACACCGGAAUAGCCGGGAAGACUGGGUCCU
UUCUUGGAUAAAACCACUCUAUGCCCGGCCAUUUGGGGGUGCCCCCGCAAGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((.(((((..((((((....))))))....((((((....(((((......))))).......((.....)))))))).....(((....))))))))..)))))))..............(((...
.....))).. 
 
After mutations C196U, C212U and C231G: 
UAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUUUUGGAUAGACCCACUUUAUGCCCGGCCAUUUGGGGGUGCCCCCGCACGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....))))))(((.((((((.....((((((............)))))).......)))))).))).(((....)))))))).))))))))((......))...(((
(........)))). 
 
 140-281 AAG RNA: 
UAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUCUUGGAUAAACCCACUCUAUGCCCGGCCAUUUGGGCGUGCCCCCGCAGGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....))))))(((.((((((.(((.(((((..............))))).)))...)))))).))).(((....))))))))).)))))))((......))...((
((........)))). 
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After C231G: 
UAGUGGUCUGCGGAACCGGUGAGUACACCGGAAUUGCCGGGAAGACUGGGUCCU
UUCUUGGAUAAACCCACUCUAUGCCCGGCCAUUUGGGGGUGCCCCCGCAGGACUG
CUAGCCGAGUAGCGUUGGGUUGCGAAAGGCCUU 
(((((((((((((..((((((....))))))(((.((((((.(((.(((((..............))))).)))...)))))).))).(((....))))))))).)))))))((......))...((
((........)))). 
 
 44-118 CAG RNA: 
CUGUGAGGAACUACUGUCUUCACGCAGAAAGCGCCUAGCCAUGGCGUUAGUAUG
AGUGUCGUAGAGCCUCCAGGC 
(((.((((..(((((((......))))..((((((.......)))))).............)))..))))))).. 
 
After U105G: 
CUGUGAGGAACUACUGUCUUCACGCAGAAAGCGCCUAGCCAUGGCGUUAGUAUG
AGUGUCGGAGAGCCUCCAGGC 
(((.((((.....((((......))))...(((((.......)))))...................))))))).. 
 
8.5 HCV subype 1a sequences 
8.5.1 List of Hepatits C virus subtype 1a isolates 
Number Isolate Accession Bases  
 
Number Isolate Accession Bases  
1  03_32_P1_10.16.03 EF032883 9275 
 
220  BID V260 EU255957 9334 
2  03_32_P2_5.14.04 EF032884 9242 
 
221  BID V261 EU482872 9316 
3  03_32_P4_11.5.05 EF032885 9270 
 
222  BID V262 EU155352 9272 
4 1002 EF407412 9352 
 
223  BID V263 EU482857 9295 
5 1003 EF407457 9286 
 
224  BID V264 EU256074 9308 
6 1013 EF407432 9395 
 
225  BID V265 EU255958 9304 
7  1013_FU24 EU362876 9340 
 
226  BID V267 EU155353 9302 
8  1013q EU362899 9170 
 
227  BID V268 EU255959 9292 
9 1024 EF407428 9323 
 
228  BID V269 EU155354 9303 
10  1024_FU24 EU362877 9342 
 
229  BID V270 EU155355 9303 
11 1030 EF407437 9387 
 
230  BID V271 EU482858 9302 
12  1030_FU24 EU362878 9178 
 
231  BID V28 EU482873 9288 
13  1030q EU362900 9171 
 
232  BID V29 EU155379 9279 
14 1036 EF407441 9386 
 
233  BID V3 EU256043 9273 
15 2005 EF407452 9390 
 
234  BID V31 EU862824 9289 
16 2011 EF407434 9360 
 
235  BID V316 EU239713 9441 
17  2011q EU362901 9360 
 
236  BID V317 EU155284 9263 
18 2027 EF407449 9395 
 
237  BID V318 EU155285 9300 
19  2027_FU24 EU362881 9167 
 
238  BID V319 EU155286 9328 
20  2027q EU362902 9167 
 
239  BID V32 EU256106 9296 
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21  20E AY956468 8901 
 
240  BID V320 EU155287 9402 
22  25B AY956464 8926 
 
241  BID V321 EU256096 9307 
23  25E AY956469 8934 
 
242  BID V322 EU155288 9306 
24 3005 EF407431 9332 
 
243  BID V323 EU155289 9332 
25  3005_FU24 EU362882 9349 
 
244  BID V324 EU256097 9408 
26 3018 EF407415 9392 
 
245  BID V325 EU155290 9325 
27 4012 EF407416 9164 
 
246  BID V326 EU155291 9295 
28 4025 EF407456 9419 
 
247  BID V327 EU155292 9332 
29  4025_FU24 EU362883 9177 
 
248  BID V328 EU155293 9461 
30  4025q EU362903 9178 
 
249  BID V329 EU155294 9311 
31 4035 EF407453 9367 
 
250  BID V33 EU482832 9288 
32  4035_FU24 EU362884 9376 
 
251  BID V330 EU482876 9437 
33 4040 EF407417 9383 
 
252  BID V331 EU155295 9370 
34  4681_6 EU677253 9022 
 
253  BID V332 EU155296 9402 
35 5003 EF407419 9387 
 
254  BID V333 EU155297 9374 
36 5009 EF407445 9358 
 
255  BID V334 EU155298 9398 
37  5009q EU362904 9120 
 
256  BID V335 EU155299 9368 
38 5012 EF407413 9371 
 
257  BID V336 EU155248 9385 
39 5014 EF407435 9342 
 
258  BID V337 EU155249 9420 
40  5014_FU24 EU362886 9362 
 
259  BID V35 EU155380 9388 
41 5043 EF407411 9326 
 
260  BID V357 EU155310 9412 
42 5069 EF407424 9218 
 
261  BID V358 EU155250 9344 
43  5159_2 EU677256 9022 
 
262  BID V359 EU155251 9389 
44  5159_4 EU677257 9021 
 
263  BID V360 EU256060 9393 
45  5159_6 EU677258 9022 
 
264  BID V361 EU482838 9385 
46  5309_3 EU677250 9022 
 
265  BID V362 EU155252 9375 
47  5309_6 EU677251 9022 
 
266  BID V378 EU256044 9283 
48  54E AY956466 8911 
 
267  BID V38 EU482884 9067 
49  59B AY956463 8918 
 
268  BID V386 EU482840 9315 
50  59E AY956465 8925 
 
269  BID V387 EU482841 9310 
51 6001 EF407422 9333 
 
270  BID V388 EU155265 9383 
52 6018 EF407448 9169 
 
271  BID V389 EU482842 9378 
53 6020 EF407450 9332 
 
272  BID V39 EU529676 9310 
54  6020_FU24 EU362887 9354 
 
273  BID V390 EU155266 9335 
55 6025 EF407427 9378 
 
274  BID V391 EU155267 9360 
56  6025_FU24 EU362888 9069 
 
275  BID V392 EU256046 9395 
57  6025q EU362905 9153 
 
276  BID V393 EU256047 9304 
58 6030 EF407444 9338 
 
277  BID V394 EU256048 9408 
59  6030_FU24 EU362889 9069 
 
278  BID V395 EU256049 9304 
60  6030q EU362906 9135 
 
279  BID V396 EU155268 9349 
61 6031 EF407454 9359 
 
280  BID V397 EU256050 9421 
62 6071 EF407425 9365 
 
281  BID V398 EU155269 9411 
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63 7002 EF407440 9378 
 
282  BID V399 EU155270 9421 
64  7002_FU24 EU362890 9178 
 
283  BID V4 EU256051 9300 
65  7002q EU362907 9166 
 
284  BID V401 EU155271 9304 
66 7003 EF407430 9118 
 
285  BID V402 EU256067 9305 
67  7003q EU362908 9118 
 
286  BID V403 EU256052 9323 
68 7012 EF407438 9369 
 
287  BID V404 EU155272 9416 
69  7012_FU24 EU362892 9401 
 
288  BID V405 EU256068 9370 
70 7018 EF407414 9330 
 
289  BID V406 EU155273 9349 
71 7020 EF407418 9359 
 
290  BID V407 EU155274 9278 
72 7024 EF407443 9390 
 
291  BID V408 EU255939 9297 
73 7032 EF407420 9125 
 
292  BID V409 EU155275 9450 
74 7040 EF407436 9348 
 
293  BID V41 EU256002 9318 
75  7040q EU362909 9124 
 
294  BID V410 EU482882 9300 
76 7041 EF407451 9365 
 
295  BID V411 EU155311 9222 
77  7041q EU362910 9132 
 
296  BID V412 EU155312 9424 
78 7043 EF407429 9086 
 
297  BID V413 EU155313 9462 
79  7043_FU24 EU362895 9358 
 
298  BID V414 EU155314 9334 
80  7043q EU362911 9124 
 
299  BID V422 EU482834 9260 
81 7046 EF407433 9393 
 
300  BID V423 EU239715 9530 
82  7046_FU24 EU362896 9407 
 
301  BID V424 EU155319 9389 
83 7065 EF407455 9403 
 
302  BID V425 EU155320 9347 
84  7065_FU24 EU362897 9400 
 
303  BID V426 EU155321 9331 
85 8003 EF407439 9375 
 
304  BID V427 EU482835 9311 
86 8004 EF407447 9410 
 
305  BID V428 EU155322 9295 
87 8009 EF407446 9335 
 
306  BID V429 EU155323 9333 
88 8012 EF407442 9331 
 
307  BID V430 EU256104 9307 
89  8012_FU24 EU362898 9337 
 
308  BID V431 EU239716 9303 
90 8028 EF407423 9369 
 
309  BID V432 EU155276 9397 
91 8030 EF407421 9327 
 
310  BID V433 EU255940 9310 
92  BID V1 EU155247 9339 
 
311  BID V434 EU155277 9368 
93  BID V10 EU260395 9591 
 
312  BID V435 EU482843 9304 
94  BID V100 EU660383 9304 
 
313  BID V436 EU482844 9311 
95  BID V101 EU155213 9391 
 
314  BID V437 EU155278 9327 
96  BID V102 EU255993 9398 
 
315  BID V438 EU482845 9310 
97  BID V103 EU255994 9288 
 
316  BID V439 EU482846 9308 
98  BID V104 EU155214 9313 
 
317  BID V44 EU595698 9294 
99  BID V105 EU155215 9450 
 
318  BID V440 EU256053 9304 
100  BID V106 EU255995 9377 
 
319  BID V444 EU256003 9310 
101  BID V107 EU255996 9315 
 
320  BID V445 EU155233 9298 
102  BID V108 EU255931 9304 
 
321  BID V446 EU482861 9303 
103  BID V109 EU255997 9281 
 
322  BID V45 EU256004 9291 
104  BID V11 EU260396 9314 
 
323  BID V450 EU155236 9300 
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105  BID V110 EU256086 9345 
 
324  BID V451 EU256005 9306 
106  BID V111 EU255932 9415 
 
325  BID V452 EU256006 9312 
107  BID V112 EU255933 9389 
 
326  BID V453 EU255934 9312 
108  BID V113 EU255998 9305 
 
327  BID V454 EU482862 9303 
109  BID V114 EU256087 9273 
 
328  BID V456 EU482863 9307 
110  BID V115 EU155216 9319 
 
329  BID V457 EU155237 9302 
111  BID V116 EU255999 9291 
 
330  BID V459 EU482864 9310 
112  BID V13 EU569723 9297 
 
331  BID V46 EU482865 9283 
113  BID V1562 EU687193 9272 
 
332  BID V460 EU482866 9310 
114  BID V1563 EU687194 9304 
 
333  BID V461 EU482867 9311 
115  BID V1564 EU687195 9311 
 
334  BID V462 EU255935 9307 
116  BID V16 EU256039 9297 
 
335  BID V464 EU256007 9295 
117  BID V166 EU255963 9318 
 
336  BID V465 EU155238 9339 
118  BID V167 EU255964 9288 
 
337  BID V47 EU256008 9273 
119  BID V168 EU255965 9302 
 
338  BID V49 EU256009 9291 
120  BID V169 EU155338 9309 
 
339  BID V5 EU482847 9294 
121  BID V17 EU482837 9294 
 
340  BID V50 EU256010 9273 
122  BID V170 EU255966 9315 
 
341  BID V505 EU256105 9400 
123  BID V1705 FJ024087 9304 
 
342  BID V506 EU482836 9305 
124  BID V1706 FJ181999 9288 
 
343  BID V507 EU595697 9293 
125  BID V1707 FJ024274 9230 
 
344  BID V508 EU250017 9336 
126  BID V1708 FJ024275 9269 
 
345  BID V51 EU256011 9273 
127  BID V1709 FJ205867 9337 
 
346  BID V510 EU255936 9304 
128  BID V171 EU255967 9318 
 
347  BID V511 EU256012 9311 
129  BID V1710 FJ024276 9269 
 
348  BID V52 EU529677 9305 
130  BID V1712 FJ182000 9271 
 
349  BID V53 EU256013 9302 
131  BID V1713 FJ024278 9271 
 
350  BID V54 EU155239 9469 
132  BID V1714 FJ205868 9313 
 
351  BID V55 EU660384 9326 
133  BID V1716 FJ182001 9295 
 
352  BID V56 EU256014 9273 
134  BID V1717 FJ024280 9286 
 
353  BID V57 EU256015 9296 
135  BID V1718 FJ024281 9301 
 
354  BID V58 EU256016 9293 
136  BID V1719 FJ024282 9289 
 
355  BID V59 EU256017 9300 
137  BID V172 EU155339 9295 
 
356  BID V6 EU256055 9300 
138  BID V1720 FJ205869 9271 
 
357  BID V60 EU256018 9292 
139  BID V173 EU255968 9288 
 
358  BID V61 EU256019 9301 
140  BID V174 EU255969 9300 
 
359  BID V62 EU256020 9311 
141  BID V1745 FJ390394 9287 
 
360  BID V63 EU529678 9291 
142  BID V1746 FJ410172 9272 
 
361  BID V64 EU256021 9295 
143  BID V1747 FJ390395 9264 
 
362  BID V65 EU256022 9295 
144  BID V1751 FJ390399 9248 
 
363  BID V67 EU256023 9318 
145  BID V176 EU255970 9296 
 
364  BID V68 EU155240 9394 
146  BID V177 EU234063 9432 
 
365  BID V69 EU482868 9294 
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147  BID V179 EU482889 9311 
 
366  BID V696 EU155282 9335 
148  BID V18 EU256040 9415 
 
367  BID V697 EU255941 9309 
149  BID V180 EU255973 9298 
 
368  BID V698 EU155283 9288 
150  BID V181 EU255974 9306 
 
369  BID V699 EU255942 9309 
151  BID V182 EU234064 9310 
 
370  BID V7 EU256056 9281 
152  BID V183 EU255975 9303 
 
371  BID V70 EU482869 9294 
153  BID V184 EU255976 9307 
 
372  BID V700 EU255937 9294 
154  BID V185 EU155340 9295 
 
373  BID V701 EU660387 9294 
155  BID V186 EU482850 9298 
 
374  BID V702 EU256057 9312 
156  BID V187 EU255977 9302 
 
375  BID V71 EU155241 9275 
157  BID V188 EU255978 9292 
 
376  BID V72 EU256024 9347 
158  BID V189 EU255979 9305 
 
377  BID V73 EU155242 9330 
159  BID V19 EU482878 9303 
 
378  BID V74 EU256094 9305 
160  BID V190 EU255980 9296 
 
379  BID V75 EU482870 9319 
161  BID V191 EU255981 9311 
 
380  BID V76 EU529679 9292 
162  BID V192 EU155341 9324 
 
381  BID V77 EU482871 9287 
163  BID V194 EU255982 9302 
 
382  BID V79 EU256025 9283 
164  BID V195 EU255983 9297 
 
383  BID V8 EU256058 9296 
165  BID V197 EU155342 9281 
 
384  BID V80 EU529680 9314 
166  BID V198 EU862826 9209 
 
385  BID V81 EU256095 9314 
167  BID V2 EU256041 9309 
 
386  BID V82 EU256026 9309 
168  BID V200 EU255984 9290 
 
387  BID V83 EU256027 9417 
169  BID V201 EU255985 9307 
 
388  BID V84 EU256028 9306 
170  BID V203 EU255986 9305 
 
389  BID V85 EU256029 9291 
171  BID V205 EU255987 9286 
 
390  BID V86 EU155243 9323 
172  BID V206 EU255988 9300 
 
391  BID V87 EU256030 9287 
173  BID V208 EU255989 9311 
 
392  BID V88 EU255938 9310 
174  BID V209 EU255990 9310 
 
393  BID V89 EU256031 9302 
175  BID V210 EU255991 9306 
 
394  BID V9 EU482848 9309 
176  BID V212 EU234065 9385 
 
395  BID V90 EU155244 9375 
177  BID V213 EU255992 9299 
 
396  BID V91 EU155245 9309 
178  BID V214 EU155343 9274 
 
397  BID V92 EU256032 9302 
179  BID V215 EU569722 9312 
 
398  BID V93 EU155246 9360 
180  BID V216 EU155344 9301 
 
399  BID V94 EU256033 9420 
181  BID V217 EU482852 9294 
 
400  BID V95 EU256034 9308 
182  BID V218 EU862827 9293 
 
401  BID V96 EU256035 9311 
183  BID V221 EU155345 9348 
 
402  BID V97 EU256036 9304 
184  BID V222 EU255927 9299 
 
403  BID V98 EU256037 9311 
185  BID V223 EU255943 9313 
 
404  BID V99 EU256038 9313 
186  BID V224 EU255944 9280 
 
405  BID_V356 EU155309 9330 
187  BID V225 EU255945 9297 
 
406  BR111_P1_01-30-01 EF032896 9115 
188  BID V226 EU255946 9345 
 
407  BR111_P2_6.25.01 EF032897 8840 
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189  BID V227 EU482853 9297 
 
408  BR111_P3_2.6.02 EF032898 9132 
190  BID V228 EU255947 9311 
 
409  BR111_P4_10.31.02 EF032899 9107 
191  BID V229 EU256069 9378 
 
410  BR111_P5_4.30.03 EF032900 9269 
192  BID V230 EU255948 9306 
 
411  BR554_P1_5.23.03 EF032887 9286 
193  BID V231 EU255928 9309 
 
412  BR554_P10_10.21.03 EF032888 9261 
194  BID V232 EU256070 9303 
 
413  BR554_P16_6.24.04 EF032889 9257 
195  BID V233 EU255929 9303 
 
414  BR554_P17_10.21.04 EF032890 9294 
196  BID V234 EU256071 9276 
 
415  BR601 EF032886 9328 
197  BID V235 EU255949 9304 
 
416  colonel  AF290978 9365 
198  BID V236 EU155346 9322 
 
417  H77 NC_004102 9646 
199  BID V237 EU255930 9304 
 
418  H77 clone pCV-H11 AF011752 9599 
200  BID V238 EU256072 9285 
 
419  H77 clone pCV-H77C AF011751 9599 
201  BID V239 EU155347 9415 
 
420  H77 clone pH21 AF011753 9599 
202  BID V240 EU155348 9324 
 
421  HC-J1 D10749 9502 
203  BID V241 EU255950 9296 
 
422  HC-TN EF621489 9599 
204  BID V242 EU482854 9294 
 
423  LIV23 DQ838739 9022 
205  BID V245 EU255951 9410 
 
424  LIV23 clone 10 DQ838743 9022 
206  BID V246 EU155349 9367 
 
425  LIV23 clone 11 DQ838745 9022 
207  BID V247 EU255952 9299 
 
426  LIV23 clone 12 DQ838744 9022 
208  BID V248 EU255953 9387 
 
427  LIV23 clone 4 DQ838740 9022 
209  BID V249 EU482855 9294 
 
428  LIV23 clone 9 DQ838741 9022 
210  BID V25 EU482831 9283 
 
429  LTD6-2 AF511950 9395 
211  BID V250 EU482856 9302 
 
430  PD101 AY695437 8475 
212  BID V251 EU529681 9300 
 
431  PD102 AY695436 8484 
213  BID V252 EU255954 9372 
 
432  pHCV-1 SF9 A AF271632 9618 
214  BID V254 EU255955 9286 
 
433  TN168-1FL DQ430811 8936 
215  BID V256 EU155350 9278 
 
434  TN168-25FL DQ430813 8910 
216  BID V257 EU155351 9306 
 
435  TWB_1 AY615798 8791 
217  BID V258 EU660385 9287 
 
436  AJ278830 AJ278830 9610 
218  BID V259 EU255956 9305 
 
437 M62321 M62321 9401 
219  BID V26 EU155378 9329 
 
438 M67463 M67463 9416 
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8.5.2 HCV 5’UTR subtype 1a consensus sequence 
 
